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Chapter 1Introduction and Overview9
10
11
Percutaneous intervention of coronary stenoses has undergone dramatic evolution in the last 30 years. The
utilisation of stents has dramatically increased in the last 10-15 years with stenting becoming applicable in a
wide variety of lesion morphologies and clinical settings. Stents provide a scaffold which supports the arterial
wall thereby sealing dissections and eliminating elastic recoil which reduces the rate of abrupt vessel closure
compared to balloon angioplasty alone. 1,2 Angiographically, stents provide a very pleasing immediate result;
however the long-term success is hindered by the development of restenosis which has proven to be extremely
difficult to treat effectively. The struts of an expanding stent cause focal deep vascular trauma, and the severity
of arterial injury has been shown to directly correlate with inflammation and the development of late neointimal
growth and restenosis. 3 
Drug-eluting stents, whilst maintaining the beneficial effect of scaffolding the vessel, have been shown
to reduce the rate of subsequent restenosis. Large randomised studies evaluated outcomes in selected
populations, and demonstrated efficacy of drug-eluting stents when used to treat relatively simple lesions. 4-7
However, the short- and long-term efficacy of percutaneous coronary intervention is related to the baseline
patient and lesion characteristics, and the majority of coronary intervention carried out in current clinical practice
involves the therapy of such complex lesions, which were excluded from these studies. 
The aim of this thesis was to evaluate contemporary coronary intervention of two of the most complex
lesion subtypes: chronic total occlusions (CTOs) and bifurcations. In patients with significant coronary disease,
both these lesion subtypes are commonly found on diagnostic angiography. However, both lesions are
associated with lower procedural success rates: CTOs because of the difficulty in crossing the lesion with a wire
and / or balloon; and bifurcations because of a higher rate of procedural myocardial infarction commonly related
to impairment of flow in the side branch. In addition, data with bare metal stents show that both these lesions
are subject to a relatively high rate of restenosis. We evaluated the impact of drug-eluting stent implantation on
the outcomes of patients treated in the “real world” of interventional cardiology, in particular looking at the
impact of these stents in patients treated for chronic total occlusions and bifurcation lesions.
 Part 1 of the thesis evaluates chronic total occlusions (CTOs), with an overview described in Chapter 2.
In chapter 3, we review the outcomes and trends of all patients treated for a CTO between 1992 and 2002. Prior
to drug-eluting stents, intracoronary brachytherapy was the treatment of choice for in-stent restenosis. However,
recent data has suggested that this therapy is associated with late recurrence of restenosis including CTO. 8 In
chapter 4, we describe the predictors, incidence and prognosis of patients who develop a coronary occlusion
following intracoronary beta-radiation therapy. 
Despite the development of improved technologies to facilitate CTO recanalization, the overall success
rate remains <70% in most catheterization laboratories. In chapter 5 we evaluate the value of pre-procedural
multislice CT scanning in order to predict a subsequent successful recanalization attempt. In chapters 6,7 and 8
we evaluate the efficacy of a novel dedicated CTO recanalization technology. The system comprises of a
guidewire that combines guidance from optical coherence reflectometry, with power provided by radiofrequency
ablation to enable penetration through the occlusion. 
The long-term outcomes of CTOs with respect to stent type are assessed in chapters 9 and 10.
Consecutive patients treated with sirolimus-eluting, and paclitaxel-eluting stents are compared with an historical
cohort treated with bare metal stent implantation, in order to determine the efficacy of drug-eluting stents in this
patient subgroup.
In part 2, we assess the treatment of bifurcation lesions, with overviews presented in chapters 12 and
13. The difficulty in this situation relates to the presence of a sizeable side branch (usually defined as ≥2.0mm
diameter). Even temporary loss of such a branch may be associated with a significant (≥2x upper limit of
normal) release of creatine kinase. This is important as even minor elevations of CK-MB after successful
coronary interventions identify a population with a worse long-term prognosis compared with patients with no
enzyme release. 9
In addition, the side branch is at particular risk of subsequent restenosis and the most effective strategy
for stenting bifurcation lesions is currently undefined. Studies have evaluated a variety of techniques, however
data with bare metal stents demonstrated that stent implantation of both the main vessel and side branch is
12
associated with a trend towards a higher rate of adverse events compared with use of single stent implantation
of the main vessel only. 10-13
The efficacy of drug-eluting stents for bifurcations is demonstrated in Chapters 14 and 15. The
introduction of drug-eluting stents has led to a resurgence of techniques involving elective stent implantation in
the side branch. Strategies such as the “crush” technique and Culotte stenting ensure complete lesion
coverage, and the results are evaluated in Chapters 16 and 17. 
In part 3, the treatment of both chronic total occlusions and bifurcations are put into the context of
results of drug-eluting stent implantation in an unselected population. One of the concerns of drug-eluting stents
is that by impairing the process of re-endothelialization, these stents might be subject to higher rates of stent
thrombosis despite prolongation of the duration of prescribed dual anti-platelet therapy. Such an event is
associated with a high rate of mortality and morbidity. 14 In chapter 18, we assess the incidence of stent
thrombosis at 30 days following sirolimus- and paclitaxel-eluting stents as compared with previous patients
treated with bare metal stents, and evaluate the independent predictors of stent thrombosis. 
In chapter 19, we evaluate the clinical, angiographic, and procedural predictors of angiographic
restenosis after sirolimus-eluting stent implantation in complex patients, including whether chronic total
occlusions and bifurcations are predictors of restenosis. Chapter 20 evaluates the clinical outcomes following
the use of paclitaxel-eluting versus sirolimus-eluting stents in unselected populations. Multivariate analysis of
the populations determines the independent predictors of both major adverse cardiac events and target vessel
revascularization. 
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Introduction
A chronic total occlusion (CTO) remains a technical challenge to the interventional cardiologist. Procedural
success rates vary in the literature and are very much dependant on patient selection, age of occlusion, and
operator experience. Despite technological advances, even in those patients selected to be suitable for
percutaneous therapy, published success rates are between 40-80%,1,2 considerably lower compared to non-
occlusive lesions. However, there are several advantages to opening a CTO, with studies demonstrating a
reduction in long-term mortality, improvement in anginal symptoms and left ventricular function and a reduction
in the need for subsequent coronary artery bypass surgery.3-8
Incidence
Recent data suggests that in patients found to have significant coronary disease (defined as ≥70% diameter
stenosis) at least one CTO will be found in 52%.9 However, the presence of a CTO has a significant impact on
choice of therapy, with the majority of these patients managed with either medical therapy or referred directly for
coronary artery bypass surgery. In most centres, percutaneous intervention for CTO generally comprises ≈10%
of angioplasty procedures. 
Definition
CTO is commonly defined as a complete occlusion within a coronary artery with TIMI 0 flow, though some
studies have also included lesions with TIMI I flow, so-called ‘functional occlusions’ where late antegrade
opacification of the distal vessel is detected though without a discernible luminal continuity. 
Determining the duration of occlusion can be difficult without angiographic data, and relies somewhat
empirically on the clinical history of onset of angina pain or an episode of prolonged pain which may indicate
vessel occlusion. The definition of what is ‘chronic’ is also variable, many studies have included lesions of more
than 15 days duration, though it is generally accepted that to be truly chronic, lesions are of more than 3 months
duration.
Pathophysiology
CTO’s are thought to either develop after an episode of acute occlusion with plaque rupture and subsequent
thrombosis, or relate to progression of a flow-limiting atherosclerotic stenosis. Histology reveals variable
amounts of atheroma and thrombus that are increasingly replaced by fibrous tissue and calcification (figure 1).10
Neointimal channels of 160-230µm in diameter form and are present in 85% lesions older than 1 year (figure
2).10 There is debate as to whether these channels, which are too small to be visible on angiography, help in
providing a route for a guidewire, or hinder angioplasty success due to connection between the vasa vasorum
and adventitia thus increasing the likelihood of extra-luminal wire passage.
Figure 1: Low power view (hematoxylin-eosin stain)
of a hard or fibrocalcific chronic total occlusion with
extensive calcification (arrow)
Reproduced with permission from Srivatsa SS et al
Histologic correlates of angiographic chronic total
coronary artery occlusions: influence of occlusion
duration on neovascular channel patterns and intimal
plaque composition. J Am Coll Cardiol. 1997;29:955-63.
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Figure 2: A Low power view (hematoxylin-eosin stain) of a chronic total occlusion lumen recanalization by large
central neovascular channels (arrow). B High power view (hematoxylin-eosin stain) demonstrating extensive
small, medium and large intimal plaque neovascular channels (arrow). 
Reproduced with permission from Srivatsa SS et al Histologic correlates of angiographic chronic total coronary artery
occlusions: influence of occlusion duration on neovascular channel patterns and intimal plaque composition. J Am Coll
Cardiol. 1997;29:955-63. 
The Procedure
The limitation of a successful outcome to angioplasty of a CTO is the inability to cross with a wire / balloon.
Adverse predictors of successful recanalisation are documented in the list below, and demonstrated in figures 3
and 4. 
• Age of occlusion > 3 months
• Length of occlusion > 15mm
• Presence of calcification
• An abrupt blunt stump as opposed to one which is tapered
• Presence of a side branch at the site of occlusion
• Tortuosity proximal to the occlusion
• Presence of bridging collaterals
• Multivessel disease
• Occlusion in the circumflex 
In general, the older the occlusion, the more likely it is to be composed of dense fibrous tissue and calcification,
though age alone should not necessarily preclude an attempt to open the artery. 
Figure 3: Chronic total occlusion with features
consistent of a high chance of recanalization
success: short length of 4.2mm, tapered tip (arrow),
and central entry point.
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Figure 4: Chronic total occlusion with features
suggesting it may be difficult to recanalise: long
length of occlusion of 18.6mm with bridging
collaterals, a blunt / abrupt cut-off, and a side-
branch at the site of the stump
The Equipment: choice of guiding catheter 
Whichever artery is involved, good support from the guiding catheter is essential. For the right coronary artery,
a standard Judkins right curve catheter is usually the first choice, though a left Amplatz will provide additional
support and is particularly useful if the proximal part is a “Shepherds crook”. In the left anterior descending
artery, a standard Judkins left catheter can be used though a Voda or Extra Backup provides extra support. For
the circumflex artery, a left Amplatz may be preferable.
Choice of wire 
For non-occlusive stenoses, wires with a floppy tip are used which avoid wall or plaque injury. However in a
CTO, the wire needs to penetrate the proximal cap, which may be fibrous, thus one with a stiffer tip is likely to be
needed. Commonly an intermediate-strength wire is used initially, progressing, for safety reasons, to stiffer wires
in a step-wise fashion. For comparison, it is useful to know the tip load of individual wires. This is defined as the
weight needed to be applied to bend / buckle the tip of the guidewire; for intermediate wires this is ≈3g. Some
manufacturers make specialized stiffer CTO wires with tip loads of >3g (eg the family of Miracle wires from
Asahi-Intecc (Japan) available with tip loads of 3g, 4.5g, 6g, or 12 g).
Hydrophilic wires have a coating, which when wet, makes them extremely slippery. This incurs improved
steerability and trackability, though with the disadvantage of a relative lack of feeling resistance by the operator.
Most of these wires have a very floppy tip, and unfortunately, if the lesion is particularly tough, have a tendency
to “follow the path of least resistance" and take a subintimal route leading to dissection. For CTOs, these wires
are most useful in the presence of some antegrade filling of the distal vessel.
Specialised tapered-tip wires are available which are more able to penetrate dense fibrous tissue.
Examples include the family of Cross-it wires from Guidant which have a tip of 0.010”, and are available in a
range of tip stiffness, and the Confianza / Conquest wire from Asahi-Intecc, Japan which has a very stiff tip that
is 0.009” diameter. The major disadvantage of these wires is the risk of perforation, and they must be advanced
across the lesion with care.
Specialised devices 
The Intraluminal Wire (figures 5 and 6):
This system combines guidance from optical coherence reflectometry, with the power of radiofrequency ablation
to penetrate and cross a CTO. The system emits near infrared light and analysis the backscatter in an A-scan
mode, to determine the position of the wire tip in relation to the vessel wall compared with the true vessel lumen.
It is therefore a truly forward-looking system, and scans a distance of approximately 5mm. The 0.014” wire is
equipped with the capability of radiofrequency ablation with low frequency (250-500 kHz) short duration
(100millisecond) pulses.
22
Figure 5:  The Safe-Cross system display.
When the Intraluminal wire is within the lumen a green band appears on the monitor and the operator can
ablate forwards enabling the wire to advance (a). If the wire is directed outside the vessel, a red band appears
on the monitor and the ability to ablate is disabled (b). Once the wire has been manoeuvred back towards the
lumen, the band is again green and ablation is once again permitted (c)
Only when the wire is within the true lumen, is the operator allowed to ablate the tissue ahead advance the wire;
when the wire is heading extra-luminal the system does not allow ablation. Preliminary experience suggests
that the device facilitates recanalization in an additional 52% of lesions that have been unsuccessful using
conventional means.11 Importantly, use of the device was associated with no procedural major adverse events.
Figure 6: Case example using the Intraluminal™ wire.
Chronic total occlusion at the ostium of the left anterior descending (LAD), thought, on the clinical history, to be
two years old. A: By quantitative coronary angiography it was measured to be 21.7mm in length. B: The distal
LAD is well filled via retrograde collaterals from the right coronary artery (red arrows). These are demonstrated
utilizing a dual injection technique with a diagnostic catheter in the right coronary artery. C/D: The Intraluminal™
wire, which has a 10mm distal radio-opaque tip, successfully ablates a path forwards (yellow arrow). E:
Following successful wire passage, the Intraluminal™ wire was exchanged for a conventional floppy tip wire
using an over-the-wire balloon. The lesion was pre-dilated and then stented with a 3.5 x 28mm stent. F: Final
excellent result.f
A
D E
B
F
C
a                                      b                                     c
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The Frontrunner catheter:
The distal part of this device can be shaped to improve torquability and it has a hydrophilic coating to improve
penetrability. The tip itself is blunt and the ‘jaws’ open allowing controlled blunt dissection and advancement of
the device. Preliminary data has shown the device to be successful in 53% lesions with a history of failure using
conventional wires.12 However, in this study of 50 patients, there was a relatively high rate of vessel perforation
(18%), leading to tamponade in 2 (4%) patients. The rate of coronary perforation did decrease with time and
more experience, but emphasises that care is needed when using this catheter.
Figure 8: Case example using the Frontrunner catheter to open a chronic total occlusion of a long segment of
stented vessel
Technique
It is vital to make a detailed coronary angiogram at the start of the procedure to clearly delineate the site of
occlusion and stump. With a supportive guiding catheter in position, the tip of the guidewire is shaped in the
usual manner with a 30-45˚ angle, though some operators also place a secondary 20-30˚ angle more proximal
to the first. Stiff wires have a risk of traumatising the proximal vessel particularly if this is tortuous; this can be
avoided by advancing such wires via a support catheter or over-the-wire balloon that has been positioned just
proximal to the occlusion. In current practice, wiring technique is to gently rotate the tip (no more than 90˚
clockwise / counter-clockwise) whilst maintaining gentle forward pressure, and aiming the tip towards the distal
vessel lumen. It is important to ensure that the wire tip remains ‘on track’ and it must be visualised in at least
two projections. Though not mandatory, the advantage of using biplane is that co-axial views can be evaluated
simultaneously, otherwise the operator should change projection at frequent intervals. Unfortunately at times,
the “path of least resistance” may lead the wire into the subintima at which point the operator may detect the
feeling of some resistance. The wire may be withdrawn and an alternative path sought.
Particularly when the stump is blunt, progression to a relatively stiffer wire may be necessary to penetrate the
fibrous cap at the proximal edge. Because of the dangers of artery perforation, some operators may then switch
back to a softer wire to traverse the middle part of the occlusion. The distal edge may also be difficult to
penetrate due to fibrous tissue and may again require a stiffer wire. Bridging collaterals are relatively fragile
vessels; when present, wires must be used with extreme caution because of the increased risk dissection or
perforation.
Once the occlusion has been crossed, the operator should have free movement of the tip of the wire, which
advances easily. Confirmation of an intraluminal wire position must be made at least two co-axial projections. It
is particularly important with both the stiff and hydrophilic wires to ensure that once advanced distally, they
remain within the lumen of a large artery and are not at risk of perforating a small branch. After balloon
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dilatation of the occlusion, a standard wire with a safer floppy tip may be advanced through to the distal vessel
and the stiffer wire removed.ffffffffffff
Double injection technique (figure 9):
The presence of collateral filling from the contralateral artery helps to preserve viable myocardium. Such a
lesion is liable to be associated with angina, as there remains an insufficient blood supply to meet the increased
metabolic needs of physical stress. When antegrade flow is not seen beyond the occlusion, simultaneous
injection of contrast into the contralateral artery provides information on the true length of the occlusion and
helps direct safe positioning of the guidewire into the distal vessel. In this situation, it is preferable to obtain a
second arterial access and position a diagnostic catheter (5F or 6F) at the start of the procedure.
Figure 9: Double injection technique to help with guidance of the wire and facilitate recanalization
The RCA is occluded at the ostium (block arrow) with no antegrade flow. Contrast injection is made via a
separate guiding catheter in the left coronary artery ostium to visualise the distal collaterals from the distal LAD
to the RCA (open arrow) and help direct the wire.
Guide catheter support and deep engagement
It is important for guide catheters to have a soft and relatively atraumatic tip. However, the shaft of catheters
from different manufacturers provide differing degrees of “active” backup support – for a CTO, a more
supportive catheter may be an advantage. For this reason, some operators routinely use catheters of 7F or 8F
for CTOs. Alternatively, if the lesion is tough and difficult to cross, additional support can be gained from a less
supportive guiding catheter by deeply engaging it. A 5F guiding catheter can be particularly useful in this
situation, and may even be advanced down the vessel right up to the site of occlusion. In Japan, some 6F
guiding catheters have an inner lumen big enough to accommodate a 5F catheter, through which the procedure
can be attempted. The combination of both (mother-and-child) catheters provides excellent back-up support.
Balloon support
Support catheters or over the wire (OTW) balloons significantly increase the ‘pushability’ (and thereby the
penetration ability) of guidewires. They can be advanced up to the occlusion (using a floppy wire particularly if
there is proximal tortuosity), and used to maintain position whilst allowing change of guidewires. For particularly
tough lesions which cannot be penetrated with a wire, the system can be stabilised to allow the wire to be
pushed with greater penetration force, by inflating a balloon in the proximal vessel. This can either by using a
second wire and a balloon in a side branch, or a balloon within the proximal part of the main vessel. In these
situations, a compliant balloon is used with the same diameter of the vessel, and inflated to nominal pressure.
With the balloon inflated, the wire is advanced in the usual manner.
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Multiple wire techniques
It is common for several wires with different properties to be used to achieve a successful result in opening a
CTO. However, it may also be useful to use several wires at the same time:
• If a wire takes a subintimal course when it is advanced, it is fixed within the false channel (thus
occluding it) and a second wire taken and progressed along a new path (double wire technique).
• If a side-branch originates at the site of occlusion, one wire may be positioned in the branch, sometimes
together with a small balloon, to try to block entry into the branch and deflect the tip of a second wire
towards the occlusion. Occasionally in this situation an IVUS catheter may be placed in such a side
branch and used to image and guide the second wire penetrate and cross the CTO.
The dilation process
Once the lesion is crossed with the wire, most procedures will have a successful outcome with increasing sizes
of balloon utilised until a good calibre lumen is achieved. Very occasionally however, it proves impossible to
cross the lesion with even the smallest low-profile balloon and the best guide catheter support. If this happens,
it can be useful to advance a second wire parallel to the first into the distal lumen. Alternatively, specialized
technologies may be considered eg rotational atherectomy, and laser technology (Spectranetics Corporation,
Colorado Springs). The Tornus device (Asahi Intecc, Japan) is a novel penetration catheter that is a coreless
stainless steel coil consisting of 8 stranded stainless steel wires to cross a severe stenosis by manual rotation.
The learning curve for use of the device is relatively short, and preliminary results are encouraging. It is
currently under evaluation by the regulators for licensed use.
Stenting
Evidence from several randomised studies demonstrated that long-term results are superior with stenting
compared with balloon-only angioplasty. However, the long-term results following bare metal stent implantation
suggested a relatively high rate of restenosis of 32-55%. 13-17 However, recent excellent results have been
demonstrated following implantation of drug-eluting stents, with restenosis rates for the sirolimus- and
paclitaxel-eluting stents of 9% and 8% respectively. 18,19
Complications
Intervention in CTO’s is subject to the same complications as intervention in non-occlusive stenoses, with
reported rates of serious complication (death, or myocardial infarction) in 1-2%. There are, however, several
complications more specific to the treatment of CTO’s:
• Impairment of collateral flow may occur through several mechanisms including distal embolisation of
debris or extension of wire-induced dissection. This may be associated with a rise in cardiac enzymes
consistent with myocardial infarction.
• Passage of the wire may be associated with varying degrees of dissection and / or perforation of the
artery (figure 10) which may lead to pericardial tamponade.
Figure 10: Wire exit has caused this appearance of
extraluminal contrast staining. The procedure was
stopped; the patient remained asymptomatic with
no clinical sequelae.
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Abstract
Background: Chronic total occlusions are commonly found on diagnostic angiography, and
there is some evidence from one study that successful percutaneous revascularization leads
to an improvement in long-term survival rates. However, this study included patients treated
for unstable angina with short-duration occlusion, and stent implantation was utilized in only
7%. We re-evaluated the long-term outcomes of a large consecutive series of patients with a
CTO of >1 months’ duration treated at our centre, with stent implantation utilized in the
majority.
Methods: All patients treated with PCI between 1992 and 2002 were retrospectively
identified from a dedicated database. A total of 874 consecutive patients were treated for 885
CTO lesions. Mean follow-up time was 4.47 ± 2.69 years (median 4.10 years). Patients were
evaluated for the occurrence of major adverse events (MACE) comprising death, acute
myocardial infarction, and need for repeat revascularization with either CABG or
percutaneous coronary intervention (PCI).
Results: Successful revascularization was achieved in 576 lesions (65.1%), in which, stent
implantation was used in 81.0%. At 30 days, the overall MACE rate was significantly lower in
those patients with a successful recanalization (5.5% versus 14.8%, p<0.00001). At 5 years,
patient survival was significantly higher in those with successful revascularization (93.5%
versus 88.0%, p=0.02). In addition, there was a significantly higher survival-free of MACE
(63.7% versus 41.7%, p<0.0001), with the majority of events reflecting the need for repeat
intervention. Independent predictors for survival were successful revascularization, lower
age, and the absence of diabetes mellitus and multivessel disease.
Conclusions: Successful percutaneous revascularization of a CTO leads to a significantly
improved survival rate, and a reduction in major adverse events at 5 years. Most events
relate to the need for repeat re-intervention, and the introduction of drug-eluting stents, with
low restenosis rates, encourages the development of technologies to improve recanalization
success rates. However, failed recanalization may be associated acutely with an adverse
event, and new technologies must focus on a safe approach to successful recanalization.
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Introduction
At least one chronic total occlusion (CTO) is found on approximately one-third patients found to have significant
coronary disease on angiography. 1 Yet data suggest that percutaneous coronary intervention (PCI) for a CTO
accounts for approximately only 10-15% of angioplasty procedures, with the majority of patients treated with
either coronary artery bypass surgery (CABG) or medical therapy. Compared with non-occlusive lesions, PCI
for a CTO is associated with lower procedural success rates predominantly related to the inability to cross the
lesion. However, technical advances in the design of angioplasty equipment, particularly of specialized wires,
have improved recanalization rates. The choice of therapy for patients with a CTO (PCI versus CABG versus
medical therapy) is dependant on local policies, and outcomes of revascularization are dependent on operator
experience. In the current study, we analysed the trends in revascularization and the treatment of CTOs at the
Thoraxcenter, Rotterdam between 1992 and 2002.
In addition, the long-term outcomes of patients with PCI for a CTO were analysed. Previously, a large
single centre series of more than 2000 patients importantly demonstrated that successful percutaneous
revascularization of a CTO confers a significant 10-year survival rate compared with failed revascularization. 2
This study, analysed patients treated between 1980 and December 1999 in the Mid-America Heart Institute,
and included all patients treated for an occluded vessel provided they had not had a myocardial infarction within
the preceding 7 days. Therefore, those with relatively recent thrombotic occlusions and unstable angina were
included. Indeed, one of the multivariable predictors for long-term mortality was percutaneous intervention
undertaken in patients with unstable angina. In addition, only 7% patients with successful revascularization
were treated with stent implantation. Long-term outcomes of CTOs have been improved since the widespread
introduction of stent utilization, which is associated with reduced rates of restenosis and re-occlusion compared
with balloon-only angioplasty. 3-6 In the current study, we analysed whether the benefits demonstrated in the
MAHI study are applicable to PCI carried out in chronic occlusions in another tertiary centre. In our study,
chronic total occlusion was more strictly defined, those with occlusion related to unstable angina and recent (<1
month) occlusion were excluded, and in addition, stent implantation was used in the majority.
Methods
Demographic and procedural data regarding all patients undergoing PCI at our centre are prospectively entered
into a dedicated database. All procedures undertaken for an occluded vessel between 1st January 1992 and 31st
December 2002 were retrospectively identified (n=2131). Those treated in the setting of acute myocardial
infarction (AMI), and recent (<1 month) occlusion were excluded, leaving a total of 874 consecutive patients
treated for CTO.
Chronic total occlusion was defined as a lesion exhibiting Thrombolysis In Myocardial Infarction flow
grade 0-1. All patients included had at least one occlusion within a native vessel; occlusions within saphenous
vein grafts were excluded. Duration of occlusion was estimated to be at least 1 month, on the basis of either a
history of sudden chest pain, a previous AMI in the same target vessel territory, or the time between the
diagnosis made on coronary angiography and PCI. Procedures were undertaken using standard techniques of
the time. All patients were treated with heparin to maintain an ACT>250 seconds, and all were on long-term
aspirin therapy. For those treated with stent implantation prior to 1996, additional anticoagulation was provided
with the use of warfarin given for 1 month. Subsequent to that time, a thienopyridine was used (ticlopidine or
clopidogrel). Procedural success was defined as successful recanalization and dilatation of the vessel with or
without stent implantation, with a final residual diameter stenosis <50%.
Median follow-up time was 4.48 years (quartiles 2.72, 6.64 years). All patients were assessed for the
occurrence of major adverse cardiac events (MACE) comprising death, non-fatal AMI, and repeat
revascularization (PCI and / or CABG). Long-term survival status was assessed by written inquires to the
Municipal Civil Registries. Follow-up clinical data were determined from electronic hospital archives and by
questionnaires sent to all living patients. The referring physician and institutions as well as the general
practitioners were directly approached whenever necessary. Complete 30-day clinical follow-up was obtained in
all patients, with complete long-term follow-up data obtained in 99% patients up until 1st April 2004. The
diagnosis of AMI required an elevation of creatine kinase to twice the upper limit of normal, together with a rise
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in creatine kinase-MB fraction. If made following patient admission to another hospital, the diagnosis of AMI was
confirmed through direct contact with the referring physician, using the same criteria.
Statistics: Discrete variables are presented as percentages and compared with Fisher exact test. Continuous
variables are expressed as mean ± standard deviation and compared with Student’s t test. Cumulative survival-
free of major adverse events were calculated according to the Kaplan-Meier method. The log-rank test was
used to compare event-free survival between the groups. Multivariable analyses were performed using
backward and forward stepwise Cox regression. Baseline characteristics were included if they were (i)
associated with high incidence of cardiac events (p<0.1), or (ii) known risk factors from literature. Pre-selected
variables were: age, gender, diabetes mellitus, hypertension, hypercholesterolaemia, presence of multivessel
disease, impaired left ventricular function, prior AMI, prior PCI, prior CABG, use of a glycoprotein IIb/IIIa
inhibitor, target vessel, successful procedure, and use of a stent. The proportional hazard assumptions were
investigated by testing the constancy over time of the log hazard ratio for each model. In addition, the
proportional hazard assumption for all covariates was tested using Schoefeld residuals. According to these
tests, the proportional hazard assumption was not validated. Linearity was checked graphically and by inclusion
continuous variables both as such according to quintiles. Absence effect of the grouped variable indicates that
the effect is linear. Also assumptions of linearity were assessed and satisfied using a general linear model
(GLM) univariate method. No deviation from linearity was found in any continuous variable. To investigate
interaction, an interaction model was performed using a likelihood ratio test in the multivariable Cox. Interaction
was performed on all selected variables. However, no interaction was found. Odds ratio with corresponding
95% confidence intervals are reported. All tests were two-tailed; due to the large number of statistical tests, p-
values should be interpreted with caution. While no specific level of significance is defined, a p-value of 0.01
should be considered for strong evidence in support of a true effect.
Table 1: Baseline patient demographics and target vessel site with respect to a successful versus an
unsuccessful chronic total occlusion revascularization procedure
CTO success
n=567
CTO failure
n=304
p value
Age (years) 59.6 ± 10.8 60.5 ± 10.4 0.2
Male sex (%) 73.6 72.2 1.0
Diabetes mellitus (%) 12.0 9.1 0.2
Hypertension (%) 20.3 21.0 0.7
Hypercholesterolaemia (%) 48.6 43.3 0.2
Family history of coronary disease (%) 21.9 18.8 0.3
Impaired LV function (%) 32.5 38.1 0.5
Previous myocardial infarction (%) 55.7 49.2 0.2
Previous PCI (%) 24.3 23.0 0.9
Previous CABG (%) 8.7 10.4 0.4
Vessel disease 0.03
Single-vessel (%) 46.0 32.6
2 vessel (%) 36.2 40.5
3 vessel (%) 17.8 27.0
Number of lesions 573 306
Target vessel of the lesion 0.8
RCA (%) 42.2 52.6
LAD (%) 33.2 26.5
LCX (%) 24.4 20.6
LMS (%) 0.2 0.3
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Results
Between 1st January 1992 and 31st December 2002, a total of 874 patients underwent PCI for at least one CTO.
Of these, 11 had attempted revascularization of 2 CTO’s, making a total of 885 attempted lesions. Overall,
successful revascularization was achieved in 576 lesions (65.1%), with failure in the remaining 309 (34.9%). Of
the 11 patients with attempted therapy of 2 CTOs, PCI outcome was the same in both lesions in 8 patients. The
remaining 3 patients with both one success and one unsuccessful PCI have been excluded from further
analysis. The baseline demographics for the remaining patients are presented in table 1.
There were no significant differences in characteristics, though a trend towards an increase in 2- and 3-
vessel disease in those in whom PCI for occlusion was unsuccessful. Over time, the proportion of patients with
coronary disease who underwent revascularization with PCI as opposed to CABG surgery, increased with time
(figure 1). Similarly, there was a trend to an increased proportion of PCI for CTO (figure 2). Percutaneous CTO
therapy was undertaken utilizing the contemporary techniques of the time including specialized hydrophilic,
tapered tip, and stiff wires when available, with the laser wire used in 72 (8.1%). However, despite the
introduction of more specialised technologies, the success rate of recanalization did not improve (figure 2).
Following successful recanalization, the overall use of stent implantation was 81.0%, with stent utilization
increasing with time (figure 3).
Figure 1: Trends in the number of revascularization procedures with percutaneous coronary intervention (PCI)
versus coronary artery bypass surgery (CABG) at the Thoraxcenter.
Figure 2: Trends in the increase in the proportion of percutaneous intervention (PCI) for a chronic total
occlusion (CTO), and success rates for PCI for CTO with respect to year of intervention.
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Figure 3: Utilization of stent implantation following successful recanalization of a chronic total occlusion with
respect to the year of intervention.
The 30-day MACE rates are presented in table 2. In addition, this table demonstrates the events directly related
to the procedure and occurring within the first 48 hours. A failed recanalization procedure was associated with a
significantly higher rate of MACE in the immediate period following the procedure.
Table 2: Incidence of major adverse cardiac events at 2 and 30 days
CTO success
n=567
CTO failure
n=304
p value
2 days 2 (0.4) 3 (1.0) 0.2Death, n (%)
30 days 4 (0.7) 6 (2.0) 0.09
2 days 3 (0.5) 5 (1.6) 0.1Death or acute myocardial infarction, n (%)
30 days 7 (1.2) 7 (2.3) 0.2
2 days 7 (1.2) 13 (4.3) 0.004Death or CABG, n (%)
30 days 10 (1.8) 30 (9.9) <0.00001
2 days 14 (2.5) 17 (5.6) 0.02MACE, n (%)
30 days 31 (5.5) 45 (14.8) <0.00001
In the long-term, all outcomes were significantly worse following a failed attempt at revascularization. The 5-
year survival was significantly lower than when revascularization was successful (figure 4), and the survival-free
of AMI, CABG, and MACE were also significantly lower (figures 5-7). By multivariable analysis, the independent
predictors for survival and MACE following PCI for CTO are presented in table 3. The presence of multivessel
disease was an independent predictor for both survival and MACE. The cumulative survival-free of MACE with
respect to the presence of single versus multivessel coronary disease is shown in table 4.
Table 3: Independent predictors of death and major adverse cardiac events (MACE) after attempted
percutaneous coronary intervention of a chronic total occlusion
Hazard ratio 95% confidence intervals p value
Death
Successful revascularization 0.58 0.34 – 0.98 0.04
Age 1.04 1.02 – 1.07 0.002
Diabetes mellitus 2.49 1.33 – 4.66 0.005
Multivessel disease 4.29 1.93 – 9.55 <0.001
Major adverse cardiac events
Successful revascularization 0.55 0.44 – 0.70 <0.001
Multivessel disease 1.43 1.14 – 1.79 0.002
Use of a stent 0.69 0.54 – 0.88 0.002
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Figure 4: Cumulative survival at 5 years with
respect to the outcome of attempted recanalization
of a chronic total occlusion.
Figure 6: Cumulative survival-free of coronary
artery bypass surgery (CABG) at 5 years with
respect to the outcome of attempted recanalization
of a chronic total occlusion.
Figure 5: Cumulative survival-free of acute
myocardial infarction (AMI) at 5 years with respect
to the outcome of attempted recanalization of a
chronic total occlusion.
Figure 7: Cumulative survival-free of major adverse
cardiac events (death, acute myocardial infarction, or
repeat reintervention (percutaneous or bypass
surgery)) at 5 years with respect to the outcome of
attempted recanalization of a chronic total occlusion.
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Table 4: Cumulative survival-free of major adverse cardiac events at 5 years with respect to the presence of
single versus multivessel coronary disease
 Single vessel Multivessel
CTO success
n=261
CTO failure
n=99
p value CTO success
n=306
CTO failure
n=205
p value
Death (%) 97.3 99.0 0.3 92.5 86.3 0.02
Death / AMI (%) 94.6 96.0 0.6 88.6 82.0 0.03
Death / CABG (%) 91.6 70.7
<0.000
1
86.9 61.5
<0.000
1
MACE (%) 72.0 47.5
<0.000
1
61.1 42.9
<0.000
1
Figure 8: Cumulative survival at 5 years with respect to diabetic status
Figure 9: Cumulative survival-free of major adverse cardiac events (death, acute myocardial infarction, or
repeat reintervention (percutaneous or bypass surgery)) at 5 years with respect to diabetic status, and the
outcome of attempted recanalization of a chronic total occlusion
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Overall survival was significantly lower in those patients with diabetes mellitus (figure 8). Within the diabetic
population, 5-year survival was 84.9% in those with a successful recanalization versus 79.1% following
unsuccessful recanalization (p=0.4), suggesting that most of the benefit in terms of survival following successful
recanalization is in the non-diabetic group. However, the beneficial effect of successful recanalization of a CTO
on survival-free of MACE remains clearly apparent (figure 9), irrespective of diabetic status. Successful
recanalization led to a 5 year MACE-free survival of 63.7% and 62.3% in those with and without diabetes
mellitus respectively. Following unsuccessful recanalization, the 5 year MACE-free survival was 42.0% and
41.5% for those with and without diabetes mellitus respectively, p<0.0001.
Discussion
The present study evaluated only consecutive patients with chronic total occlusions (CTO) of at least one
months’ duration, and for the first time confirms a 5-year survival benefit in successful recanalization of these
lesions. In addition, there was a significant reduction in major adverse cardiac events, particularly the need for
revascularization with CABG. Independent predictors of survival were a successful recanalization, lower age,
and the absence of diabetes mellitus and multivessel disease. Independent predictors of major adverse events
were an unsuccessful recanalization, multivessel disease, and non-usage of stent implantation.
Although one large series of the long-term outcomes of patients following PCI for CTO has been
published, the authors acknowledged that their study was limited as they did not always know the duration of
occlusion. 2 Indeed, analysis of 100 consecutive patients who had been included in the study demonstrated that
42% were <1 months’ duration. These patients are likely to have thrombotic occlusions, rather than the fibrotic /
calcific lesion of a CTO. This difference in lesion pathophysiology may affect the long-term outcome, indeed one
of the independent predictors for survival in the MAHI study, was therapy for unstable angina. In the present
study, we have confirmed that a successful outcome following PCI for a truly chronic occlusion does confer a
significant benefit on survival, and reduces the rate of MACE with a marked reduction in the need for CABG.
The difference in the rate of MACE between those with a successful versus unsuccessful recanalization
was apparent immediately (at 48 hours), predominantly related to the need for emergency CABG in the failed
recanalization group. An acute complication of CTO recanalization therefore confers serious adverse
consequences in the short-term, which would have been potentially avoided if an alternative treatment option
had been undertaken. It is particularly important to note that the mortality rate of those with a failed procedure
was not insignificant at 1.9% at 30 days.
The present study demonstrated a 5-year survival benefit following successful CTO recanalization. The
possible reasons for the improved survival are beyond the scope of the present study.  There were differences
in the medical therapy received by the 2 groups which could potentially be a confounding factor. Unlike those
with a failed recanalization, the group with a successful recanalization together with stent implantation were
treated with additional medical therapy with warfarin, ticlopidine, or clopidogrel. However, this was given for only
1 month, and it is unlikely that such a short duration of therapy is the reason for the improved long-term
outcomes. More likely, improved survival may relate to the greater proportion of viable but inadequately
perfused myocardium. The improvement in prognosis following successful revascularisation might relate to the
associated improvement in left ventricular function, 7 or a reduction in the risk of ischaemic-driven malignant
arrhythmia. In addition, a successful procedure could potentially avoid the need for CABG with its’ associated
mortality risk.
In the present study, the survival benefit of successful CTO recanalization was most apparent in those
with multivessel rather than single vessel disease. Indeed, the patients with single vessel disease and failed
recanalization had a very high rate of survival at 5-years of 98.9%. Approximately half of these patients
underwent CABG or repeat re-intervention with PCI, with a survival-free of MACE at 5 years of 45.8%. The
remaining patients were treated with medical therapy alone, and although this constitutes only a relatively small
number of patients, the excellent survival rate suggests that from a prognostic point of view medical therapy
may not be unreasonable. Little data is currently available on the outcomes of patients with a CTO who are
managed with optimal medical therapy (aspirin, beta-blocker, statin, ACE-inhibitor etc). In particular, those with
an excellent collateral circulation may have a very good prognosis. Our manuscript does not therefore provide
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scientific proof to support a broad generalized recommendation to try to open all CTOs; a randomised study
comparing “best” medical therapy with a more aggressive strategy of attempted recanalization would be
required to assess this. Importantly, studies are needed with more detailed assessment of left ventricular
function, degree of viability, and ischaemic burden both pre-procedure and at follow-up, to determine the
relationship these have with long-term survival.
The Thoraxcenter in Rotterdam is a tertiary referral centre for PCI, taking referrals from 13 surrounding
hospitals covering a large region. The majority of patients requiring repeat re-intervention, whether it be
percutaneous or surgical, come back to be re-treated in our centre. As in other centres, the number of
percutaneous revascularizations increased over time, whilst that of CABG gradually decreased. In addition, the
relative number of PCI procedures carried out for a chronic occlusion also increased with time. However, the
overall success rate of recanalization remained stable despite advances in the technology of specialised wires
and other equipment. The chances of successful recanalization are known to be dependent on lesion
morphology and it is possible that with time and the increase in PCI for CTO, relatively more complex lesions
were attempted.
It is well recognised from large scale studies that mortality is higher following percutaneous coronary
intervention procedures in those with diabetes compared to those without diabetes mellitus. 8,9 Our study
concurs with these results, with a significantly lower 5 year survival in diabetics (83.6% versus 92.7%, p=0.001).
However, the beneficial effect of successful recanalization of a CTO on overall survival-free of major adverse
events was clearly apparent to be irrespective of diabetic status (figure 9).
Of those patients with a successful revascularization, the majority of subsequent adverse events relate
to a need for repeat reintervention. Long-term results have been shown to improve with the advent of stent
implantation, with reduced rates of restenosis and re-occlusion when compared with results of balloon-only
angioplasty. However, the recent introduction of drug-eluting stents will further improve on these results. Data
from our own centre have shown a significant higher cumulative survival-free of major adverse cardiac events at
1 year with the sirolimus-eluting stent compared with bare metal stent implantation (96.4% versus 82.8%,
p<0.05). 10 These results encourage the development of further technologies to facilitate safe and successful
CTO recanalization.
Limitations:
The present study is limited by being a retrospective observational analysis of outcomes. However, it is
comprised of a large cohort of patients with complete clinical follow-up obtained in virtually all. The study is
further limited by the lack of randomised comparison with a group of patients treated with medical therapy
alone, or those treated directly with CABG. In addition, the possible reasons for improved survival in the
successful recanalization group have not been fully explored and require further study.
Conclusions:
Successful percutaneous revascularization of a CTO leads to a significantly improved survival rate, and a
reduction in major adverse events at 5 years. Most events relate to the need for repeat re-intervention, and the
introduction of drug-eluting stents, with reduced restenosis rates, encourages the development of further
technologies to improve recanalization success rates. However, failed recanalization may be associated acutely
with a major adverse event, and new technologies must focus on a safe approach to successful recanalization.
Additional studies are needed to evaluate the comparative prognostic value of CTO recanalization compared
with optimal medical therapy, particularly in patients with single vessel disease.
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Abstract
Background: Intracoronary brachytherapy (IRT) has been associated with the development
of late vessel occlusion.
Objectives: To assess the incidence, predictors and prognosis of coronary occlusion in a
consecutive series of patients following beta-radiation therapy
Methods: Between April 1997 and December 2001, 301 consecutive patients were
successfully treated with IRT, and 37 patients (12.3%) were subsequently found to have an
occlusion of the treated vessel and form the present study population. Patient and procedural
data were retrospectively analysed from a dedicated database.
Results: One patient had subacute thrombosis on day 21, and over a mean follow-up of 40.3
months, target lesion occlusion was found in a further 36 patients at a mean time after IRT of
16.0 months (range 3.4-66.8 months). In 12 patients (32.4%), vessel closure caused an
acute myocardial infarction, and was associated with 3 (8.1%) cardiac-related deaths. At 4
years, the cumulative survival-free of target lesion closure was 85.4%.
By multivariate analysis, the factor predictive for development of occlusion was
treatment of a de novo lesion rather than in-stent restenosis (15.4% versus 7.9%, p=0.03
(HR=2, 95% CI: (1.1-5)). Occlusion was not related to the dosage administered, the source
length, the duration of dual anti-platelet agents, or the “learning curve” of therapy.
Conclusions: A high incidence of late vessel occlusion is observed after IRT. Prolongation
of dual anti-platelet therapy to 6 months duration is insufficient to protect against the
development of occlusion, which is associated with significant morbidity.
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Abstract
We performed multislice computed tomographic coronary angiography in 45 patients who
had chronic total occlusions and were scheduled for percutaneous recanalization.
Multivariate analysis identified a blunt stump (by conventional angiography), occlusion length
>15 mm, and severe calcification (by multislice computed tomographic coronary
angiography) as independent predictors of procedural failure.
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Sixteen-row multislice spiral computed tomographic (MSCT) coronary angiography has recently been shown to
allow reliable noninvasive evaluation of coronary morphology.1-3 In the present study, we analyzed the potential
of preprocedural MSCT coronary angiography to provide additional information and thus predict the procedural
outcome in patients who had chronic total occlusion (CTO) and were referred for percutaneous coronary
recanalization.
Forty-five patients referred for percutaneous recanalization of ≥1 CTO lesion underwent MSCT coronary
angiography before the coronary procedure (median interval 29 days, interquartile range 9 to 53). The diagnosis
of CTO was made on diagnostic angiograms that demonstrated complete occlusion of a major epicardial
coronary artery, which was deemed to be of ≥3 months' duration from the date from the previous angiogram, a
clinical history of myocardial infarction, or onset of or a severe episode of prolonged anginal chest pain. In
addition, inclusion into the study required a serum creatinine level <120 mmol/L, presence of sinus rhythm, and
the ability to hold a breath for 20 seconds. The protocol was approved by the institutional review board, and all
patients gave written informed consent.
Conventional angiographic assessment was performed by observers who were unaware of the results of MSCT
scans. Parameters previously reported to have prognostic importance for procedural failure were assessed:
absence of anterograde flow through bridging collaterals, absence of a tapered stump, presence of severe
calcification at the occluded segment, side branch at the occlusion site, and tortuosity of the vessel proximal to
the occlusion (defined as an angle >45° in any projection). Where possible, occlusion length was measured
from the view with the longest lesion on quantitative coronary angiography as the distance between a stump
and a distal vessel as visualized by anterograde filling through bridging collaterals. In addition, in some other
patients, length was determined from the baseline angioplastic procedure film using a bilateral coronary
injection.
Twenty-two patients who had a heart rate >65 beats/min before multislice spiral computed tomography received
an oral dose of 100 mg of metoprolol 1 hour before scanning. All examinations were performed with a 16-row
MSCT scanner (Sensation 16, Siemens, Forehheim, Germany; collimation 16 × 0.75 mm, rotation time 420 ms,
table feed 3.0 mm/rotation, tube voltage 120 kV, tube current 400 to 450 mA). After intravenous administration
of 120 ml of nonionic contrast material (Visipaque 320, Amersham Health, Little Chalfont, United Kingdom), an
automatic bolus-tracking technique triggered the start of MSCT scanning. Images were reconstructed with
retrospective electrocardiographic gating during the mid- to end-diastolic phase to provide nearly motion-free
image quality; additional reconstruction windows (e.g., early diastolic phase) were explored when necessary.
All MSCT scans were analyzed off-line by operators who were blinded to angiographic and procedural data.
Parameters similar to those of conventional angiography were evaluated: a blunt rather than tapered stump,
severe calcification, side branch at the occlusion site, proximal tortuosity, and occlusion length. Severe
calcification was defined as the presence of high-density plaques (≥130 HU) involving >50% of the coronary
wall on a cross-sectional image and localized within the occlusion stump or occluded segment.
All procedures were performed by operators who were highly experienced in the treatment of CTOs, with the
interventional strategy left to the discretion of the operator. Wires were used in a stepwise progression, starting
with a wire that had a relatively less traumatic tip (Graphix Intermediate, Boston Scientific Corporation, Miami,
Florida) or a hydrophilic wire (Choice PT Plus, Boston Scientific Corporation, or Crosswire NT Terumo
Corporation, Tokyo, Japan) and progressing to stiffer wires (Miracle, Asahi Intec, Nagoya, Japan) and
specialized technologies (Safe-Cross, Intraluminal Therapeutics, Carlsbad, New Mexico).4,5 Procedural failure
was defined as an inability to cross the occlusion with a guidewire.
Multivariate logistic regression analyses were performed to identify angiographic and MSCT parameters
associated with procedural failure (all univariate predictors with a p value ≤0.1 were tested for their multivariate
predictive value, and final models were built by backward stepwise selection). Angiographic parameters
assessed were those identified in previous studies: 6 the occluded artery, duration of occlusion, multivessel
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disease, anterograde and retrograde collateral filling, type of stump, side branch at the site of occlusion, calcific
deposits, vessel tortuosity, and occlusion length >15 mm. The predictive strengths of the models were
evaluated by means of the −2 log-likelihood statistic, and models' lack of fit with the Hosmer-Lemeshow test,
and their global predictive accuracy were assessed by the C index (area under the receiver-operating
characteristic curve).
Patients' mean age ± SD was 57.0 ± 10.1 years, 40 (89%) were men, 10 (22%) were diabetic, and 14 (31%)
had multivessel disease. Forty-seven CTO lesions were treated. Angiographic measurement of CTO length was
possible in 39 lesions (83%), 31 (66%) from the diagnostic film and an additional 8 (17%) from bilateral injection
and assessment of retrograde collateral filling. The mean length of occlusion was longer by MSCT coronary
angiography than by angiography (21.8 ± 18.6 vs 14.6 ± 10.9 mm, respectively). Procedural data, including type
and number of guidewires used, are presented in Table 1. The only difference between success and failure was
in the increased use of the Miracle wire in the failure group. Overall mean procedural time was 148 ± 53
minutes, with a mean fluoroscopic time of 47 ± 24 minutes. Overall, 45% of interventional procedures failed
(Table 2). Success versus failure was not dependent on the operator or choice of interventional strategy. At
univariate analysis, the following were associated with procedural failure: clinical assessment (occlusion
duration ≥9 months), angiographic assessment (lack of anterograde collateral filling, a blunt rather than a
tapered stump, and side branch at the occlusion site), and MSCT coronary angiographic assessment (a blunt
rather than a tapered stump, severe calcification, and occlusion length >15 mm; Table 2).
Table 1: Procedural Duration and Use of Contrast Material and Guidewires for Percutaneous Intervention of a
CTO With Respect to Successful Versus Unsuccessful Recanalization
Success
(n = 26 lesions)
Failure
(n = 21 lesions)
p value
Mean total procedural time (min) 148 ± 61 148 ± 44 1.0
Mean volume of contrast used (ml) 451 ± 258 453 ± 265 1.0
Mean no. of wires 2.0 ± 1.2 2.1 ± 0.8 0.9
Wire type*
Graphix Intermediate 20 (76.9%) 12 (57.1%) 0.2
Choice PT Plus 5 (19.2%) 3 (14.3%) 0.8
Crosswire NT 8 (30.8%) 10 (47.6%) 0.3
Miracle 5 (19.2%) 12 (57.1%) <0.01
Intraluminal 3 (11.5%) 4 (19.0%) 0.5
Over-the-wire balloon support 15 (57.7%) 17 (81.0%) 0.1
* Wire type not mutually exclusive.
When analyzed separately, the following “traditional” clinical and angiographic characteristics were identified as
multivariate predictors of procedural failure: occlusion duration >9 months and stump morphology (Table 3).
Separate multivariate analysis that assessed only MSCT coronary angiographic parameters identified the
following predictors: occlusion length >15 mm, severe calcification, and stump morphology. Final best model
testing for pooled clinical, angiographic, and MSCT parameters identified a blunt rather than a tapered stump
(by angiography), occlusion length >15 mm (by MSCT coronary angiography), and severe calcification (by
MSCT coronary angiography) as multivariate independent predictors of procedural failure (Figure 1).
The current selection process of technically appropriate candidates for percutaneous recanalization of CTO is
based on the evaluation of a relatively restricted number of clinical and angiographic characteristics. In this
study, we show that noninvasive evaluation of patients who have CTO by preprocedural MSCT coronary
angiography improves the ability to predict the outcome of a percutaneous recanalization attempt. Our findings
indicate that MSCT coronary angiography may aid in the therapeutic decision making for patients who have
CTO. In addition, accurate preprocedural characterization of CTO features may assist in outlining the
therapeutic interventional strategy.
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MSCT coronary angiography of CTOs adds important information compared with “conventional” coronary
angiography. The length of the occluded segment has long been identified as an important predictor of failed
recanalization. However, accurate measurement of lesion length using conventional angiography may be
difficult, mainly due to foreshortening, calibration limitations, and lack of visualization of the distal vessel in the
absence of collateral filling. In the present study, lesion length could be measured in only 66% of diagnostic
films. Conversely, MSCT coronary angiography allowed reliable 3-dimensional length measurement of coronary
segments.7 In the present series, when angiographic and MSCT coronary angiographic occlusion lengths were
measured, results of the MSCT coronary angiography were “longer,” perhaps reflecting the inaccuracy of
quantitative coronary angiography as previously described. Moreover, MSCT coronary angiography allows
evaluation of the morphology of the occlusion trajectory, including detailed delineation of coronary calcification.
Long occlusions and severe calcifications on MSCT coronary angiograms were found to be important
predictors of procedural failure, whereas neither feature was identified as an independent predictor on
conventional angiograms.
The need to use contrast material may pose a limitation to preprocedural MSCT coronary angiography for
interventions scheduled to be performed shortly after scanning. However, the elective nature of CTO
recanalization angioplasty allows a safe time lag between these procedures. In our study, multislice computed
tomography was performed 1 month before coronary intervention. The relatively high radiation exposure
during MSCT coronary angiography, reportedly between 6.7 and 13.0 mSv,8-10 remains a matter of concern.
However, MSCT coronary angiography may optimize therapeutic strategy (e.g., calcifications may require
intraluminal techniques), resulting in shorter procedures. MSCT coronary angiography is currently feasible for
selected patients, and further studies are needed to evaluate its value in a more general patient population.
Figure 1: (A, inset) CTO of the left anterior descending coronary artery with favorable invasive angiographic
CTO characteristics, tapered stump, absence of calcifications, and occlusion length <15 mm (arrowheads) in a
patient who had been referred for percutaneous recanalization. Volume-rendered MSCT image that provides a
3-dimensional overview of the coronary arteries, and (B) maximum intensity projection of the same MSCT
image show a severely calcified occlusion stump (arrows). (C) Curved multiplanar reconstructed MSCT image
of the left anterior descending coronary artery shows a severely calcified stump (arrow) and an occluded
segment (arrowheads). Collateral filling is clearly visible distal to the occlusion. This percutaneous attempt at
recanalization of the CTO was unsuccessful.
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Abstract:
Successful percutaneous therapy of chronic total occlusions is limited predominantly by the
inability to cross the lesion. We report our experience of 29 chronic total occlusions (CTO)
that could not be crossed with conventional wires and subsequently underwent attempted
recanalization facilitated using a wire navigated with optical coherence reflectometry. Mean
length of occlusion was 22.1mm (range 4.5-88.7mm). Successful recanalization was
achieved in a further 15 (51.7%), with no complications of tamponade, myocardial infarction
or death. These results demonstrate that this wire can be a useful tool in addition to
conventional wires in the treatment of chronic total occlusions.
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Introduction:
Chronic total occlusions (CTO) are common and continue to present a challenge to the Interventional
Cardiologist. In patients undergoing angiography who are found to have significant coronary disease, at least
one CTO will be found in approximately one third.1 Yet most of these patients are currently treated with either
medical therapy or are referred for bypass surgery with percutaneous intervention of a CTO accounting for
approximately only 10% of all angioplasties. The major limitation of percutaneous intervention is the inability to
cross the occlusion with a wire. Success rates in CTO`s vary, and are dependant on both patient selection and
operator experience; even in those patients selected to be suitable for percutaneous therapy, success rates are
between 40 and 80%.2,3
The Safe-Cross system (Intraluminal Therapeutics, Carlsbad, CA):
This is comprised of the IntraluminalTM guidewire which is plugged directly into a console. 4 The wire itself is
0.014” in diameter and notably has a blunt tip (figure 1A); the distal 10mm is seen as opaque on fluoroscopy.
The system uses optical coherence reflectometry to enable accurate guidance of the wire and a reduced risk of
wire perforation. Near-infrared light is emitted from the tip of the 0.014” IntraluminalTM guidewire (figure 1B) and
the system then measures the reflectivity of the beam. Near-infrared light is used because it has a much
shorter wavelength (1.3microns) compared to the sound waves used in conventional ultrasonography
(100microns). This confers several advantages: firstly, light is less strongly reflected by calcified tissues so that
information can still be gathered even from behind calcified plaque. In addition, it enables the system to be
`forward looking` with a very high resolution of up to 15 microns. Different tissue types such as plaque and
intima can be accurately differentiated on the basis of variable absorption rates and scattering coefficients. 4,5
In addition to this, the current IntraluminalTM Guidewire has the capability of radiofrequency ablation
with short duration bursts (100 millisecond pulses) of low frequency energy (250-500 kHz) delivered at the tip to
enhance forward wire passage.5 Histological examination has shown that the associated collateral damage
around the ablated hole is contained, and lies within a 75-100 micron zone. When the tip detects lumen or
plaque, the systems` monitor demonstrates a green bar (figure 2) and radiofrequency ablation is enabled.
However, when the tip is too close to the vessel wall, a red bar is demonstrated on the system monitor, ablation
is disabled, and the operator is alerted with an audible sound. The operator then gently rotates the wire until the
green bar returns to confirm the tip is heading in a proper direction, and the wire may then be advanced.
 Previous reports have shown the efficacy of this wire in the therapy of long occlusive in-stent
restenosis. 6 We present our results utilising this wire in a consecutive series of patients with at least one
chronic total occlusion who had had failed recanalization using conventional wire techniques.
Figure 1: A close-up view of the 0.014” IntraluminalTM Guidewire. The tip is relatively blunt (A), and emits a
beam of near-infrared light which can be seen (arrow B).
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Figure 2: The display seen on the monitor derived from the optical coherence reflectometry waveform from the
wire tip.
A: When the wire tip is within the vessel lumen, the display features a green bar, and the radiofrequency
ablation capability is enabled. B: The wire tip is now at the vessel wall and taking an incorrect path, the monitor
displays a red bar, and ablation is disabled. C: The wire tip is gently rotated until it once again takes an
intraluminal course, the bar changes to green, and once again ablation is enabled.
Materials and Methods:
Following failed recanalization of a chronic total occlusion with conventional techniques, the IntraluminalTM wire
was used in a series of 27 patients. Total number of lesions was 29; mean length of occlusion could be
estimated in 25 lesions (86.2%) either due to antegrade flow from bridging collaterals, or retrograde filling
evaluated using simultaneous double injection technique into both coronaries. All occlusions were estimated to
be at least 3-months old on the basis of either the time between the diagnostic angiogram and intervention (in
59%), or the time from the onset of angina or a prolonged period of pain (in 41%).
All patients were initially treated with conventional wires. In the majority, the policy was to first use a
Graphix Intermediate tip wire (Boston Scientific, Miami, Florida, USA), followed by a Miracle 3 wire (Asahi
Intecc Co. Ltd, Aichi, Japan). Wires were used with additional support provided by an over the wire Maverick
balloon (Boston Scientific, Miami, Florida, USA). If successful recanalization was not achieved despite
aggressive use of these wires, the IntraluminalTM wire was then utilised to facilitate further progress, though
with the option of switching back to a conventional wire if wanted. All the IntraluminalTM wire procedures were
carried out by operators who are highly experienced in the treatment of CTO`s, with the majority done by a
single operator. All patients provided written informed consent.
Multivessel disease was defined as >50% diameter stenosis of more than one major epicardial artery.
Procedural success was defined as wire passage through to the lumen of the distal vessel with subsequent
angioplasty leading to a residual diameter stenosis of <30% together with TIMI 3 flow.
Results:
Baseline patient demographics and lesion characteristics are presented in tables 1 and 2 respectively.
Multivessel disease was present in 13 patients (48.1%). Of these, during the CTO procedure, stenting was
carried out in at least one other major epicardial artery 7 (25.9%). Two patients had two separate procedures
with recanalization attempted on 2 CTO`s for each patient, therefore in total, 29 lesions were treated in 27
patients. All occlusions were more than 3 months old, with a mean age estimated to be 1.9 years (range 3
months to 19 years). Mean length of occlusion was 22.1 ± 17.2mm (range 4.5mm to 88.7mm). A previous failed
attempt to recanalize the target lesion had been carried out on a separate occasion in 6 lesions (20.7%). Only
one lesion (3.4%) was a chronic in-stent occlusion. This patient was previously treated with brachytherapy for
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in-stent restenosis, but presented 2 years later with stable angina, and had complete stent occlusion. After an
initial attempt to recanalize the artery failed, he returned for a second (successful) procedure utilising the
Intraluminal.
Table 1: Baseline patient characteristics
Patient population
n=27
Male sex 20 (74.1%)
Diabetes mellitus 3 (11.1%)
Hypercholesterolemia 24 (88.9%)
Hypertension 13 (48.1%)
Current smoking (%) 5 (18.5%)
Presence of multi-vessel disease (%) 13 (48.1%)
Previous myocardial infarction (%) 17 (63.0%)
Previous PCI (%) 12 (44.4%)
Previous CABG (%) 2 (7.4%)
PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft surgery
Table 2: Baseline lesion characteristics
Lesion
n=29
LAD 9 (31.0)
LCX 3 (10.3)
Target vessel (%)
RCA 17 (58.6)
Ostial location of occlusion * (%) 5 (17.2)
Length of occlusion >15mm (%) 15 (51.7)
Central 7 (24.1)
Eccentric 2 (6.9)
Stump morphology (%)
Blunt 20 (69.0)
Side branch at the site of occlusion (%) 18 (62.1)
Bridging collaterals (%) 14 (48.3)
Retrograde collateral filling (%) 26 (89.7)
Angiographic evidence of calcification (%) 8 (27.6)
Proximal tortuosity (>45° angle) (%) 3 (10.3)
LAD: left anterior descending; LCX: left circumflex artery; RCA: right coronary artery
*The occlusion was defined as ostial if it occurred <5mm from the origin of the vessel
Visualisation of the distal vessel was enhanced by using ‘double injection technique’ (simultaneous injection
into both the left and right coronary arteries) in 21 of 29 lesions (72.4%). The mean total procedure time was
165 ± 45 minutes with a mean fluoroscopy time of 82 ± 35 minutes. The mean total amount of contrast used
was 465 ml. The mean procedural time between starting the attempt with conventional wires, and the decision
to switch to the Intraluminal wire was approximately 30 minutes. Successful recanalization was achieved in
15 of the 29 lesions (51.7%). All were subsequently stented with either bare stents (n=5) or drug-eluting stents
(n=10), and, at the end of the procedure had a successful angiographic result with a residual diameter stenosis
of <30%.  For the CTO lesion, mean number of stents implanted was 2.8 with a mean diameter of 2.8 ±
0.33mm, and a mean length of stented segment of 63.9 ± 27.5mm (range 26-112mm).
There were no patient or lesion characteristics predictive for success versus failure. There were no
procedural / in-hospital complications of tamponade, acute myocardial infarction or death. The procedure was
unsuccessful in 14 patients. The decision to halt the procedure was at the operator`s discretion and related to
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failure to cross the lesion in 8 (57.1%), and the occurence of dissection in the remaining 6 (42.9%). All episodes
of dissection occurred whilst a conventional wire (rather than the Intraluminal wire) was in use, and all were
without clinical sequelae. Of these 14 patients with unsuccessful recanalization, 3 (21.4%) were referred for
coronary artery bypass graft surgery, and the remaining 11 (78.6%) were managed with medical therapy.
Discussion:
Previous studies have demonstrated the importance of the revascularization of chronic total occlusions with
significant benefits on quality of life with improvement in both anginal symptoms and exercise capacity. 7 In
addition, successful recanalization of a chronically occluded artery reduces the need for subsequent bypass
surgery and the rate of myocardial infarction. 8 There is also evidence that, provided the artery remains patent,
there is an improvement in left ventricular function. 9 Importantly, long-term evaluation has shown a 10-year
survival advantage following successful PCI compared to those in whom PCI is unsuccessful (survival 73.5%
versus 65.1%, p=0.001). 10
The inability to cross the lesion is the primary reason why a percutaneous strategy for revascularization
is unsuccessful. Results of other guidewire technologies specifically designed for treating CTO`s, including the
hydrophilic coated wire, the ball-tipped wire, and laser wire, have been disappointing with success rates of 45-
60%.3,11,12 Failure generally relates to either perforation with an extraluminal passage of the wire, or failure of
the wire to advance forwards due to dense fibrous tissue or heavy calcification within the occlusion. With
regards to the laser wire, the TOTAL surveillance study 13 suggested that because of its ablation capacity, there
was an advantage conferred by the wire in improving successful recanalization rates. Following a failed attempt
utilising a mechanical guidewire, 182 patients were treated with the laser wire, with success achieved in 105
patients (58%). However, perforation occurred in 21%, with tamponade in 1% cases. The subsequent TOTAL
trial 3 randomized patients to either the laser wire or “conventional” mechanical wires, with the possibility of
crossover to the other modality for a second attempt, should the first fail. In all, 303 patients were treated, with
no significant difference in overall success rates between the 2 groups. Failure with the laser wire was primarily
related to it taking a false route, whereas failure with mechanical wires was felt to be mainly due to absence of
wire progression. The Safe-Cross system provides the operator with the potential to overcome both of these
limitations. The technology of optical coherence reflectometry provides the means to precisely navigate the
guidewire forward thereby minimising the risk of perforation, and the capability of radiofrequency ablation
increases the crossing potential of the wire. In-vitro studies have confirmed that the system is able to accurately
differentiate plaque from the media / adventitia boundary, 14 and in vivo evaluation has shown efficacy of the
ablation capacity even when used in heavily calcified vessels. 5 In the current study, failure of successful
recanalization occurred in 48.3% lesions, related to dissection in six (42.9%). However, all these episodes
occurred whilst a conventional wire was in use and not the Intraluminal wire.
One of the most important drawbacks of percutaneous revascularization of a CTO is that the prolonged
procedural time is associated with increased radiation exposure to both the patient and operator. Excessive
radiation dosage can cause skin injury ranging from a temporary erythema, to deep ulceration and permanent
scarring. 15 One further advantage of the Safe-Cross system is that the wire has the potential to be manipulated
with guidance from the monitor display, without the need for continuous fluoroscopy. The fluoroscopy times in
the current study (82 minutes) are slightly lower than those seen during the pilot study of the laser guidewire
(99 minutes). 16 Importantly, there were no complications utilizing this system, in particular no episodes of
tamponade, and this now provides reassurance of the ability to use the system with less fluoroscopy in the
future. In addition to this, although the mean amount of contrast used in the present study (465ml) is
comparable to that of the laser wire pilot study 16 (515ml), less fluoroscopy should correlate with a lower amount
of contrast utilization.
Our population was a difficult one with all occlusions being older than 3 months duration (a typical case
example is presented in figure 3). Other than age, other factors suggested to be predictive for unsuccessful
percutaneous therapy include multivessel disease, a blunt stump, the presence of a side branch at the site of
occlusion, calcification, bridging collaterals, and lesion length >15mm. 2,8,17 The overall mean length of
occlusion in our patients was long at 22.1mm, and following successful recanalization, a relatively long total
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length of stents (mean 63.9mm) was required to ensure coverage of the entire lesion. All the lesions treated
had at least one of these additional characteristics, with the majority (69.0%) having at least 3 additional
adverse characteristics. With such a high prevalence of these characteristics in our group of patients, there
were no patient or lesion characteristics that appeared to be predictive for successful recanalization.
Figure 3: Case example
A 74-year old man with two previous coronary bypass surgery operations in 1983 and 1997. A) Left circumflex
artery occlusion estimated to be at least 5 years old, 12mm in length, and with a blunt stump. B) Progress
made with a Miracle wire (Asahi Intecc Co. Ltd, Aichi, Japan) but unable to fully cross the lesion. C) Successful
recanalization utilising the Intraluminal™ wire, the final 10mm of the wire is opaque and can be seen within the
lumen of the distal vessel (arrow). D) Final results following pre-dilatation and stenting with a 2.5x33mm Cypher
stent (Cordis, Johnson and Johnson).
The Safe-Cross system is easy to use, with a fairly short learning curve. The main difference compared to
conventional wires is that wire manipulation / torquing needs to be done relatively slowly in order to give the
system time to interpret the optical coherence reflectometry signal. In addition, as the wire has a blunt tip (and
therefore some potential for perforation), following successful recanalization, care must be taken to ensure safe
positioning in the distal vessel. Once a lesion is crossed, the wire can be disconnected from the console and an
outer sheath removed to maintain sterility; the wire can then be used like any other 0.014” wire.
In our patients in whom attempted recanalization with conventional wires had failed, the Safe-Cross
system improved the rate of successful CTO recanalization with a further 51.7% vessels successfully opened.
The major limitation at present is some difficulty in steering the wire, but it is hoped that this will improve with
the next generation of IntraluminalTM Guidewires, which have a tip that can be pre-shaped. Although this study
is limited by the fact that it is non-randomized and carried out in a single center on a small number of selected
patients, our preliminary data suggests that this system is a useful adjunctive device in the therapy of chronic
total occlusions. Further evaluation in the context of a large randomized study is warranted to assess the
impact of this new device in the treatment of this technically challenging patient population.
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Summary
The major limitation of percutaneous therapy (PCI) for the treatment of chronic total
occlusions (CTOs) is the inability to cross with a wire. We report successful recanalization of
a CTO situated at the ostium of the left anterior descending artery. The lesion demonstrated
several anatomical features known to be associated with an unsuccessful outcome, and
attempts with conventional wires failed. However, recanalization was facilitated with the
Intraluminal wire™, (Intraluminal Therapeutics Inc, Carlsbad, California) a novel technology
that combines guidance of the wire tip with the capability of radiofrequency ablation.
The majority of patients with CTOs are currently managed medically or referred for
coronary bypass surgery. However, drug-eluting stent (DES) implantation for the treatment
of CTOs have been shown to reduce the subsequent rate of restenosis compared with bare
metal stents. If rates of successful recanalization can be increased with new technologies
such as demonstrated here, then the advent of DESs will lead to more widespread
applicability of PCI for this complex group.
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Case Report: A 58-year old woman was referred with a 2-year history of chest pain. Risk factors for coronary
disease were smoking, hypertension, and a positive family history. Though the resting ECG was normal, an
exercise test demonstrated ST-depression across the anterior leads during stage 2 of a Bruce protocol.
Subsequent coronary angiography showed single vessel disease of the left anterior descending artery (LAD)
which was completely occluded at the ostium, with a blunt stump (figure 1). Notably, there was clearly identified
heavy calcification, and a ring of calcium can be seen in figure 1B (arrow). There was some antegrade filling via
small bridging collaterals originating from the proximal part of the left circumflex artery (figure 1A). The distal
vessel was also filled via retrograde collaterals from the right coronary artery (figure 1B). Left ventricular
function was normal with no anterior wall movement abnormality.
Figure 1A: Diagnostic angiography of the left coronary artery demonstrating complete occlusion at the ostium
of the left anterior descending artery (LAD). The distal vessel is filled via small bridging collaterals originating
from the proximal left circumflex artery (arrow). B: Diagnostic angiography of the right coronary artery which
supplies retrograde collateral filling of the LAD. A ring of heavy calcification at the occlusion site is readily
apparent (arrow).
The patient was taking long-term aspirin, and before the procedure was pre-loaded with 300mg clopidogrel.
Heparin was administered to maintain the activated clotting time >250 seconds. A 7F left Amplatz 2 guiding
catheter was used to catheterize the left main coronary artery, and the procedure was carried out utilising
biplane X-ray screening. By quantitative coronary angiography, the estimated length of the occlusion was 13.6
mm. Initial attempts to open the LAD were made using an Intermediate tip 0.014” guidewire (Boston Scientific),
and then a 0.014” Miracle 3g wire (Asahi Intecc Co. Ltd, Aichi, Japan) with over-the-wire balloon support.
However, both these wires prolapsed into the circumflex artery with no antegrade progress into the LAD (figure
2B). The Intraluminal wire was then advanced to the stump and radiofrequency ablation applied which was
able to penetrate the proximal cap of the occlusion (figure 2C). The Intraluminal wire™ was substituted for the
Miracle wire, with successful wire passage into the distal vessel lumen (figure 2D). Following pre-dilatation, a
3.0x18mm sirolimus-eluting stent (Cypher stent, Cordis Corporation, Miami, Florida) was implanted (figure 2E)
and subsequently post-dilated with a 3.5mm balloon; the final result was excellent (Figure 2F). At 6-months
follow-up the patient was symptom-free and underwent a repeat exercise test. On this occasion she managed
10 minutes of a Bruce protocol (maximum predicted heart rate attained) without chest discomfort or ECG
changes.
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Figure 2A: Baseline angiography of the occlusion at the time of angioplasty. B: Conventional wires with over-
the-wire balloon support failed to penetrate the proximal cap of the occlusion and simply prolapsed into the left
circumflex artery. C: The tip of the Intraluminal wire™ can be seen penetrating through the cap (arrow). D:
Successful crossing of the occlusion into the lumen of the distal vessel with a Miracle 3g wire. E: Stent
implantation with a 3.0x18mm sirolimus-eluting stent. F: Final result.
Discussion:
Previous studies have demonstrated the importance of CTO revascularization, with improvement in anginal
symptoms, exercise capacity, and left ventricular function. 1-3 In addition, successful recanalization reduces the
need for subsequent coronary artery bypass surgery, 4 and long-term evaluation has shown a 10-year survival
advantage of 73.5% compared to 65.1% in those in whom PCI is unsuccessful. 5
The Safecross system with the Intraluminal guidewire™ (Intraluminal Therapeutics, Carlsbad,
California) uses optical coherence reflectometry to determine the position of the wire tip. The system has been
previously described, 6-9 briefly, a beam of near-infra red light is emitted and the reflected beam analysed to
differentiate the vessel lumen from the outside vessel wall. The technology therefore provides information for
guidance of the wire, to reduce the risk of taking an extra-luminal passage potentially leading to perforation and
pericardial tamponade. In addition, the wire has the capability of radiofrequency ablation at the tip, emitting
short bursts (100ms) of low frequency 250-500 kHz energy. This facilitates forward passage of the wire with
efficacy demonstrable even in calcified vessels. 7 The system combines these 2 capabilities such that ablation
is only enabled when the wire tip is heading correctly. In the present case, the Intraluminal was of great value in
penetration of the proximal cap of the occlusion which, particularly when the stump appears blunt, can be
composed of very dense fibrotic material. The cap was unable to be breached by conventional wires, yet once
a few millimetres of antegrade passage had been made with the Intraluminal wire, the remainder of the
occlusion could be traversed.
Importantly, the distal LAD was filled via collaterals thereby facilitating wire guidance, and enabling
reassurance of successful recanalization with visualization of the wire within the distal lumen. However, the
Intraluminal system uses optical coherence reflectometry to determine the position of the distal tip of the wire in
relation to the vessel wall. This does not therefore rely on angiographic visualization, and with more experience
in the future, it may be possible to use the system even when the distal vessel is not well seen.
When treating CTO’s, whatever the technology used, the principles of good backup support remain
important, and in this case a left Amplatz guide catheter proved effective. In addition, to facilitate the exchange
of wires and to provide additional backup, we routinely utilize a 1.5mm over-the-wire balloon, which can then be
used for pre-dilatation once the occlusion has been successfully crossed with a wire.
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Certain lesion characteristics have been shown to affect the success rate of recanalization. Some of
the most important adverse features include increased age and length of the occlusion, the presence of
bridging collaterals, a side branch at the site of occlusion, calcification, and an abrupt rather than tapered
stump. 10 Our patients’ clinical history suggested that the occlusion was 2-years old, it was ostial in location with
the large circumflex artery originating at the occlusion, was heavily calcified and the stump abrupt (figures 1
and 2). All these features suggested that the chances of successful recanalization would be low, and might
have lead many cardiologists to refer similar patients directly for bypass surgery. Indeed, in the BARI study,
clinicians provided their views on the suitability of lesions for a revascularization strategy of PCI versus CABG,
and both ostial lesion location and a CTO were deemed to be strong non-favourable characteristics for PCI. 11
Percutaneous treatment of ostial LAD lesions could potentially jeopardize the circumflex artery,
however in the present case, the use of biplane imaging facilitated precise stent positioning, which, together
with a relatively large angle of the left main stem carina meant that the final result was excellent. Long-term
results of PCI with bare metal stents have been hindered by the development of restenosis, with rates of non-
occlusive ostial LAD lesions as high as 26%. 12 Furthermore, CTOs are well-known to be at increased risk of
restenosis, with rates of 32-55%. 13-16 However, recent data have confirmed the efficacy of sirolimus-eluting
stents for CTOs, with a 1 year survival-free of major adverse events of 96%, and binary restenosis rate of 9%.
17
Conclusions:
This case demonstrates the potential of this novel technology, in particular at successfully penetrating the
proximal cap of a CTO following failed attempts using conventional guidewires. Future improvements in such
specialized technologies will improve the ability to achieve successful recanalization of CTOs. This, together
with the use of drug-eluting stents, means that the use of PCI, rather than CABG, will be more widely applicable
for the revascularization of patients with complex CTOs.
77
References
1. Finci L, Meier B, Favre J, Righetti A, Rutishauser W. Long-term results of successful and failed angioplasty for chronic total coronary
arterial occlusion. Am J Cardiol 1990;66:660-662.
2. Rambaldi R, Hamburger JN, Geleijnse ML, Poldermans D, Kimman GJ, Aiazian AA, Fioretti PM, Ten Cate FJ, Roelandt JR, Serruys PW.
Early recovery of wall motion abnormalities after recanalization of chronic totally occluded coronary arteries: a dobutamine
echocardiographic, prospective, single-center experience. Am Heart J 1998;136:831-836.
3. Melchior JP, Doriot PA, Chatelain P, Meier B, Urban P, Finci L, Rutishauser W. Improvement of left ventricular contraction and relaxation
synchronism after recanalization of chronic total coronary occlusion by angioplasty. J Am Coll Cardiol 1987;9:763-768.
4. Ivanhoe RJ, Weintraub WS, Douglas JS, Jr., Lembo NJ, Furman M, Gershony G, Cohen CL, King SB, 3rd. Percutaneous transluminal
coronary angioplasty of chronic total occlusions. Primary success, restenosis, and long-term clinical follow-up. Circulation 1992;85:106-115.
5. Suero JA, Marso SP, Jones PG, Laster SB, Huber KC, Giorgi LV, Johnson WL, Rutherford BD. Procedural outcomes and long-term
survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year
experience. J Am Coll Cardiol 2001;38:409-414.
6. Cordero H, Warburton KD, Underwood PL, Heuser RR. Initial experience and safety in the treatment of chronic total occlusions with
fiberoptic guidance technology: optical coherent reflectometry. Catheter Cardiovasc Interv 2001;54:180-187.
7. Neet J, Winston T, Siglinger M, Janssen M, Balaster A. Optical coherence reflectometry (OCR) guided RF ablation guide wire for total
occlusions. SPIE 2001;4244:419-427.
8. Chen WH, Ng W, Lee PY, Lau CP. Recanalization of chronic and long occlusive in-stent restenosis using optical coherence
reflectometry-guided radiofrequency ablation guidewire. Catheter Cardiovasc Interv 2003;59:223-229.
9. Hoye A, Onderwater E, Cummins P, Sianos G, Serruys PW. Improved Recanalization of Chronic Total Coronary Occlusions Using an
Optical Coherence Reflectometry-Guided Guidewire. Cathet Cardiovasc Interv. 2004;63(2):158-63
10. Puma JA, Sketch MH, Jr., Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Percutaneous revascularization of chronic
coronary occlusions: an overview. J Am Coll Cardiol 1995;26:1-11.
11. Botas J, Stadius ML, Bourassa MG, Rosen AD, Schaff HV, Sopko G, Williams DO, McMilliam A, Alderman EL. Angiographic correlates
of lesion relevance and suitability for percutaneous transluminal coronary angioplasty and coronary artery bypass grafting in the Bypass
Angioplasty Revascularization Investigation study (BARI). Am J Cardiol 1996;77:805-814.
12. Park SJ, Lee CW, Hong MK, Kim JJ, Park SW. Stent placement for ostial left anterior descending coronary artery stenosis: acute and
long-term (2-year) results. Catheter Cardiovasc Interv 2000;49:267-271.
13. Buller CE, Dzavik V, Carere RG, Mancini GB, Barbeau G, Lazzam C, Anderson TJ, Knudtson ML, Marquis JF, Suzuki T, Cohen EA,
Fox RS, Teo KK. Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada
(TOSCA). Circulation. 1999;100:236-42.
14. Rubartelli P, Niccoli L, Verna E, Giachero C, Zimarino M, Fontanelli A, Vassanelli C, Campolo L, Martuscelli E, Tommasini G. Stent
implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. Gruppo Italiano di Studio sullo Stent
nelle Occlusioni Coronariche. J Am Coll Cardiol. 1998;32:90-6.
15. Lotan C, Rozenman Y, Hendler A, Turgeman Y, Ayzenberg O, Beyar R, Krakover R, Rosenfeld T, Gotsman MS. Stents in total
occlusion for restenosis prevention. The multicentre randomized STOP study. The Israeli Working Group for Interventional Cardiology. Eur
Heart J. 2000;21:1960-6.
16. Sirnes PA, Golf S, Myreng Y, Molstad P, Emanuelsson H, Albertsson P, Brekke M, Mangschau A, Endresen K, Kjekshus J. Stenting in
Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll
Cardiol. 1996;28:1444-51.
17. Hoye A, Tanabe K, Lemos PA, Aoki J, Saia F, Arampatzis C, Degertekin M, Hofma SH, Sianos G, McFadden E, Van Der Giessen WJ,
Smits PC, De Feyter PJ, Van Domburg RT, Serruys PW. Significant reduction in restenosis after the use of sirolimus-eluting stents in the
treatment of chronic total occlusions. J Am Coll Cardiol. 2004;43:1954-8.
78
79
Chapter 8
Jose Ruiz-Cantador
Angela Hoye
Eugene McFadden
Journal of Invasive
Cardiology
2005;17(10):E7-E10
Multimodality Plaque Ablation to Allow
Successful Stent Implantation Following
Failure of Conventional Wires and Balloons
to Cross a Chronic Total Occlusion
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Abstract:
The present report illustrates several potential difficulties that may arise when treating a
chronic total occlusion, one of the most challenging coronary lesions to be faced in the
catheterization laboratory. We describe how we overcame each of these problems, including
the utilization of specialized technologies with the Intraluminal wireTM and rotablator.
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Introduction
Percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) has procedural and ultimate long
term success rates that are significantly less than those currently reported for non-occlusive lesions. A CTO is
generally defined as an occlusion with Thrombolysis In Myocardial Infarction (TIMI) grade 0 or 1 antegrade
flow, that is more than 3 months old. On angiography, CTO lesions occur in approximately one third of patients
with significant coronary lesions, but PCI for CTO only accounts for around 10% of patients undergoing PCI. 1
Successful recanalization of CTO with PCI reduces the need to resort to bypass surgery; furthermore,
observational studies have shown lower cumulative rates of cardiac death or myocardial infarction and an
improvement in symptomatic status after successful PCI for CTO. 2-5
The lower procedural success and higher restenosis rates in the era of balloon angioplasty have improved in
recent years. However, inability to cross the lesion remains the major cause of procedural failure. 6-8
Improvements in guidewire technology and novel approaches such as the optical coherence reflectometry-
guided radiofrequency ablation (IntraluminalTM guidewire, Intraluminal Therapeutics, Carlsbad, California), the
Frontrunner catheter (LuMend, Redwood City, California), and other technological advances have improved the
ability to cross the lesion. 9-13 The second major cause of procedural failure is the inability to cross or to dilate
the lesion with a balloon. In this situation, rotational atherectomy or an excimer laser may lead to a successful
outcome. 14,15 Finally, the long term success rate of PCI in general has been improved by the use of stent
implantation. 16,17 Though experience with CTO lesions is currently limited, the introduction of drug-eluting
stents, in particular, has reduced the subsequent rate of restenosis. 18-21 This case report illustrates many of the
technical problems encountered in treating CTOs and shows how they were successfully overcome with both
classic and novel technology.
Case Report
A 51-year-old man with a six-month history of Canadian Class 3 stable angina was referred for percutaneous
revascularization. Risk factors for atherosclerosis were non-insulin-dependent diabetes mellitus,
hypercholesterolemia, previous smoking, and a positive family history of premature coronary artery disease.
Coronary angiography performed at the referring center, showed a chronic total occlusion of the mid-right
coronary artery. The left coronary artery had no significant stenosis and the left ventricular function was normal.
Based on the history, the duration of the occlusion was estimated to be around 6 months. Medical therapy
consisted of aspirin, statin, beta-blocker, and clopidogrel, with tight glycemic control maintained through oral
hypoglycemic agents.
Figure 1: Baseline angiography of the right coronary artery, right anterior oblique view, with a CTO in segment
2. The stump is blunt in morphology (block arrow), there is a side branch at the level of the occlusion (open
arrow), and bridging collaterals are filling the distal vessel.
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Coronary angiography showed a total occlusion of segment 2 of the right coronary artery (RCA) with antegrade
TIMI 0 flow. Bridging collaterals filled the distal RCA. The occlusion site had a blunt stump and there was a side
branch at the level of the occlusion (figure 1). The estimated length of the occlusion at quantitative coronary
angiography (CAAS II; Pie Medical Imaging, The Netherlands) was 8 mm. Heparin (10,000 IU) was given at the
start of the procedure and additional heparin boluses were administered to maintain activated clotting time
>250 seconds. A biplane X ray system was used.
The first difficulty encountered was the appropriate choice of guiding catheter to provide coaxial
intubation and adequate support. The RCA had an anteriorly located ostium with an intermediate lesion.
Multiple guiding catheters were tried; a 6 French Mach1 ART 3.5 gave optimal coaxial intubation. However, due
to the intermediate ostial lesion, there was suboptimal support and the guiding catheter repeatedly became
disengaged when the wire was advanced to cross the lesion. A Taxus stent 2.5x12 mm (Boston Scientific,
Maple Grove, Minnesota) was deployed at the ostium, thus allowing a deeper intubation and improved back-up.
Despite the use of multiple guidewires including a 0.014” PT Graphix Intermediate (Boston Scientific),
and a 0.014” Miracle 3g (Asahi Intecc Co. Ltd, Aichi, Japan), through a Maverick (1.5/15 mm) over-the-wire
balloon (Boston Scientific), it proved impossible to cross the lesion. When the Miracle wire appeared to have
taken a sub-intimal course, a second wire, the Safe-Cross straight (Intraluminal Therapeutics) was advanced
parallel to the first (figure 2A). At this point, the Safe-Cross Straight wire was advanced through the over-the-
wire balloon to the level of the occlusion, with eventual success. The system was activated and the wire was
used to burn a channel through the first few millimeters of the occlusion. Subsequently, this wire was removed
and replaced by a second Miracle 3g wire that then easily crossed into the distal vessel (figure 2B).
Figure 2A: Double-wire technique: a Miracle wire has taken an incorrect sub-intimal path. In order to “block”
entry into the abnormal path, this wires’ position is maintained, and a second wire (Intraluminal wire™) is
advanced and directed into the correct lumen (block arrow). B: The Intraluminal wire has been replaced by a
second Miracle 3g wire, with successful passage into the distal vessel.
Despite several attempts, the occlusion could not be crossed with any available balloon: Maverick
(1.5/15) over-the-wire balloon, Worldpass rapid-exchange balloon 1.5x30mm (Cordis Corporation), or Hayate
balloon Pro 1.5x20mm (Terumo, Tokyo, Japan). Furthermore, the guiding catheter position was lost. This
required a difficult reintubation of the guiding catheter in the presence of a stent protruding into the aorta; and
the wire was readvanced across the occlusion. However, the balloon could not then be advanced into the
ostium. It became apparent that the wire had passed through the struts of the stent that were protruding in the
aorta. Thus, a second wire was advanced into the artery and the balloon was advanced without difficulty over
this wire to the lesion. However, crossing still proved impossible. As a last resort, we decided to advance a
Rotablator wire (Boston Scientific) parallel to the first wire; this did not cross the lesion until the first wire was
removed. Then, the Rotawire floppy 0.009 inch wire was successfully manipulated into the distal vessel. A 1.5
mm burr was advanced and easily crossed the lesion (figure 3). Successive inflations with a Hayate Pro
1.5x20mm and a Maverick 2.5x20mm were followed by placement of a Taxus stent (2.5x24mm) in segment 2.
The residual diameter stenosis was 10%, the minimal lumen diameter 1.93mm, and the reference vessel
A B
84
diameter 2.14mm, with TIMI 3 flow and a normal blush (figure 4). The patient was discharged 24 hours later,
and has since been symptom-free.
Figure 3: Rotablator wire 0.009 inch in the lumen
of the RCA and a 1.5 mm burr crossing the lesion.
A provisional pacemaker wire has been placed in
right ventricle apex.
Figure 4: Angiography of the RCA showing the
final result, with TIMI 3 flow, a normal blush and a
residual diameter stenosis of 10%.
Discussion
This case illustrates many of the problems that can be encountered during attempted PCI of a CTO. Although
there were somewhat unfavorable angiographic characteristics (blunt stump morphology, side branch at the
level of the CTO, and bridging collaterals), the RCA location in conjunction with the absence of other significant
lesions, the short length of the occlusion, and it’s relatively short presumed  duration, led us, after consultation
with our surgical colleagues, to attempt PCI.
The initial problem was related to the ability to obtain coaxial intubation and adequate guiding catheter
support that required the use of multiple catheters in conjunction with implantation of a stent at the ostium. The
second problem was the inability to cross the lesion with a wire. Many different types of wire are available and
the initial choice is generally a matter of operator preference. Usually, softer tip wires are used first, followed by
progressively stiffer wires in order to minimize the risk of perforation. 9 When a wire appears to have taken a
subintimal course, as occurred in this case, it is sometimes useful to leave it in place thereby blocking the
entrance into this channel, and to advance a second wire in parallel to the first, to find an alternative route.
The IntraluminalTM guidewire is a recently developed technology that delivers radiofrequency energy
pulses capable of ablating tissue. In addition, the system monitors, in real-time, the position of the 0.014 inch
wire using optical coherence reflectometry. Near-infrared light is emitted and by analyzing the signal that is
reflected from tissue interfaces, the system is able to determine whether the position of the distal tip of the wire
is correct, or too close to the outer vessel wall. Ablation pulses are only allowed when the wire is in the true
lumen. Initial studies have demonstrated the utility of this technique to cross CTO’s. 11,12
  The next problem we encountered was the inability to cross the lesion with several different balloons.
Attempted balloon crossing resulted in loss of guiding catheter position which was resolved with difficulty due to
the fact that the stent in the ostium protruded in the aorta. The use of rotational atherectomy finally allowed a
balloon to cross and to dilate the lesion, and the procedure was completed with placement of a paclitaxel-
eluting stent, our default strategy.
Although the use of such complex technologies undoubtedly increased the procedural costs, such a
successful outcome reduces the likelihood that the patients will undergo bypass surgery and improves his long-
term survival. 2,5 Stenting CTO lesions has been shown to improve long term outcome; the use of a drug eluting
stent in this diabetic patient with a small diameter vessel reflects current best medical practice. 16-22 Preliminary
studies suggest that drug-eluting stents remain patent in more than 95% of cases. 21
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Abstract
Objectives: The aim of this study was to assess sirolimus-eluting stent (SES) implantation
for the treatment of chronic total coronary occlusions (CTO).
Background: Long-term results after percutaneous coronary intervention (PCI) in the
treatment of CTOs is hindered by a significant rate of restenosis and reocclusion. In the
treatment of relatively simple nonocclusive lesions, SESs have shown dramatically reduced
restenosis rates compared with bare metal stents (BMS), but whether these results are more
widely applicable is unknown.
Methods: From April 2002, all patients at our institution were treated with SES as the device
of choice during PCI. During the first six months, 563 patients were treated solely with SES,
with treatment of a de novo CTO in 56 (9.9%). This CTO cohort was compared with a similar
group of patients (n = 28) treated in the preceding six-month period with BMS.
Results: At one year, the cumulative survival-free of major adverse cardiac events was
96.4% in the SES group versus 82.8% in the BMS group, p < 0.05. At six-month follow-up,
33 (59%) patients in the SES group underwent angiography with a binary restenosis rate
(>50% diameter stenosis) of 9.1% and in-stent late loss of 0.13 ± 0.46 mm. One patient
(3.0%) at follow-up was found to have reoccluded the target vessel.
Conclusions: The use of SESs in the treatment of chronic total coronary occlusions is
associated with a reduction in the rate of major adverse cardiac events and restenosis
compared with BMS.
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Introduction
Chronic total occlusions (CTO) are common, and found in approximately one-third of patients with significant
coronary disease who undergo angiography. 1,2 Percutaneous intervention (PCI) of CTOs accounts for 10% to
15% of all angioplasties; however, after successful recanalization, there is an increased rate of subsequent
restenosis and reocclusion compared with nonocclusive stenoses. 3,4 Although several randomized trials
demonstrated the efficacy of stent implantation over balloon-only angioplasty, even with stents there remains a
significant rate of both restenosis (32% to 55%) and reocclusion (8% to 12%). 5-9
In the treatment of relatively simple lesions, sirolimus-eluting stents (SES) markedly reduce the restenosis rate,
with continued benefit documented up to two years follow-up. 10,11 Whether these results can be extrapolated to
more complex lesions such as CTOs has yet to be determined. We sought to evaluate the effectiveness of the
SES in a consecutive series of patients with at least one de novo CTO compared with a similar series treated
with bare metal stents (BMS).
Methods
Patient population
Commencing in April 2002, all PCI at our institution was done solely with SESs, irrespective of clinical
presentation or lesion morphology; these patients comprise the Rapamycin-Eluting Stent Evaluated at
Rotterdam Cardiology Hospital registry (RESEARCH) registry (further details of the methodology are described
elsewhere). 12,13 Those deemed at an increased risk of restenosis (including the CTO population) were
considered for six-month angiographic follow-up. Sirolimus-eluting stents were available in lengths between 8
mm and 33 mm, and diameters 2.25 mm to 3.0 mm. In the first six months, 563 patients were treated, including
56 (9.9%) with successful revascularization of at least one CTO. These patients make up the present study
cohort; all received six months dual antiplatelet therapy with clopidogrel in addition to aspirin. As predetermined
by the RESEARCH protocol, this study cohort of patients were compared with all those treated for a CTO in the
preceding six months with BMS, identified from the departments' dedicated database. Both groups were treated
by the same operators utilizing standard techniques, the only difference being the type of stent. The protocol
was approved by the local ethics committee and is in accordance with the principles of Good Clinical Practice
for Trials of Medicinal Products in the European Community and the Declaration of Helsinki. All patients signed
a written informed consent
CTO definition
Chronic occlusion was defined as an occlusion on angiography with no antegrade filling of the distal vessel
other than via collaterals. All patients included had a native vessel occlusion estimated to be at least one
month's duration 9 based on either a history of sudden chest pain, a previous acute myocardial infarction in the
same target vessel territory, or the time between the diagnosis made on coronary angiography and PCI.
Length of occlusion
The length of occlusion was measured by quantitative coronary angiography either utilizing antegrade filling via
collaterals, or assessment of the retrograde collateral filling. This was achieved by catheterizing both the left
and right coronary arteries, and making a simultaneous injection to delineate the distance between the site of
occlusion and the most proximal part of the vessel filled retrogradely.
Follow-up
Patients were followed up prospectively and evaluated for survival-free of major adverse cardiac events
(MACE) using questionnaires and telephone enquiries; MACE was predefined as: 1) death; 2) nonfatal
myocardial infarction; or 3) repeat target vessel revascularization (TVR). The diagnosis of acute myocardial
infarction required an elevation of creatine kinase to twice the upper limit of normal, together with a rise in
creatine kinase-MB fraction. Target vessel revascularization was defined as either surgical or percutaneous
reintervention driven by significant (>50%) luminal narrowing within the treated vessel, and was undertaken in
the presence of either anginal symptoms or objective evidence of ischemia.
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Angiographic analysis
Quantitative analysis in those SES patients with follow-up angiography was undertaken in three coronary
segments: in-stent (encompassing the entire length of stented segment), and the 5-mm proximal and distal
edge segments either side of the in-stent segment. The target lesion comprised the in-stent plus the proximal
and distal edge segments. Binary restenosis was defined as >50% diameter stenosis within the target lesion.
Late lumen loss was calculated from the difference in minimal lumen diameter between postprocedure and
follow-up.
Statistical analysis
Discrete variables are presented as percentages and compared with Fisher exact test. Continuous variables
are expressed as mean ± SD and compared with Student t test. Survival-free of adverse events was calculated
according to the Kaplan-Meier method. The log-rank test was used to compare MACE-free survival between
the two groups. All tests were two-tailed, and a p value of <0.05 was considered statistically significant.
Results
The baseline patient and lesion characteristics of the two groups are presented in Table 1 and Table 2. One
patient in the BMS group underwent successful recanalization and stent implantation in two CTOs, thereby
making a total of 29 lesions in this group. Mean length of occlusion could be determined in 45 (80.4%) of the
SES group and 17 (58.6%) of the BMS group. There was no significant difference between the groups with
respect to the postprocedural quantitative angiography; however, the mean diameter of stent utilized was
greater in the BMS cohort.
Table 1: Baseline patient demographics
Bare stents
n=28
SESs
n=56
p value
Mean age (years) 59.8 ± 11.1 60.2 ± 10.0 0.89
Male sex (%) 85.7 71.4 0.2
Current smoker (%) 35.7 26.8 0.5
Diabetes mellitus (%) 7.1 14.3 0.5
Hypertension (%) 39.3 39.3 1.0
Hypercholesterolemia (%) 57.1 55.4 1.0
Previous myocardial infarction (%) 46.4 55.4 0.64
Previous PCI (%) 21.4 12.5 0.34
Previous CABG (%) 0 0 -
Glycoprotein IIb/IIIa inhibitor usage (%) 25.0 21.4 1.0
Presence of multivessel disease (%) 60.7 46.3 0.25
PCI in at least one additional (non-occluded) major epicardial
vessel during the index procedure (%)
28.6 42.6 0.24
SES: sirolimus-eluting stents, CABG: coronary artery bypass grafting, PCI: percutaneous coronary intervention
There were no in-hospital MACE. Clinical follow-up data was obtained in 100% of both groups. There were no
deaths in either group; one non–Q-wave acute myocardial infarction occurred related to subacute stent
thrombosis 11 days after SES implantation. This was successfully recanalized percutaneously; intravascular
ultrasound suggested underexpansion of the SES (2.5 × 33 mm), and the patient was treated with abciximab
and balloon dilation of the previously implanted stent. At one year, the cumulative survival-free of MACE was
96.4% in the SES group compared with 82.8% in the BMS group, p < 0.05 (Fig. 1). One patient in each group
had a reocclusion (1.8% SES group vs. 3.6% BMS group, P = NS).
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Table 2: Baseline procedural characteristics
Bare stents
n=29
SESs
n=56
p value
Target vessel 0.06
LAD (%) 27.6 51.8
LCX (%) 27.6 25.0
RCA (%) 44.8 23.2
Mean length of occlusion (mm), (range)  12.7 (2.4 - 31.8) 11.3 (4.0 - 32.1) 0.5
Bifurcation stenting (%) 17.9 14.3 1.0
Mean number of stents in the target vessel 1.8 2.0 1.0
Mean nominal diameter of stent in the main vessel (mm) 3.03 ± 0.56 2.75 ± 0.26 <0.001
Mean length of stent in the main vessel (mm) 23.31 ± 9.34 23.89 ± 9.21 0.7
Mean total length of overlapping stents in the main vessel
(mm), (range)
41.8 (18 - 112) 45.2 (8 – 117) 0.7
Reference diameter (mm) 2.37 ± 0.50 2.35 ± 0.46 0.9
Minimal lumen diameter (mm) 2.18 ± 0.49 2.06 ± 0.48 0.3
Post-procedure
QCA data
Diameter stenosis (%) 10.4 11.6 0.6
LAD: left anterior descending artery, LCX: circumflex artery, RCA: right coronary artery, QCA: quantitative
coronary angiography
Figure 1: Kaplan-Meier curves for survival-free of death, acute myocardial infarction, or target vessel
revascularization.
At six months, 33 (58.9%) patients in the SES group underwent follow-up angiography (none in the BMS group)
(Table 3). The binary restenosis rate was 9.1%: one occlusion, one stenosis at the ostium of a side branch after
T-stenting, and the third at the distal outflow of the SES (this is the same patient with the subacute thrombosis,
and restenosis occurred at the site of balloon dilation during the second procedure). The patient with occlusion
had undergone bifurcation T-stenting after successful recanalization of a heavily calcified left anterior
descending artery. At follow-up, the artery had reoccluded, and there was new akinesis of the left ventricular
anterior wall. This patient with occlusion was managed with medical therapy; the other two patients with
restenosis underwent percutaneous revascularization.
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Sirolimus stent: 96.4%
Bare stent: 82.1%
p<0.05 (log-rank test)
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Table 3: Post-procedural and 6 month follow-up quantitive angiographic data for the sirolimus-eluting stent
(patient number n=33)
Discussion
Previous studies have demonstrated the importance of revascularization of CTOs, with improvement in anginal
symptoms, exercise capacity, and left ventricular function. 14-16 In addition, successful recanalization reduces
the subsequent need for bypass surgery and, importantly, long-term evaluation has shown a 10-year survival
advantage of 73.5% after successful PCI compared with 65.1% in those with unsuccessful PCI. 4,17
To our knowledge, this is the first report regarding the efficacy of SES in CTOs, a subset of patients
previously excluded from other protocols and, importantly, at increased risk of developing restenosis after
conventional stent implantation. 3 Of the patients who underwent follow-up angiography, both the in-stent and
proximal 5-mm segments analyzed showed an encouraging late loss of 0.13 ± 0.46 mm and 0.10 ± 0.80 mm,
respectively. The distal 5 mm actually showed an overall benefit, with enlargement of the vessel (late loss,
−0.06 ± 0.54 mm).
In addition to the angiographic data, the clinical follow-up is very encouraging. Importantly, there were
no significant differences in baseline demographics between the SES and BMS groups, and all procedures
were carried out in the same center by the same operators. There was an episode of subacute thrombosis in
the SES group, but there appears to be an underlying mechanical cause with underexpansion of the stent
documented on intravascular ultrasound. The restenosis rate for BMS is known to be inversely related to the
postprocedural minimal lumen diameter and the number of stents utilized. 18 In the current study, although the
mean diameter of stent used was significantly greater in the BMS cohort (related to a maximum available SES
diameter of 3.0 mm) with free utilization of postdilation, the postprocedural minimal lumen diameter was not
significantly different between the two groups. The majority of events related to TVR, with, at one year, a
significantly higher rate of survival free of MACE of 96.4% in the SES group versus 82.8% in the BMS group.
Four major randomized trials have demonstrated the efficacy of stent implantation over balloon-only
angioplasty in the treatment of CTOs, reducing the six-month restenosis rate from 68% to 74%, to 32% to 55%.
5-8 Compared with this historical data, our study suggests that the SES confers a marked further advantage with
a significantly lower binary restenosis rate of 9.1% (p < 0.05) (Fig. 2). In addition, we had only one patient
(3.0%) with vessel reocclusion, compared with rates of between 8% to 12% in the same published trials utilizing
BMS. A recent study of the clinical results of 376 patients discharged from hospital without an adverse event
after successful intervention of a CTO showed, at one-year follow-up, a MACE rate of 12.2%; 19 our results are,
therefore, quite remarkable, with a MACE-free survival rate of 96.4%.
Study limitations
This study evaluated only a small cohort of patients, and angiographic follow-up was not obtained in all, so
additional patients with silent reocclusion cannot be excluded. However, those who did not undergo repeat
angiography were all symptomatically well at follow-up. In addition, despite the discrepancy in follow-up
angiography rates between the two groups, which might have biased the results towards more
revascularization in the SES group, the MACE rate remained statistically significant with a beneficial effect in
Post-procedure Proximal 5mm In-stent Distal 5mm
Mean diameter (mm) 2.82 ± 0.66 2.58 ± 0.55 2.10 ± 0.64
Minimal lumen diameter (mm) 2.43 ± 0.51 2.04 ± 0.45 1.75 ± 0.53
% diameter stenosis 14.1 12.9 21.8
6 month follow-up
Vessel reference diameter (mm) 3.02 ± 0.53 2.46 ± 0.81 2.12 ± 0.83
Minimal lumen diameter (mm) 2.33 ± 0.90 1.91 ± 0.68 1.81 ± 0.75
% diameter stenosis 20.1 21.9 18.2
Late lumen loss (mm) 0.10 ± 0.80 0.13 ± 0.46 -0.06 ± 0.54
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favor of the SES. The study was not randomized, and used a retrospective comparitive population; however,
the same operators and interventional techniques were utilized.
Conclusions
The use of SESs in the treatment of complex patients with CTOs is associated with a reduction in the rate of
MACE and restenosis compared with BMS.
Figure 2: The percentage binary restenosis rate (>50% diameter stenosis) and reocclusion rate of Rapamycin-
Eluting Stent Evaluated at Rotterdam Cardiology Hospital registry (RESEARCH) compared with published data
from the patients treated with stent implantation in the randomized trials Stenting in Chronic Coronary Occlusion
(SICCO), 5 Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche (GISSOC), 6 Stents in Total
Occlusion for Restenosis Prevention (STOP), 7 and the Total Occlusion Study of Canada (TOSCA). 8
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Abstract:
Objectives: Long-term results following percutaneous coronary intervention (PCI) with bare
metal stents in the treatment of chronic total occlusions (CTOs) is hindered by a significant
rate of restenosis and re-occlusion. Drug-eluting stents have shown dramatically reduced
restenosis rates for the treatment of relatively simple non-occlusive lesions, though there is
only limited data as to the efficacy in CTO’s. We evaluated the long-term results of the
sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) for the treatment of CTOs.  
Methods and results: From April 2002, all patients at our institution were treated with SES
as the device of choice during PCI. During the first quarter of 2003 the default strategy
changed to the use of PES. Drug-eluting stent implantation was carried out in CTOs (defined
as >3 months’ duration) in 9% of de novo PCI procedures. A total of 76 consecutive patients
were treated with SES implantation, followed by a consecutive series of 57 patients treated
with PES implantation. These patients were compared with a similar group of patients (n=26)
treated with BMS in the 6-month period preceding April 2002.
At 400 days, the cumulative survival-free of target vessel revascularization was 80.8%
in the BMS group versus 97.4% and 96.4% in the SES and PES groups respectively
(p=0.01).
Conclusions: The use of both the SES and PES in the treatment of chronic total coronary
occlusions reduces the need for target vessel revascularization compared to bare metal
stents.
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Introduction
Successful percutaneous therapy of chronic total occlusions (CTOs) has been shown to improve symptoms of
angina and left ventricular function, and reduce the subsequent need for coronary artery bypass surgery. 1-5 In
addition, in the long-term, recanalization of a CTO can reduce mortality compared with those with an
unsuccessful attempt at recanalization. 6 However, the long-term outcome of percutaneous coronary
intervention (PCI) for chronic total coronary occlusions is subject to an increased risk of restenosis and re-
occlusion compared with non-occlusive lesions. 1,7 The advent of drug-eluting stents is revolutionising the
practice of interventional cardiology. Several randomized trials have demonstrated a dramatic reduction in
restenosis rates compared with bare metal stents when used for the treatment of relatively simple lesions. 8-11
In addition, preliminary data has confirmed the efficacy utilizing the sirolimus-eluting stent (SES) for the
treatment of chronic total occlusions. 12 In the present report, we evaluate the use of drug-eluting stent
implantation for chronic total occlusions in a consecutive series of patients, with comparison between the
sirolimus- and paclitaxel-eluting stents.
Methods
The sirolimus-eluting stent (Cypher™, Johnson & Johnson - Cordis unit) received CE mark approval in April
2002. Since that time, all patients undergoing percutaneous therapy in our institution have been treated with
drug-eluting stent implantation as the default strategy. During the first quarter of 2003, our strategy switched
from the sirolimus- to the paclitaxel-eluting stent (Boston Scientific) enabling a comparison of the two stent
types. All consecutive patients with successful chronic occlusion recanalization were enrolled. Those patients
treated with drug-eluting stent implantation were compared to all those treated for a CTO in the preceding 6-
months with bare metal stents (BMS), identified from the departments` dedicated database. All groups were
treated by the same operators utilizing standard techniques; the only difference being the type of stent.
During the procedure, heparin was given to maintain an activated clotting time ≥ 250 seconds. All
patients received lifelong aspirin, and before the procedure were pre-treated with a loading dose of 300mg
clopidogrel. Addition anti-platelet therapy was given with clopidogrel for 1 month in the BMS group, and for 6-
months in the drug-eluting stent groups. The use of Glycoprotein IIb/IIIa inhibitor therapy was at the discretion
of the operator and was only given once wire passage was confirmed as successful. The protocol was
approved by the local ethics committee and is in accordance with the principles of Good Clinical Practice for
Trials of Medicinal Products in the European Community and the Declaration of Helsinki. All patients signed a
written informed consent
Chronic total occlusion definition: Complete occlusion of a coronary artery on angiography, with no
antegrade filling of the distal vessel other than via collaterals. All patients included, had a native vessel
occlusion estimated to be of at least 3-months` duration, based on either a history of sudden chest pain, a
previous acute myocardial infarction in the same target vessel territory, or the time between the diagnosis made
on coronary angiography and PCI.
Length of occlusion: This was measured by quantitative coronary angiography (CAAS II; Pie Medical
Imaging, The Netherlands) either utilizing antegrade filling via collaterals, or assessment of the retrograde
collateral filling achieved through making a simultaneous injection into both the left and right coronary arteries
to delineate the distance between the site of occlusion and the most proximal part of the vessel filled
retrogradely. This length evaluated only the occluded vessel, and did not therefore include stenosis of the
vessel pre- and post- the occlusion.
Follow-up: Patients were prospectively followed-up for clinical events, and evaluated for survival-free of major
adverse cardiac events (MACE) using questionnaires and telephone enquiries. MACE was pre-defined as: 1)
death, 2) non-fatal myocardial infarction (AMI), or 3) repeat target vessel revascularization (TVR). The
diagnosis of AMI required an elevation of creatine kinase to twice the upper limit of normal, together with a rise
in creatine kinase-MB fraction. TVR was defined as either surgical or percutaneous reintervention driven by
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significant (>50%) luminal narrowing within the treated vessel, and was undertaken in the presence of either
anginal symptoms or objective evidence of ischemia. Follow-up angiography was undertaken in all patients in
the presence of anginal symptoms at clinical evaluation; in addition those patients treated during the first 6-
months of DES implantation were invited.
Statistical analysis: Discrete variables are presented as percentages and compared with Pearson’s chi-
square test. Continuous variables are expressed as mean ± standard deviation and compared with one-way
ANOVA. Cumulative survival and MACE-free survival were calculated according to the Kaplan-Meier method.
The log-rank test was used to compare MACE-free survival between the groups. A p value of <0.05 was
considered as significant.
Results
There were no significant differences between the groups with respect to baseline patient characteristics (table
1). Procedural characteristics are presented in table 2. One patient in both the BMS and PES groups had stent
implantation in 2 chronic occlusions. Occlusion length was able to be measured in 74.1%, 84.2%, and 72.4%of
the BMS, SES, and PES groups respectively (p=0.3). Both drug-eluting stent cohorts were treated with a higher
number of stents resulting in a longer length of stented segment.
At one year, there was a single death occurring in hospital, 22 days after successful RCA
recanalization and PES implantation. The patient had been admitted 1 week previously, with no evidence of a
cardiac problem, and the cause of death was related to an inoperable glioblastoma. There were 4 patients who
had an acute myocardial infarction, all treated with drug-eluting stent implantation. The first had SES
implantation for a RCA CTO together with PCI of the LAD. There was a peri-procedural elevation of creatine
kinase (maximum elevation of 854IU/l) related to loss of a sizeable septal branch related to the LAD stent (non-
occluded vessel). The second related to subacute thrombosis occurring 11 days after SES implantation (a
2.5x33mm and a 3.0x33mm) in a LAD occlusion. IVUS suggested that 2.5mm stent was under-expanded and
the patient was treated with a glycoprotein IIb/IIIa inhibitor and balloon dilatation. The third had PES
implantation for a RCA CTO together with treatment of the left main stem. On day 14, he complained of chest
pains and had a maximum CK elevation of 819. Angiography demonstrated an excellent result in the RCA, but
haziness of the ostium of the left circumflex artery which was subsequently treated with further PCI (culprit
lesion in other vessel). The fourth patient had SES implantation (a 2.5x33mm and a 3.0x33mm) for a LAD CTO.
At 6-months, control angiography demonstrated no evidence of restenosis, but he was admitted 4 months later
to another hospital with a myocardial infarction that was managed medically.
Table 1: Baseline patient demographics
BMS
n=26
SES
n=76
PES
n=57
p value
Mean age (years) 60.3 ± 11.0 61.1 ± 10.6 58.4 ± 10.4 0.3
Male sex (%) 92.3 65.8 80.7 0.3
Current smoker (%) 30.8 18.4 22.8 0.5
Diabetes mellitus (%) 7.7 14.5 19.3 0.4
Hypertension (%) 42.3 42.1 50.9 0.7
Hypercholesterolemia (%) 57.7 67.1 75.4 0.6
Previous myocardial infarction (%) 46.2 51.3 43.9 0.8
Previous CABG (%) 0 3.9 5.3 0.5
Glycoprotein IIb/IIIa inhibitor usage (%) 23.1 18.4 19.3 0.9
PCI in at least one additional (non-occluded) major
epicardial vessel during the index procedure (%)
26.9 38.2 47.4 0.4
SES: sirolimus-eluting stents, PES: paclitaxel-eluting stents, CABG: coronary artery bypass grafting, PCI:
percutaneous coronary intervention
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n=76
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2.26 ± 0.42
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58.0 ± 32.8
2.8 ± 0.4
2.6 ± 1.3
11.2 ± 6.6
13.8
50.0
27.6
22.4
PES
n=58
0.6
0.02
0.008
0.04
<0.001
0.03
0.2
0.7
0.5
p value
Table 2: Baseline procedural characteristics
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All events in the bare stent group related to the need for target vessel revascularization. At one year,
the survival-free of target vessel revascularization was significantly higher in the SES and PES groups
compared with the BMS group (97.4% and 96.4% versus 80.8% respectively, p=0.01). Figure 1.
Figure 1: Kaplan-Meier estimates of the cumulative survival-free of target vessel revascularization following
stent implantation in a chronic total occlusion for patients treated with sirolimus-eluting (SES), paclitaxel-eluting
(PES), or bare metal stent (BMS) implantation.
In the present report we have demonstrated the efficacy of drug-eluting stent implantation for the percutaneous
treatment of chronic total occlusions when compared to bare metal stents. In addition, we have shown that both
the sirolimus- and paclitaxel-eluting stent are associated with a low rate of target vessel revascularization at
6months.
There have been several randomized trials that have demonstrated the efficacy of stent implantation
over balloon-only angioplasty for the percutaneous treatment of CTOs, reducing the 6-month restenosis rate
from 68-74% to 32-55%. 13-17 Initial randomized studies of drug-eluting stent implantation, demonstrated
efficacy in reducing restenosis compared to conventional stent implantation, but excluded patients with CTOs.
8-11 However, recent preliminary data from our own group have shown that the efficacy of the SES is applicable
in the treatment of CTOs (defined as >1 months’ duration), with a one year cumulative survival-free of major
adverse cardiac events of 96.4%. 12 In the present study, we evaluate a larger series of consecutive patients
treated for a truly chronic total occlusion (>3 months in duration) with drug-eluting stent implantation. We have
shown that both the SES and PES significantly reduce the need for TVR, with a cumulative survival-free of TVR
of 80.8% in the BMS group versus 97.4% and 96.4% in the SES and PES groups respectively (p=0.01). Figure
1.
Importantly, there were no significant differences in baseline demographics between the groups, and all
procedures were carried out in the same centre by the same operators. Restenosis following BMS implantation
is known to be inversely related to the post-procedural MLD and the number of stents utilized. 18 In the current
study, the mean nominal diameter of stent used was significantly greater in the BMS cohort, related to a
maximum available SES and PES diameter of 3.0mm and 3.5mm respectively. In addition, despite utilizing a
greater number of stents, both the SES and PES demonstrated efficacy over the BMS. Furthermore, the
beneficial effect of the SES occurred despite a smaller post-procedural MLD.
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All major adverse cardiac events in the BMS group related to the need for TVR, including 1 patient who
required coronary artery bypass surgery. Within the drug-eluting stent groups there were 5 additional non-TVR
events. One patient had a subacute thrombosis, but this might have been avoidable with evidence from IVUS
demonstrating a possible underlying mechanism of inadequate stent expansion. In addition, there is good
evidence in a further 3 of these cases that the event was unrelated to treatment of the occluded vessel. One
patient died of non-cardiac causes, and 2 of the myocardial infarctions were thought to be related to
intervention carried out in another (non-occluded) vessel. The fifth patient presented with an AMI in the territory
of the target vessel, 4 months after control angiography demonstrated patent stents. Clopidogrel medication
had been stopped at the time of the follow-up angiogram, such that the patient was on aspirin therapy alone.
The duration of dual anti-platelet therapy needed to reduce / abolish the risk of late stent thrombosis in patients
treated with DES, particularly for complex disease, is still unclear. Recently, Ong et al reported on late (>30
days) stent thrombosis following DES implantation in a consecutive cohort of >2000 patients, they found a low
incidence of 0.35% (95% confidence limits 0.17% to 0.72%). 19 Importantly, there were no episodes in patients
continuing on dual anti-platelet therapy. However, whether there is a true benefit in continuing clopidogrel in
addition to aspirin, over and above the possible disadvantages, requires further large scale evaluation.
   In patients with significant coronary artery disease, although a CTO is found in at least one third, the
majority are treated with either medical therapy or are referred for coronary artery bypass surgery, with
percutaneous treatment of CTOs accounting for only 10-15% PCI procedures. 20 The major limitation of PCI for
CTOs is the inability to cross the lesion with a wire, however great advancements have been made in the
manufacture of specialized wires, and there are additionally promising novel technologies such as the
Intraluminal wire™ and Frontrunner catheter. 21-23 The current report has demonstrated the efficacy of drug-
eluting stent implantation in CTOs and, together with improvements in recanalization rates, a strategy of
percutaneous therapy of CTOs will become more widely applicable.
Study Limitations
The study was not randomized, and angiographic follow-up data was not routinely obtained in all patients, so
additional events such as silent re-occlusion cannot be excluded. However, clinical follow-up was obtained in
>99% patients (all but one patient), and assessment of symptomatic status in those that did not require re-
intervention, showed that all were symptomatically well at follow-up. The study was not randomized, and used a
retrospective comparative population; however the same operators and interventional techniques were utilized.
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Coronary Artery
108
109
Abstract
Chronic total occlusion of the left main coronary artery (LMCA) is rare. Recently,
percutaneous coronary intervention has been increasingly applied to unprotected LMCA
lesions. We describe a patient with chronic total occlusion of the left main coronary artery
who was successfully treated with bifurcation stenting with sirolimus eluting stents.
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Introduction
Chronic total occlusion of the left main coronary artery (LMCA) is a very unusual manifestation of coronary
atherosclerotic disease in clinical practice. 1-4 The rarity of this lesion may be accounted for by the relatively
high incidence of death in these patients. Coronary artery bypass graft surgery (CABG) has been the standard
of care for LMCA disease, though recently, percutaneous coronary intervention (PCI) has been increasingly
applied to unprotected LMCA lesions. 5-12 However, the development of restenosis remains a major limitation of
late outcomes after PCI, with the occurrence of restenosis particularly associated with hazardous clinical
manifestations. Sirolimus-eluting stents (SES) have been shown to dramatically reduce the restenosis rate in
selected patients with relatively simple lesions. 13-15 We report a patient with chronic total occlusion of the left
main coronary artery who was successfully treated percutaneously with SES implantation.
Case report
A 35-year-old male presented with an acute anterior myocardial infarction that was managed medically. He
subsequently complained of on-going chest pain (CCS class II-III angina 16) and underwent coronary
angiography 9-month later. His resting 12-ECG revealed evidence of a previous Q-wave anteroseptal
myocardial infarction and echocardiography demonstrated hypokinesis of the anteroseptal wall without left
ventricle aneurysm. He was referred for coronary angiography which showed a total occlusion of the LMCA
(Figure 1); the left anterior descending coronary artery (LAD) and left circumflex coronary artery (LCX) were
retrogradely filled via Rentrop grade III collaterals 17 from the RCA, which was itself not significantly stenosed
(Figure 2). The patient rejected coronary artery bypass grafting, but consented to undergo attempted
revascularization with percutaneous coronary intervention.
A 6Fr introducer sheath was inserted in the right femoral artery. In addition, a 5Fr introducer sheath
was inserted in the left femoral artery to enable simultaneous right and left coronary injections. In the absence
of antegrade flow through the occlusion, such a dual injection technique allows visualization of the distal
vessels (LAD and LCX) via the collateral filling from the RCA, thereby facilitating correct positioning of the wire.
A 6Fr XB 3.5 guiding catheter (Cordis) was placed in the left main coronary segment, and successful
recanalization was achieved with a 0.0014” Shinobi wire (Cordis), which was advanced into the distal LAD. A
second 0.0014” Shinobi wire was taken, and passage in to the LCX was attempted. Unfortunately this was
complicated by catheter / wire-induced dissection from the LMCA to the mid-LCX (Figure 3), and the wire was
withdrawn. The LAD / distal LMCA was stabilized through stent implantation with a 3.0 x 23mm SES (Cypher,
Cordis), which was then post-dilated with a 3.5mm balloon (U-pass, Cordis) giving a good result (Figure 4).
After several attempts, a 0.0014” Sinobi wire was eventually successfully crossed, via the SES struts, into the
true lumen of the LCX. After sequential predilatation using a 2.0mm balloon (Stomer, Medtronic), both the
lesion and the mid-LCX dissection (Figure 5) were treated with implantation of a 2.5 x 33 mm SES deployed
from LCX ostium. The final angiogram showed a good result with TIMI III flow in both the LAD and LCX 18
(Figure 6).
The patient made an unremarkable recovery and was allowed home. There were no major adverse
cardiac events during the in-hospital period, and at 9-months clinical follow-up he remains well with no
recurrence of angina.
Discussion
Chronic total occlusion (CTO) of the LMCA is rare. In patients who are investigated in the catheter laboratory
its` prevalence varies from 0.04 percent to 0.4 percent. 1-4 CABG has been considered the treatment of choice
in LMCA disease and in particular, is the most favored strategy for chronic total occlusion of the LMCA. There
are a few published reports showing that the results of CABG for this group of CTO`s are beneficial compared
to medical therapy, 1,2 however, there are no studies comparing PCI with CABG for such patients. The advent
of improved PCI equipment including stents and atherectomy devices, have been shown to be a safe and
effective in selected patients with unprotected elective LMCA stenosis, 5-12 and recently Trehan et al have
reported a single case of successful percutaneous stenting of a CTO of an unprotected left main coronary
artery. 19
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Figure 1: Left coronary artery angiogram,
revealing total occlusion of the left main stem
artery.
Figure 3: Left coronary angiogram showing the
dissection of the left main stem artery to the mid-
circumflex artery.
Figure 5: Left coronary angiogram showing that a
wire has successfully crossed through the stent
struts and into the true lumen of the distal left
circumflex artery. The region of dissection can
clearly be seen in the proximal and mid parts of
the vessel (contrast staining).
Figure 2: Right coronary angiogram
demonstrating grade III retrograde collaterals
arising from the right coronary artery to both the
left anterior descending and left circumflex
arteries.
Figure 4: Left coronary angiogram following
stent deployment with a 3.0 x 23mm sirolimus-
eluting stent in the left main stem / left anterior
descending artery.
Figure 6: The final angiogram following
additional stent implantation with a 2.5 x 33mm
sirolimus-eluting stent up to the ostium of the
circumflex artery, showing a good result in both
the left anterior descending and left circumflex
arteries.
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There are 2 major problems associated with PCI for chronic total occlusion of the LMCA. The first
relates to the initial procedural difficulty of crossing the occlusion with a wire; published procedural success
rates for CTO`s are generally in the range of 40-81%. 20,21 The second relates to restenosis; both bifurcation
lesions and CTO`s are subject to a higher rate of restenosis compared with simpler lesions, 22-25 and
importantly, the occurrence of restenosis in the LMCA may be associated with a significant rate of mortality. In
particular, PCI for bifurcation lesions of the distal LMCA whereby both the LAD and LCX arteries are stented, is
both technically demanding and at high risk of restenosis. 26-28 Drug eluting stents have been shown to
dramatically reduce the restenosis rate in elective patients with simple de novo lesions. 13-15 The development
and more widespread application of drug eluting stents hold the promise of a significant reduction in restenosis
and the need for repeat revascularization. Arampatzis et al have reported the effectiveness of SES for the
treatment of LMCA. A total of 31 consecutive patients were treated solely with SESs either electively, for acute
myocardial infarction, or due to procedural complication-related LMCA dissection. In this study, the rate of out-
of-hospital clinical events was extremely low (mortality rate was 0% and target vessel revascularization rate
was 4%). 29 In addition, low subsequent binary restenosis rates following SES implantation have been
documented both in CTO`s (9.1% at 6 months) and bifurcation lesions (22.7% at 6 months). 30,31 The technique
of bifurcation stenting (T, culotte, kissing, or crush stenting) with drug-eluting stents is still controversial. 30
Those techniques resulting in overlapping stent struts lead to an increase in the local concentration of drug,
which may induce endothelial function impairment and thus be associated with an increased rate of stent
thrombosis. In the current report, we present a patient who underwent successful recanalization of a LMCA
CTO without the need for a cardiac support device, and underwent bifurcation stenting, with SESs. There were
no major adverse cardiac events either in-hospital, or over the subsequent 9 months follow up period. Further
data is needed to fully evaluate the use of this strategy in such an unusual patient population, however, SES
supported angioplasty may be a reasonable alternative to CABG in the treatment of LMCA chronic total
occlusion.
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Percutaneous coronary intervention (PCI) of bifurcation lesions is associated with a lower rate of procedural
success,1 and an increased subsequent rate of major adverse cardiac events (MACE) and restenosis
compared with PCI of non-bifurcated lesions. The complexity of bifurcation lesions relates to the need to
maintain patency of both the main vessel and (sizeable) side branch. However, the term “bifurcation lesion”
covers a range of anatomical variations, and, at present, the most effective strategy of PCI for individual lesions
is currently unknown. Indeed studies published thus far have evaluated the efficacy of different stenting
strategies when applied to treat bifurcations in general, and have not been targeted to the individual lesion.
There have been several proposed classifications of bifurcation lesions, one of these, the Duke classification, is
depicted in figure 1. The recently introduced Medina classification is a simple binary system whereby the
presence of significant plaque is represented by a 1 for the proximal main vessel, distal main vessel, and side
branch. The corresponding Medina classification for each lesion subtype is also presented in figure 1. However,
even when only one of the two branches is significantly stenosed at baseline, plaque shift or the “snow-plough
effect” can pose a problem. In addition to plaque distribution, lesions also differ in respect of the degree of
angulation between the main vessel and side branch, something which is of particular importance when utilizing
techniques such as “T-stenting” and specialized bifurcation stents. 
Figure 1: The Duke Classification of bifurcation lesions together with the corresponding Medina binary
classification with respect to variations of plaque distribution.
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Figure 2: Illustrates the rates of cardiac death with respect to the level of creatine kinase following a successful
coronary angioplasty. A series of 4863 consecutive patients were followed up for a mean duration of 41 ± 23
months. If the procedure was associated with an increase in creatine kinase, there was a significant adverse
effect on long-term outcome (p<0.001), even when the elevation was relatively small. From Abdelmeguid et al
Circulation. 1995;91:2733-41. 6
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 Table 1
Study
Length of clinical follow-up
Strategy No. In-hospital MACE
(%)
Restenosis
(%)
TLR (%) MACE
(%)
1 stent 47 4 - 17 25Pan et al 11
   18 months FU 2 stents 23 8 - 39 56
1 stent 39 0 48 36 38Yamashita et al 12
   6 months FU 2 stents 53 13 62 38 51
1 stent 77 3 - 21 27Al Suwaidi et al 13
   1 year FU 2 stents 54 6 - 19 48
1 stent 45 4 28 16 20Anzuini et al 14
   1 year FU 2 stents 45 4 43 36 39
Sheiban et al 15
   9 months FU
2 stents 54 0 63 33 33
Frontier stent 16 
   6 months FU
Bifurcation
stent
105 3 45 13 17
1 stent 22 9 19 5 14Colombo et al 17
   6-months FU 2 stents 63 10 28 10 19
1 stent 47 4 7 2 9Pan et al 18 
   11-months FU 2 stents 44 2 20 5 7
Tanabe et al 19       
   6-months FU
2 stents 58 2 23 9 10
MACE: Major adverse cardiac events; TLR: target lesion revascularization
Stent implantation: drug-eluting stents
The advent of drug-eluting stents, with a marked reduction in the development of restenosis, has lead to the re-
evaluation of bifurcation lesion stenting strategies. Preliminary data of the sirolimus-eluting stent (SES) has
confirmed efficacy when compared with historical data, with overall rates of restenosis of 23-26%, and need for
target lesion revascularization in 8-9%.17,19 In an observational study of the SES in a consecutive group of
patients, restenosis occurred particularly at the ostium of the side branch following the use of a T-stenting
strategy (described below).19 This might reflect incomplete coverage of the ostium thereby reducing the efficacy
of the drug-elution, and suggested that it may be beneficial when using drug-eluting stents to adopt a strategy
that ensures complete lesion coverage. There are currently several on-going randomised trials underway to
evaluate this. 
Preliminary data from Colombo et al of 85 patients randomized to either a single SES versus a 2-SES
strategy, found no significance difference in restenosis rates between the two groups (19% for provisional side-
branch stenting versus 28% for double-stenting).17 However, these results are limited because of a notably high
rate of crossover in the single-stent group to the 2-stent strategy because of a sub-optimal result (51%). In
addition, the strategy of 2-stent implantation was not standardised. Pan et al also randomized patients with a
bifurcation lesion to a single versus a 2-stent strategy, and showed no difference in terms of clinical outcomes.
18 At 6-months angiographic follow-up, restenosis occurred in the main vessel in 2% and 10%, and in the side
branch in 5% and 15%, of patients treated with a single versus a 2-stent strategy respectively. 
Techniques of stenting
General principles 
Angiography must adequately evaluate the bifurcation, in particular whether the side branch ostium is involved
or not. The use of 2 wires is a simple method to ensure that access to each branch is preserved throughout the
intervention. In general the use of pre-dilatation is recommended, and has the advantage of assessing how the
lesion behaves with evaluation of any plaque shift, and facilitation of subsequent stent implantation. Whatever
the stenting strategy chosen, kissing balloon post-dilatation is strongly recommended particularly when both
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branches are stented. Though not detectable on angiography, stent deformation may occur whatever the
technique utilized, and is corrected with kissing balloons.20   
  The most effective technique of stenting of bifurcation lesions remains undefined. Several techniques
and variations of them have been described:
• Single stent with provisional side branch stenting
• T-stenting
• V-stenting
• Culotte technique
• Crush technique
Single stent with provisional side branch stenting (figure 3)
Bare metal stent data favour the use of a single stent within the main vessel. If, at baseline, the side branch
ostium is significantly diseased, then stent implantation may be best preceded by balloon dilatation of the side
branch. Following stent deployment, any compromise of side branch flow can be optimised by re-wiring the side
branch through the stent struts, and carrying out kissing balloon post-dilatation. However, the side branch result
may remain sub-optimal particularly if dissection has occurred. In this case, there remains the option of stenting
the side branch, with the aim of placing the proximal part of the stent just at the side branch ostium without
causing obstruction to the flow within the main vessel. An example is shown in figure 3. Following stent
implantation in the main circumflex artery, the ostium of the obtuse marginal branch was pinched and this was
associated with reduced (TIMI II) flow. After pre-dilatation, the side branch was stented with the proximal part of
the stent located at the ostium. Following deployment, the bifurcation was treated with kissing balloon post-
dilatation with an excellent final result. 
Figure 3: Type B T-stenting of a type D bifurcation of the circumflex / obtuse marginal (A). 
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T-stenting (figure 4)
As shown in figure 4, this involves electively stenting first the side branch, positioning the proximal part at the
ostium, followed by stent implantation within the main vessel. However, the efficacy of both provisional side
branch stenting and T-stenting are limited due to the angle between the main vessel and side branch.
Complete lesion coverage can be accomplished only when there is a large angle between the vessels (a T-
shape). Figure 5. However, in >75% bifurcations, this angle is significantly <70˚ and more of a “Y” shape.21
Even with precise stent positioning, this means that either the ostium of the side branch is incompletely covered
(figure 5a), or the side branch stent protrudes into the main vessel (figure 5b).  
Figure 4: Type A T-stenting of a type F bifurcation lesion of the LAD / diagonal (A). Both vessels were pre-
dilated, and the diagonal branch was stented first with a 2.75x23mm stent placed at the ostium (B), and with a
good result (C). The main vessel was then stented with a 3.0x23mm stent positioned to cover the lesion
thereby covering the ostium of the diagonal (D,E). The final result in both vessels is good (F). 
Figure 5: Only one quarter of bifurcations are of a
“T” shape such that the angle between the 2
branches is >70˚. The majority of bifurcations are
more of a “Y” shape. This means that when
stenting both the main vessel and side branch,
even with precise positioning, either part of the side
branch stent lies within the main vessel thereby
compromising flow (a), or part of the ostium of the
side branch is incompletely covered by stent (b). 
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V-stenting and kissing stents (figure 6)
These techniques similarly involve implantation of both stents simultaneously and therefore require a guiding 
catheter of at least 7F. In general for these techniques both branches are of similar reference diameter. During
kissing stent implantation, the proximal parts of each of the 2 stents are positioned at the same level and the
stents lay side-by-side, similar to a “double-barrelled shotgun,” and thereby bringing forward the carina. In V-
stenting, the proximal parts of the stents only just touch and form a “V” shape. If necessary, a third stent can be
implanted in the main vessel in a so-called “trouser stent” formation.
Figure 6: “V” stenting technique: there is significant plaque in the ostium of a large diagonal branch, and further
plaque more distally within the LAD (A). To minimise problems associated with plaque shift from the diagonal
into the main vessel, both are stented simultaneously. Each vessel is wired, and both stents positioned with the
proximal markers lying alongside each other (arrows, B). The stents are deployed at the same time (C), with an
excellent final result (D). This technique requires a guiding catheter of at least 7F. If there is additionally plaque
within the proximal part of the main vessel, and in the situation whereby both branches are of similar diameter,
the technique can be modified to a “kissing stents” strategy which is done in a similar manner but with the
proximal parts of the stents lying parallel to ensure complete lesion coverage.
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Crush technique (figure 8)
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the struts are opened initially with a small balloon, and then with a balloon of ≥nominal stent diameter size
taken to high pressure. The final result is optimised with kissing balloon post-dilatation. 
Figure 7: Culotte stenting of a type D bifurcation lesion of the distal left main stem (A). 
Both vessels are wired and pre-dilated to facilitate subsequent stent implantation. The circumflex vessel (LCx)
is, in this case, the branch associated with the greatest degree of angulation from the main vessel and is
therefore stented first (B), ensuring the proximal part lies well within the main vessel. This will “trap” the wire in
the left anterior descending (LAD), and another wire is taken and passed through the LCx stent struts to lie
within the lumen of the LAD. The first LAD wire is then withdrawn. After pre-dilatation to open the struts (C), the
LAD is stented such that the proximal part lies in the main vessel within the LCx stent at the same level (D).
This will “trap” the LCx wire, which will need to be withdrawn and the vessel re-wired through the LAD stent
struts. A small balloon is used to open the struts of the LAD stent thereby facilitating passage of a larger
balloon and enabling optimisation with kissing balloon post-dilatation (E), leading to an excellent final result
(F,G).   
Figure 8: Crush stenting of a type F bifurcation lesion of the LAD / diagonal (A). 
Both vessels are wired, and pre-dilated to facilitated stent implantation and positioning. The stents are
positioned as shown in B. Notably, the proximal part of the side branch stent (red arrow) lies well within the
main vessel thereby avoiding incomplete stent coverage of the ostium. Importantly, the entire side branch stent
is covered by the stent within the main vessel (yellow arrow, B). The side branch stent is implanted (C) and the
balloon withdrawn carefully to avoid displacing the stent within the main vessel. The main vessel stent is then
deployed, thereby crushing the proximal part of the side branch stent against the vessel wall (D). The final
result is excellent (E).    
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Dedicated bifurcation stents (figures 9 & 10)
Several stents have been specifically designed for bifurcations with particular emphasis on maintaining ease of
access to the side branch. The JoStent (figure 9A) is designed with an 8 cell mesh at either end, but only 4
larger cells in the middle potentially improving side branch access. Other specialized bifurcation stent designs
incorporate a double balloon system (figure 9B,C) mounted on a single shaft. The Twin-Rail coronary
bifurcation system (Invatec, Italy) consists of a single stent pre-mounted on two balloons in its proximal portion
(both a main vessel and side branch vessel balloon), and only on the main-vessel balloon in its distal portion
(figure 9B). During deployment, guidewire access to the side branch is maintained throughout, and the stent
cell that faces the side branch is well dilated by the side branch balloon. Similarly the ML Frontier stent
(Guidant Corporation) consists of a stainless steel stent mounted on a delivery system with two balloons and
two guide wire lumens. The advantages of these designs are that guide wire crossing is avoided and side
branch access is maintained throughout the whole procedure. The major disadvantage is that these stents are
relatively bulky and can be difficult to track so are not as deliverable as standard stents. Evaluation of the
Frontier stent in a multicenter study of 105 patients demonstrated successful implantation in 96 (91%). At 6-
months, the rate of MACE was just 17%, with a main vessel in-stent binary restenosis rate of 25%, and side
branch restenosis of 29%.16
The Petal™ Stent (AST / Boston Scientific Corp) is depicted in figure 9D. It incorporates a Petal feature
in the middle of the stent (figure 9E), which is designed to expand into the side branch, permitting blood to flow
into both branches of the bifurcation and providing mechanical support at the branch (9F). The combination of
this technology with paclitaxel drug-elution is hoped to improve outcomes.
The Devax Axxess Stent (Devax, California) is a self-expanding, flared nitinol-based stent that can be
implanted in the main vessel right to the carina (figure 10A). It allows for access to the distal branches so that
additional stent(s) can be implanted in the branches as needed (figure 10B). A successful implant will span the
ostia of both branches as indicated by the presence of distal markers, and will cover the entire carina (figure
10C). The uncoated Axxess stent received CE Mark approval in Europe in August 2003. However, an important
recent advance is that the stent has been coated with a bio-erodable polymer together with the anti-proliferative
drug biolimus A9 (Occam International BV, California) at a dose of 22 mcg/mm of stent length. This drug is an
analogue of sirolimus, and has been shown in the animal model to suppress neointimal proliferation and reduce
restenosis. The stent was evaluated in the non-randomized Axxess Plus Trial of 136 patients.26 The Axxess
stent was used together with the option of additional stent implantation distally. At follow-up, there was a low
late loss within the stent (0.09 ± 0.56 mm); the majority (55%) of restenoses were found at the ostium of the
side branch. These occurred mostly in lesions treated with only balloon angioplasty, rather than additional stent
implantation.
Discussion
 Bifurcation lesions present a challenge to the interventional cardiologist, with no clear data on the most
effective strategy of PCI. The majority of published studies do not take into account the wide anatomical
variability, and although there is a clear difference between a “true bifurcation” with disease involving both
branches, and involvement of only one of the branches, the unpredictable nature of plaque shift makes it
difficult to develop generally applicable strategy guidelines. 
 The inherent heterogeneity of lesions included in such studies, together with the lack of randomisation,
means that any comparison between different strategies / stent types should be made with some caution.
However, long-term results have improved since the introduction of drug-eluting stents with a reduction in the
rate of restenosis. Future randomized studies are needed to evaluate the most effective strategy with respect to
differing anatomical variations. In addition, there may be a role for dedicated bifurcation stents designed with
the capability of drug-elution, such stents are able to provide adequate scaffolding with preservation of side
branch access whilst avoiding double / triple layer of stent struts. Future stent designs may even allow for
targeted anti-restenotic drug elution, with delivery of variable drug dosage dependent on the risk of restenosis
in different localities.     
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Figure 9: Illustrations of some of the different stent types available that are specifically designed for side-
branch access or bifurcation treatment. A: The middle section of the Jostent has fewer and larger cells to allow
for easier side-branch access. B: The Twin-Rail coronary bifurcation system (Invatec, Italy). C: The ML
Frontier™ stent (Guidant). D,E,F: The Petal™ Stent (AST / Boston Scientific Corp) incorporates a Petal feature
in the middle of the stent to scaffold the ostium of the side branch. 
Figure 10: The Devax Axxess Stent (Devax, California) is a self-expanding, flared nitinol-based stent. It is
implanted in the main vessel right to the carina (figure 10B, red line); it allows for access to both the distal
branches so that additional stent(s) can be implanted in the branches as needed (yellow lines). The markers
demonstrate that the stent has covered the carina and the ostia of both branches (figure 10C).
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Abstract
Percutaneous coronary intervention of bifurcation lesions is associated with lower procedural
success rates, and an increased subsequent rate of major adverse cardiac events and
restenosis. Currently, an array of stenting possibilities suggests a rational approach to treat
various bifurcation lesions with appropriate techniques. This is however seldom the case.
The main problems of treating bifurcation lesions remain plaque shift leading to (threatened)
side branch occlusion, and either too much or insufficient side branch ostial stent coverage
predisposing to impaired side branch access or restenosis respectively. This paper reviews
the available technologies and their relative merits.
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Introduction
Percutaneous coronary intervention of bifurcation lesions is associated with lower procedural success rates, 1
and an increased subsequent rate of major adverse cardiac events (MACE) and restenosis compared with non-
bifurcated lesions. Various techniques and strategies have been applied in attempt to improve outcomes
including double wire technique, kissing balloon pre- and post-dilatation, stent implantation in the main branch
or both main and side branch by T-, Y-, culotte-, trousers-, skirt-, kissing stents-, crush-, or touching stents
technique. 2-5 This array of stenting possibilities suggests a rational approach to treat various bifurcation lesions
with appropriate techniques. This is however seldom the case. Usually new inventions are applied to most
lesions in an attempt to treat bifurcations in general, and the most effective strategy for different anatomical
variations is currently unknown. The present paper attempts to familiarize the reader with the successive
technical advances available to the interventional community and discuss their successes and failures.
Coronary bifurcation anatomy 
Lesions at a coronary bifurcation may involve either the main vessel alone, and / or the ostium of a side branch.
A classical scheme to categorize coronary bifurcation lesions is the Duke classification (figure 1 below):
However, even when only one of the two branches is significantly stenosed at baseline, plaque shift or the
“snow-plough effect” can pose a problem. Following balloon dilatation or stent implantation, shift of
atheromatous material may occur proximally, longitudinally, and/or circumferentially. 6 When treating the main
vessel, such shift of material can lead to side branch occlusion particularly when the ostium of the side branch
is itself diseased, the side branch is of relatively small diameter, or in the presence of thrombus in acute
coronary syndromes. The clinical consequences of loss of the side branch are dependant on the vessel size,
and are not usually serious with short-lived chest pain and only a modest rise in cardiac enzymes. In addition,
follow-up evaluation, frequently demonstrates restoration of patency. 7 However, following PCI, a more than
three-fold rise in cardiac enzymes above the upper limit of normal has been shown to have prognostic
implications. 8 In the NIRVANA study of the NIR stent implanted across a side branch, side branch occlusion
occurred in 4.7% patients. Of these, occlusion was associated with acute myocardial infarction (creatine-
kinase-MB ≥5x normal) in 40%, including Q-wave infarction in 7%. 9
Balloon angioplasty
In the 1980’s, the majority of patients with a bifurcation lesion were referred for coronary artery bypass surgery.
However, in those who were treated with percutaneous intervention, following identification of the problems
associated with plaque shift, kissing balloon dilatation became the technique of choice. 10,11 The major limitation
of balloon only angioplasty was the occurrence of acute recoil and vessel closure, and subsequent restenosis.
Technical advances in the 1990’s, led to the evaluation of debulking techniques and scaffolding of the vessel(s)
with stent implantation.    
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 Adjunctive atherectomy
Debulking with the use of adjunctive atherectomy might potentially be advantageous over balloon-alone
angioplasty through removal of plaque and prevention of plaque shift. However, results from the randomized
CAVEAT I trial (atherectomy versus PTCA) were not encouraging. 12 Although there was an improved initial
angiographic result with less residual stenosis, this was at the expense of a higher rate of side branch occlusion
and acute myocardial infarction. In the long-term, there was no difference in the incidence of death, myocardial
infarction or restenosis.  
The use of atherectomy prior to stenting has been assessed in 3 studies with some suggestion that
atherectomy might reduce the subsequent need for TLR though with an increased rate of procedural
complications. However, none were randomized, and it’s therefore difficult to make any firm conclusions. 13-15
   
Stent implantation: bare metal stents
The use of stents provides a scaffold to reduce the risk of recoil and acute vessel closure. However, long-term
results have been hampered by the excessive development of neointimal hyperplasia. Following bare stent
implantation, restenosis is known to be inversely related to the stent diameter, and this can be of particular
importance in the therapy of bifurcation lesions where the side branch vessel diameter is often ≤2.5mm. In
addition, even though the side branch may not appear stenosed at baseline, simply stenting the main vessel
may compromise side branch flow through a combination of pinching by the stent struts and plaque shift. It was
thought therefore that stenting of the side branch might be advantageous. Immediate angiographic results
following stent implantation of both the main vessel and side branch are gratifying. However, studies (albeit
non-randomized), have shown that this strategy does not reduce the subsequent rate of MACE, 16 and is
associated with a trend towards a higher rate of restenosis compared to the utilization of a single stent strategy.
17,18 Even with precise stent positioning, such a T-stenting strategy is frequently limited as the angle between
the branches for the majority of bifurcations is significantly <90˚. (Figure 2). This means that either the ostium of
the side branch is incompletely covered (figure 2A), or the side branch stent protrudes into the main vessel
(figure 2B).  
The culotte technique ensures complete coverage of the disease, but leads to a high concentration of
metal with a double stent layer at the carina and in the proximal part of the bifurcation. In addition, crossing of
the struts with a guidewire / balloon may, at times, be difficult. The technique can be time-consuming and fell
out of favour, in one study of 50 patients, though the target vessel revascularization rate was 24%, of the 25
patients with follow-up angiography, restenosis was demonstrated in 14 (56%). 19 Furthermore, an
observational study demonstrated a significantly higher rate of MACE at 1-year following Culotte versus T-
stenting (86.3% versus 30.4%, p=0.004). 16 
Figure 2: Complete lesion coverage can be
obtained with precise stent positioning so long as
the angle between the branches nears 90˚. The
majority of bifurcations however are more of a “Y”
formation. Attempts to use T-stenting will either
leave an area at the side branch ostium uncovered
by stent (A) or part of the side branch stent will
protrude into the main vessel (B). 
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Dedicated stents
Several stents have been specifically designed for bifurcations with particular emphasis on maintaining ease of
access to the side branch. The JoStent is designed with an eight-cell mesh at either end, and only 4 cells in the
middle potentially improving side branch access (figure 3A). 20 The Devax Access Stent is a self-expanding,
flared stent to allow for better access to bifurcation lesions. Additional stents are needed to treat the main
branch and the side branch. Other specialized bifurcation stent designs incorporate a double balloon system
(figure 3B, C).  Most available data are in the form of case reports or registries.
The ML Frontier stent consists of a balloon expandable stainless steel stent mounted on a delivery
system with two balloons and two guide wire lumens designed to maintain wire access to the side-branch
vessel during stent deployment. The advantages of this design are that guide wire crossing is avoided and side
branch access is maintained during the whole procedure. This two-balloon, two-wire system requires a 7F-
guiding catheter. Evaluation of this device was carried out in 105 patients treated at 11 international sites (data
presented by T. Lefèvre at TCT 2003). The ML Frontier  stent was successfully implanted in 96/105 patients,
with the LAD/diagonal bifurcation as the target in 80% of cases. Acute device success by quantitative coronary
angiography was 92%. Two patients had in-hospital myocardial infarction secondary to side branch occlusion
(1 Q-wave and 1 non-Q-wave MI), and one patient underwent planned in-hospital CABG after PCI failure. No
other MACE was observed during the 30-day clinical follow-up. At 180 days, the MACE rate was 17.1% (no
death; Q-wave-MI: 1.9%; non-Q-wave-MI: 1.9%; TLR: 13.3%) and the main branch in-stent and in-segment
binary restenosis rates were 25.3% and 29.9% respectively. These results are certainly comparable with best
results obtained utilizing conventional bare metal stents (see table).
The DBS stent (Cordis) has been evaluated in a multicenter study of 34 patients. Procedural success
was achieved in 94% with, at 6 months, a restenosis rate of 33% and TLR rate of 19%. 21 Other bifurcation
stent devices have also been developed and some data exists in the form of case reports. The Bard-XT Carina
stent is pre-mounted on 2 balloons which connect to a single shaft and are simultaneously deployed with a
single indeflator (figure 4). 22 The AVE bifurcation stent is similarly delivered using the Bard delivery system.
The AST SLK-View™ stent has an aperture in the middle segment of the stent to allow access to the side
branch using a guiding tube. In an initial study of 8 patients, the stent was successfully delivered in all but one,
with no adverse clinical events at 1 month. 23 The Invatec bifurcation stent has either a single or double balloon
stent delivery system. The single balloon system is similar to the AST system mentioned above. The double
balloon system is more like the ML Frontier™ stent except that the side branch balloon is a full dilatation
balloon (but only 1.5 mm diameter) to be used for the kissing technique whereas the ML Frontier™ stent has a
short tapered side branch balloon to allow for side branch access and the physicians choice in treating the side
branch or not.  
 Especially the double balloon stent systems have a higher profile and are less flexible than the other
designs. That means that, in particular, in calcified coronaries their optimal deployment may be less successful.
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Table: Comparative Data of Bifurcation Stenting Studies
Study N In-hosp
MACE
6-Month
RR
6-Month TLR
(total)
6-Month MACE
(total)
Lefevre 3 Period 1 182 5.1 - 20.6 29.2
Period 2 191 4.2 - 13.8 17.1
Yamashita 18 2 stents 53 13 62 38 51
1 Stent 39 0 48 36 38
Colombo 27 2 stents 63 9.5 28 9.5 19
1 Stent 22 9.1 18.7 4.5 13.6
Frontier (Eur Heart J 2004;25
(Abstract Suppl): 309)
105 2.7 44.8 13.3 17.1
Unless indicated, all parameters presented as percent of patients
RR=Restenosis Rate >50% binary restenosis rate
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Figure 3: Illustration of different stent types designed for side-branch access or bifurcation treatment. A: The
middle section of the Jostent has fewer and larger cells to allowfor easier side-branch access. B: The early
BARD side-branch stent carrying a side-branch wire crimped under the proximal main branch stent half. C: The
ML Frontier has a main branch balloon holding the distal stent and a side-branch balloon for ostial protection
that contains the OTW side-branch guide wire. D: The AVE bifurcated stent that was built on the former BARD
platform. This stent has been implanted in but a few patients.
Figure 4: Clinical implantation of one of the very first bifurcated stents in a 47-year-old patient in 1997. 31 A:
LAD/diagonal type-D bifurcation lesion at baseline. B: Positioning of the bifurcated stent at the carina after prior
predilatation. C: Acute angiographic result. D: At 6-months follow-up the bifurcation still demonstrates nice
patency. At 6-years clinical follow-up she was free of symptoms, and working full time.
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Stent implantation: drug-eluting stents
Both the sirolimus- and paclitaxel-eluting stents have demonstrated significantly reduced rates of restenosis
compared with bare metal stents, though bifurcation lesions were excluded from initial randomised studies. 25,26
Preliminary data of the sirolimus-eluting stent (SES) for bifurcation lesions has recently become available, and
has confirmed efficacy when compared with historical data with overall rates of restenosis of 23-26%, and need
for target lesion revascularization in 8-9%. 27,28 One of these studies randomized patients to either a strategy of
using a single SES versus two stents and found that restenosis rates were similar between the two groups
(19% for provisional side-branch stenting versus 28% for double-stenting). However, there was notably a high
rate of crossover to the 2 stent strategy of 51%. 27 In an observational study of the sirolimus-eluting stent in a
consecutive group of patients, restenosis occurred particularly at the ostium of the side branch following the
use of T-stenting. 28 This might reflect incomplete coverage of the ostium thereby reducing the efficacy of the
drug-elution, and suggesting that it may be beneficial when using these stents to adopt a strategy that ensures
complete coverage. Colombo et al first reported the crush technique utilizing SES in 2003, as a technically
straightforward method that ensures complete coverage of the side branch ostium. 29 Of 20 patients, an in-
hospital adverse event occurred in 3 (2 myocardial infarctions, one re-PTCA related to dissection of the main
vessel distal to the bifurcation), with no further events at 1 month. In particular there were no episodes of stent
thrombosis. Further angiographic data on the subsequent rates of restenosis with this technique are pending.
General principles
Angiography must adequately evaluate the bifurcation, in particular whether the side branch ostium is involved
or not. The use of two wires is a simple method to ensure that access to each branch is preserved throughout
the intervention. In general the use of pre-dilatation is recommended, and has the advantage of assessing how
the lesion behaves with evaluation of any plaque shift, and facilitation of subsequent stent implantation. The
major drawback however, is the risk of dissection, or distal embolization particularly of thrombotic material in
acute coronary syndromes. Whatever the stenting strategy chosen, post-dilatation with kissing balloon
dilatation is strongly recommended particularly when both branches are stented. Though not detectable on
angiography, stent deformation may occur whatever the technique utilized, and is corrected with kissing
balloons. 30
 Ostial lesions represent a specific subset of bifurcations (Duke classification E). Although it may be
attractive to simply stent the side branch, plaque shift into the main vessel may pose a problem, and the use of
two wires is to be recommended to protect access to the other vessel. In addition, as with most bifurcations, the
angle at the carina is not usually 90˚, so even with precise stent positioning either the disease is not entirely
covered, or some stent struts protrude into the main vessel.
 
Discussion
 Bifurcation lesions still present a challenge to the interventional cardiologist, with no clear data on the most
effective strategy during PCI. Thus far, the majority of published studies do not take into account the wide
anatomical variability, and although there is a clear difference between a “true bifurcation” with disease
involving both branches, and involvement of only one of the branches, the unpredictable nature of plaque shift
makes the development of hard and fast guidelines more difficult.
 The inherent heterogeneity of lesions included in such studies, together with the lack of randomization,
means that any comparison between different strategies / stent types should be made with some caution.
However, through a reduction in restenosis, drug-eluting stents are certainly having a dramatic impact on the
practice of interventional cardiology, and efficacy certainly appears to be applicable for the treatment of
bifurcations (see table). However, restenosis at the side branch ostium can be a problem following T-stenting,
and alternative strategies such as the crush or culotte technique automatically lead to a region of a double /
triple layer of stent. This increased local dosage of drug could be potentially harmful with delayed re-
endothelialization. In addition, both techniques involve the need to cross stent struts with a guidewire.
Dedicated bifurcation stent systems can be bulky to implant and are, as yet, bare and subject to not
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insignificant rates of restenosis. However, maintenance of side branch access is improved, and the need for
several stent layers is avoided.
The introduction of drug-eluting stents means that new randomized studies are needed to define
guidelines for PCI strategy in the modern era. These studies need also to better evaluate the best technique of
stent implantation particularly with respect to anatomical variations. In addition, there may be a role for
dedicated bifurcation stents designed with the capability of drug-elution. These may be able to provide
adequate scaffolding with preservation of side branch access while avoiding double / triple layer of stent struts.
In addition, future stent designs may even allow for targeted anti-restenotic drug elution, with delivery of
variable drug dosage dependent on the risk of restenosis in different localities.
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Abstract
The percutaneous treatment of coronary bifurcation stenoses is hampered by an increased
rate of subsequent restenosis. The present study reports on the outcomes of a consecutive
series of 58 patients with 65 de novo bifurcation stenoses treated with sirolimus-eluting stent
implantation in both the main vessel and side branch. At 6 months, the incidence of major
adverse cardiac events was 10.3% (1 death and 5 target lesion revascularizations) with no
episodes of acute myocardial infarction or stent thrombosis.
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Percutaneous coronary intervention of bifurcation lesions is associated with lower procedural success rates 1
and an increased subsequent rate of major adverse cardiac events (MACEs) and restenosis. Various
techniques and strategies have been applied in an attempt to improve outcomes, including kissing balloon
dilatation and the use of stent implantation in both branches. 2 The use of adjunctive atherectomy was found to
be disadvantageous in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) trial. 3
Although there was an improved initial angiographic result with less residual stenosis, this was at the expense
of a higher rate of side branch occlusion and acute myocardial infarction. In the long-term, results of
angioplasty in bifurcations have been hampered by problems of restenosis, particularly after stent implantation
within the side branch. 4,5 Recently, sirolimus-eluting stents (SESs) have demonstrated dramatically reduced
restenosis rates in patients with relatively simple lesions. 6,7 We sought to investigate the safety and efficacy of
SESs in a consecutive series of unselected patients with de novo bifurcation lesions enrolled in the Rapamycin-
Eluting Stent Evaluation At Rotterdam Cardiology Hospital (RESEARCH) registry. 8
Since April 2002, SES implantation (Cypher, Johnson & Johnson–Cordis, Miami, Florida) has been
used as the default strategy for all patients treated in our institution, as part of the RESEARCH registry. 8
Briefly, this single-center registry aims to evaluate the efficacy of SES implantation in the "real world" of
interventional cardiology. All consecutive patients were enrolled, irrespective of clinical presentation and lesion
characteristics, and the incidence of MACEs was prospectively evaluated during follow-up. At 6 months, a total
of 563 consecutive patients were treated solely with SESs. Of these, 58 patients (10.3%) with de novo
bifurcation lesions were treated with SES implantation in both the main and side branches; these patients
comprise the present study population. The patients' informed written consent was obtained in accordance with
the rules of the institutional ethics committee, which approved the study.
All procedures were performed with standard interventional techniques, except with the use of the SES
as the device of choice. The strategy of bifurcation stenting employed and the use of kissing balloon dilatation
after procedure was at the operators' discretion. One of 4 methods of stenting was used: T-stenting, culotte
stenting, kissing stents, or the "crush" technique. T-stenting and culotte stenting have been previously
described. 5,9 Kissing stents involved simultaneous implantation of the stents within both branches, with the
proximal edges alongside each other, thereby bringing forward the point of divergence. The crush technique
involves positioning both stents, with the proximal part of the side branch stent lying well within the main vessel,
while ensuring that the edge of the stent in the main vessel is more proximal than the side branch stent. The
side branch stent is deployed first, and the balloon and wire are carefully withdrawn. The main vessel stent is
then deployed, thereby crushing the proximal part of the side branch stent. 10 SESs were available in diameters
from 2.25 to 3.00 mm and lengths from 8 to 33 mm. During the procedure, intravenous heparin was given to
maintain an activated clotting time of ≥250 seconds. All patients were prescribed lifelong aspirin and clopidogrel
for 6 months. The use of glycoprotein IIb/IIIa inhibitors was at the discretion of the operator.
Clinical and angiographic follow-up was performed at 6 months. MACEs were predefined as death,
myocardial infarction, or target lesion revascularization. The diagnosis of myocardial infarction required an
elevation of creatine kinase levels to twice the upper limit of normal, together with an increase in the creatine
kinase-MB fraction. Target lesion revascularization was defined as either surgical or percutaneous
reintervention driven by significant (>50%) luminal diameter narrowing either within the stent or the 5-mm
borders proximal and distal to the stent, and was undertaken in the presence of either anginal symptoms or
objective evidence of ischemia.
Coronary angiograms were obtained in multiple views after intracoronary injection of nitrates. For the
main branches, 3 coronary segments were subjected to quantitative angiography: in-stent, proximal edge, and
distal edge segment. The in-stent analysis encompassed the length of all stents used during the procedure.
The proximal and distal edge segment included up to 5 mm from the proximal and distal edge of the total
segment treated with the study stents, respectively. For the side branches, 2 segments were analyzed: in-stent
and distal edge 5-mm segment. Quantitative coronary angiographic (QCA) analysis was performed using the
Cardiovascular Angiography Analysis System II (CAAS II; Pie Medical, Maastricht, The Netherlands). The
reference vessel diameter, minimal lumen diameter, and percent diameter stenosis were measured before and
after the procedure and at follow-up. The late loss was calculated as the difference between the minimal lumen
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diameter after the procedure and that at follow-up. Binary restenosis was defined as the presence of >50%
diameter stenosis within the target lesion.
Fifty-eight patients with 65 bifurcation lesions were included in this study. Baseline patient
characteristics are listed in Table 1. The lesion characteristics and stenting technique utilized are presented in
Table 2. At 6 months, the survival-free of MACEs was 89.7%. One patient died after bifurcation stent
implantation of the left main stem for an acute myocardial infarction. This patient was admitted in cardiogenic
shock, and despite the use of abciximab and intra-aortic balloon pump support, died shortly after the procedure
due to left ventricular failure. There were no episodes of acute or subacute stent thrombosis, and no patient
had a myocardial infarction. Target lesion revascularization was undertaken in 5 patients (8.6%) as outlined in
the following.
Table 1: Baseline Clinical Characteristics (n=58)
Age (yrs) 63 ± 10
Men 42 (72%)
Hypertension 26 (45%)
Hypercholesterolemia 35 (60%)
Diabetes Mellitus 16 (28%)
Current smoker 16 (28%)
Previous myocardial infarction 22 (38%)
Previous coronary angioplasty 5 (9%)
Previous coronary artery bypass surgery 3 (5%)
1 15 (26%)
2 28 (48%)
No. of coronary arteries significantly narrowed
3 15 (26%)
Presentation with an acute coronary syndrome 18 (31%)
Values are presented as the numbers (relative percentages) or mean value ± SD.
Table 2: Lesion and Procedural Characteristics (number of lesions = 65)
Left anterior descending / diagonal 39 60%)
Left circumflex / obtuse marginal 16 (25%)
Right coronary / posterior descending 4 (6%)
Coronary artery treated with
bifurcation stenting
Left main stem – left anterior descending / circumflex 6 (9%)
T-stenting 41 (63%)
Culotte stenting 5 (8%)
Kissing stenting 2 (3%)
Stenting technique
Crush stenting 17 (26%)
Kissing balloon dilatation after stenting 20 (31%)
Glycoprotein IIb/IIIa inhibitor use 20 (31%)
Values are presented as the numbers (relative percentages).
Of 65 lesions, 6-month angiographic follow-up was performed in 44 lesions. The binary restenosis rate was
22.7% (10 of 44 lesions). QCA data are presented in Table 3. Angiographic restenosis occurred in 4 lesions
within the main branch (1 in the proximal segment; 3 in the in-stent segment), yielding a restenosis rate of
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9.1%. Angiographic restenosis occurred in 6 of the side branches, all within the in-stent segment. Of these 6
restenoses, 5 occurred at the ostium of side branch after the use of T-stenting (Figure 1). All 4 patients with a
restenosis within the main vessel and 1 patient with a restenosis at the ostium of a side branch underwent
percutaneous target lesion revascularization with new drug-eluting stent implantation. Directional coronary
atherectomy was additionally used in 1 patient. The remaining 5 patients, all with ostial side branch restenoses,
were asymptomatic and treated with medical therapy alone.
Table 3: Quantitative Coronary Angiography
Proximal Segment In-stent Segment Distal Segment
Main branch (n=44)
Reference diameter (mm) N/A 2.64 N/A
Preprocedure N/A 0.64 N/A
Post-procedure 2.39 2.19 1.86
Minimal lumen
diameter (mm)
6-mo follow-up 2.26 2.07 1.85
Diameter stenosis at 6 mo (%) 28.3 22.9 25.4
Late lumen loss (mm) 0.12 0.12 0.01
Restenosis rate (%) 2.3 6.8 0
Side branch (n=44)
Reference diameter (mm) 1.99 N/A
Preprocedure 0.61 N/A
Post-procedure 1.80 1.57
Minimal lumen
diameter (mm)
6-mo follow-up 1.49 1.47
Diameter stenosis at 6 mo (%) 31.0 21.9
Late lumen loss (mm) 0.31 0.09
Restenosis rate (%) 13.6 0
Values are presented as mean values or relative percentages.
Figure 1: A 3.0 × 33 mm SES was implanted in the circumflex artery, and a 2.25 × 8 mm SES was implanted in
the side branch (obtuse marginal) with T-stenting technique (A). At 6-month angiographic follow-up, restenosis
occurred at the ostium of the side branch (arrowhead) (B).
A B
SES
2.25 x 8SES
3.0 x 33
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The major findings of this study of bifurcation stenting include the following. (1) SES implantation in both the
main and side branches is feasible and associated with a low procedural complication rate and no episodes of
stent thrombosis. (2) The target lesion revascularization rate of 8.6% is seemingly diminished compared with
historical controls. (3) Angiographic restenosis rates of the main and side branches are 9.1% and 13.6%,
respectively, with an overall restenosis rate of 22.7%. (4) Five of the 6 restenoses occurring in the side branch
were located at the ostium after using the T-stenting technique.
Drug-eluting stent deployment in both vessels to treat bifurcation lesions may raise theoretical
concerns that it could result in a propensity to stent thrombosis. When we treat bifurcation lesions with SESs
using the culotte, kissing, or crush stenting techniques, there are some overlapping stent struts, where the
higher concentration of sirolimus may induce endothelial function impairment and thus be associated with an
increased rate of stent thrombosis. Although these stenting techniques were applied in 37% of the lesions
treated, no stent thrombosis was reported during follow-up, implying that sirolimus has a wide safety margin.
Several strategies have been advocated to treat bifurcation lesions with percutaneous coronary
intervention, such as deployment of stents in both vessels, stenting in 1 branch with balloon angioplasty in the
other, and mechanical debulking. The published reports regarding the subsequent need for target lesion
revascularization utilizing bare stents range from 17% to 53%; 5,11,12 thus, the rate of 8.6% in our study is very
favorable. In addition, the rate observed in the present study may underestimate the true beneficial treatment
effect of SES as explained in the following.
Five of the 6 restenoses in the side branch occurred at the ostium after T-stenting. When we apply T-
stenting, stent positioning must be extremely accurate to ensure complete coverage of the side branch ostium.
This is particularly difficult and/or impossible to achieve when the angle between the 2 branches is much <90°.
Restenosis at this site may therefore be mainly a reflection of incomplete coverage. The restenosis rate in the
side branch following T-stenting was 16.7% (5 of 30 lesions), whereas that following the other stent techniques
was 7.1% (1 of 14 lesions). The present study is limited because the choice of strategy was nonrandomized,
and there is no comparison with alternative strategies, such as the use of stent implantation in the main vessel
alone, with balloon-only angioplasty of the side branch. In addition, the sample size was relatively small, and
any difference between the different techniques was not statistically significant. However, our results suggest
that it seems wise to ensure the complete coverage of the ostium with SESs using stenting techniques other
than T-stenting. The crush technique is technically easier and quicker to do than a culotte, but further data with
longer follow-up from a larger population are needed to fully determine the efficacy of these techniques.
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Abstract
Objective: Both the sirolimus-(SES) and paclitaxel-eluting (PES) stents have been shown to
reduce restenosis rates when used in relatively simple lesions. This study aimed to evaluate
the results of a consecutive series of patients treated with drug-eluting stent implantation for
de novo bifurcation lesions, and compared outcomes with respect to stenting strategy and
stent type.
Patients: From April 2002 to September 2003, all patients at our institution were treated with
drug-eluting stent implantation. A consecutive series of 144 patients were treated for 167 de
novo bifurcation lesions with SES, followed by 104 patients treated with PES for 113 lesions.
Results: Clinical follow-up at 9-months was obtained in 99% patients with survival-free of
major adverse cardiac events (MACE) of 86.7% for SES versus 78.6% for PES, p=0.09.
Independent predictors of MACE were diabetes mellitus, previous CABG, multivessel
disease, and treatment for acute myocardial infarction. Survival-free of target lesion
revascularization (TLR) was 90.9% for SES versus 81.6% for PES, p=0.03, with stent type
being the only independent predictor. Technique of stenting was not a predictor of either
MACE or TLR.
Conclusions: MACE rates for both the SES and PES are low compared with historical data
of bare metal stents. The most effective techniques for bifurcation stenting remain undefined.
Our data suggests a higher need for TLR for the PES compared with the SES, however
further randomized studies are needed to fully evaluate both stenting strategy, and any
difference between the stents.
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Introduction
The outcome of percutaneous therapy (PCI) of bifurcation lesions with bare metal stents is hindered by an
increased rate of procedural complications, 1 and a high rate of restenosis particularly when both the main
vessel and side branch are stented. 2-6 The advent of drug-eluting stents is revolutionising the practice of
interventional cardiology by demonstrating a reduction in the subsequent rate of restenosis. There is evidence
of efficacy in randomized trials for both the sirolimus- (SES) and paclitaxel-eluting (PES) stents for the
treatment of relatively simple lesions. 7,8 In addition, the sirolimus-eluting stent for the treatment of bifurcation
lesions has demonstrated a low rate of adverse cardiac events compared with historical data utilizing bare
metal stents. 9,10 However, the most effective technique of stenting for bifurcation lesions with drug-eluting
stents is currently unknown. In the present report we evaluate the rate of major adverse cardiac events
following PCI for bifurcation lesions treated with either SESs or PESs in a consecutive series of patients. In
addition, outcomes were assessed with respect to the baseline bifurcation anatomy and type of stenting
strategy employed.
Methods
Bifurcation classification: All lesions were classified on baseline angiography according to the Duke
classification (figure 1).
Figure 1: the Duke classification of bifurcation lesions
Procedure: The sirolimus-eluting stent (Cypher™, Johnson & Johnson - Cordis unit) received CE mark
approval in April 2002. Since that time, all patients undergoing percutaneous therapy in our institution have
been treated with drug-eluting stent implantation as the default strategy. During the first quarter of 2003, our
strategy switched from the sirolimus- to the paclitaxel-eluting stent (Boston Scientific) enabling a comparison of
the two stent types. All consecutive patients were enrolled irrespective of clinical presentation and lesion
characteristics, and the incidence of major adverse cardiac events (MACE) was prospectively evaluated during
the follow-up.
All procedures were performed with standard interventional techniques. The strategy of bifurcation
stenting employed, and the use of kissing balloon dilatation post-procedure were at the operators’ discretion.
One of 6 methods of stenting was used: stenting of the main vessel with balloon-only angioplasty of the side
branch; type A T-stenting (stenting first of the side branch, followed by stenting of the main vessel); type B T-
stenting (stenting of the main vessel followed by stenting of the side branch because of a sub-optimal result); 2
the `crush` technique; 11 culotte stenting; 12 or kissing stents (simultaneous implantation in the main vessel and
side branch with the proximal edges of the stents side by side). SESs were available in diameters from 2.25mm
to 3.00mm and lengths from 8mm to 33mm. PESs were available in diameters from 2.25mm to 3.5mm and
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lengths from 8mm to 32mm. During the procedure, intravenous heparin was given to maintain an activated
clotting time ≥250 seconds. Patients were preloaded with 300mg clopidogrel, and received life-long aspirin
together with 75mg clopidogrel per day for 6-months.  The use of glycoprotein IIb/IIIa inhibitors was at the
discretion of the operator. The protocol was approved by the Institutional ethics committee and is in accordance
with the principles of Good Clinical Practice for Trials of Medicinal Products in the European Community and
the Declaration of Helsinki. All patients signed a written informed consent
Follow-up: Clinical follow-up was obtained by investigators who were blinded to the PCI procedural details,
using telephone calls and questionnaires. Follow-up evaluated the rate of major adverse cardiac events
(MACE) which were pre-defined as death, acute myocardial infarction (AMI), or target vessel revascularization
(TVR). The diagnosis of AMI required an elevation of creatine kinase levels to twice the upper limit of normal,
together with a rise in creatine kinase-MB fraction. Target lesion revascularization was defined as either
surgical or percutaneous reintervention driven by significant (>50%) luminal diameter narrowing either within
the stent or the 5mm borders proximal and distal to the stent, and was undertaken in the presence of either
anginal symptoms or objective evidence of ischemia. Target vessel revascularization was defined as
revascularization within the target vessel including encompassing the target lesion. The definition of stent
thrombosis was the presence of intra-stent thrombosis, with or without stent occlusion, documented on
angiography, and was categorized as acute if occurring within 24 hours or subacute if within 30 days after stent
implantation.
Statistical analysis: Discrete variables are presented as percentages and compared with Fisher exact test.
Continuous variables are expressed as mean ± standard deviation and compared with Student’s t test.
Cumulative survival and MACE-free survival were calculated according to the Kaplan-Meier method. The log-
rank test was used to compare MACE-free survival between the two groups. The variables shown in Tables 1
and 2 were tested in Cox regression modeling to identify the independent predictors of adverse events.  Odds
ratio with corresponding 95% confidence intervals are reported. All tests were two-tailed, and a p value of <0.05
was considered as significant.
Results
The baseline patient and procedural characteristics for the SES and PES cohorts are presented in tables 1 and
2 respectively. There were no significant differences between the 2 groups with respect to baseline patient
characteristics, though there was a trend towards an increased usage of glycoprotein IIb/IIIa inhibitors in the
PES group (38.5% versus 27.8% in the SES group, p=0.07). There was no significant difference in the number
of stents used, however, the mean nominal diameter of stent used in the main vessel was greater with the PES
(2.93 ± 0.34mm versus 2.85 ± 0.23 for the SES, p=0.007). For those patients treated with stent implantation in
the side branch, though there was no significant difference in the number of stents used, the total length of
stented segment in the side branch was longer for the PES-treated patients (18.8 ± 10.5mm versus 14.1 ±
7.6mm, p=0.0001). The choice of stenting strategy during the 2 treatment periods is presented in figure 2. The
total number of lesions treated with each stenting technique was single stent utilization in 55 (19.6%), type A T-
stenting in 47 (16.8%), type B T-stenting in 46 (16.4%), crush stenting in 88 (31.4%), culotte stenting in 24
(8.6%), and kissing stents in 20 (7.1%). There was no difference with respect to the use of kissing balloon post-
dilatation between the SES and PES cohorts.
Clinical follow-up was obtained in 99.2% patients. Stent thrombosis occurred in 2 patients treated with
SES (1.4%) and 3 patients treated with PES (2.9%), p=0.4. The demographics of these patients are in table 3.
All episodes of stent thrombosis were subacute (within 30 days following stent implantation), and were treated
percutaneously with kissing balloon dilatation and administration of a glycoprotein IIb/IIIa inhibitor. The only
independent predictor for stent thrombosis was therapy for AMI (HR 9.4; 95% CI 1.57 to 56.21, p=0.01).
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Table 1: Baseline patient demographics
SES
n=144
PES
n=104
p value
Mean age (years) 62.4 ± 10.5 60.3 ± 11.8 0.1
Male sex (%) 74.3 73.1 1
Current smoker (%) 27.1 27.9 1
Diabetes mellitus (%) 18.8 17.3 1
Hypertension (%) 43.1 46.2 0.7
Hypercholesterolemia (%) 56.9 62.5 0.3
Previous myocardial infarction (%) 35.4 38.5 0.2
Previous CABG (%) 4.9 3.8 0.9
Clinical presentation 0.4
Stable angina (%) 65.3 67.3
Unstable angina (%) 21.5 17.3
Acute ST-elevation myocardial infarction (%) 13.2 16.3
Glycoprotein IIb/IIIa inhibitor usage (%) 27.8 38.5 0.07
PCI in at least one additional major epicardial vessel during
the index procedure (%)
40.3 39.4 1
Table 2: Baseline procedural characteristics
Total number of bifurcation lesions treated
SES
167
PES
113
p value
Target vessel 0.3
LAD / diagonal (%) 61.1 56.6
LCX / obtuse marginal (%) 19.2 17.7
RCA bifurcation (%) 9.6 8.0
LMS (%) 10.2 17.7
Bifurcation classification 0.4
A (%) 4.8 3.5
B (%) 7.2 5.3
C (%) 8.4 6.2
D (%) 17.5 20.4
E (%) 8.4 3.5
F (%) 44.0 50.4
Total occlusion (TIMI 0 flow) (%) 9.6 10.6
Pre-dilatation of main vessel (%) 59.3 54.0 0.4
Pre-dilatation of the side branch (%) 42.5 31.9 0.07
Pre-dilatation with kissing balloons (%) 15.0 13.3 0.9
Mean number of stents in the main vessel 1.56 ± 0.84 1.48 ± 0.67 0.4
Mean nominal diameter of stent in the main vessel (mm) 2.85 ± 0.23 2.93 ± 0.34 0.007
Mean total lengths of stent in the main vessel (mm) 30.4 ± 17.7 30.3 ± 17.8 1.0
Mean number of stents in side branch 1.11 ± 0.36 1.13 ± 0.39 0.8
Mean nominal diameter of stent in the side branch (mm) 2.53 ± 0.29 2.60 ± 0.35 0.06
Mean total lengths of stent in the side branch (mm) 14.1 ± 7.6 18.8 ± 10.5 0.0001
Nominal diameter of balloon in side branch for POBA 2.28 ± 0.44 2.19 ± 0.49 0.5
Post-dilatation with kissing balloons (%) 47.3 45.1 0.9
SES: sirolimus-eluting stents, PES: paclitaxel-eluting stents, LAD: left anterior descending artery, LCX:
circumflex artery, RCA: right coronary artery, LMS: left main stem, POBA: plain old balloon angioplasty, CABG:
coronary artery bypass grafting, PCI: percutaneous coronary intervention
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Figure 2: the type of stenting strategy employed for the sirolimus-eluting (SES) and paclitaxel-eluting stent
(PES)
Figure 3: Kaplan-Meier curves for survival-free of major adverse cardiac events (MACE) for the sirolimus-
eluting (SES) and paclitaxel-eluting stent (PES)
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The cumulative incidence of MACE at 9-months for the SES and PES groups are presented in table 4,
and the survival-free of MACE at 9-months is illustrated in figure 3. The independent predictors for MACE and
TLR are shown in table 5. The only factor found to be predictive for TLR was stent type. Neither the baseline
bifurcation anatomy, nor the type of stenting strategy utilized, were predictive of events. At 9-months, survival-
free of TLR was 90.9% for SES versus 81.6% for PES, p=0.03 (figure 4). TLR was for subacute thrombosis in 5
patients (see above), was for restenosis of the main vessel in 4 lesions treated with SES (2.4%) and 6 lesions
treated with PES (5.3%), for restenosis of the side branch in 3 lesions treated with SES (1.8%) and 3 treated
with PES (2.7%), and for restenosis of both branches in 2 lesions treated with SES (1.2%) and 2 treated with
PES (1.8%).
Table 4: Cumulative incidence of major adverse cardiac events at 9-months for the sirolimus- and paclitaxel-
eluting stents
SES
n=144
PES
n=104
p value (log rank)
Death (%) 2.8 4.8 0.4
Death or AMI (%) 6.2 11.4 0.2
Death, AMI, or TLR (%) 11.3 20.5 0.04
Death, AMI, or TVR (%) 13.3 21.4 0.09
SES: sirolimus-eluting stents, PES: paclitaxel-eluting stents, AMI: acute myocardial infarction, TLR: target
lesion revascularization, TVR: target vessel revascularization
Table 5: Independent predictors of major adverse cardiac events and target lesion revascularization at 9-
months
Odds
ratio
95% confidence
intervals
p value
MACE
Previous CABG 3.24 1.13 to 9.34 0.03
Multivessel disease 1.63 1.14 to 2.34 0.008
Diabetes mellitus 2.29 1.17 to 4.48 0.02
Presentation with acute myocardial infarction 2.85 1.31 to 6.24 0.009
TLR
Therapy with sirolimus-eluting stent 0.35 0.14 to 0.84 0.02
Figure 4: Kaplan-Meier curves for survival-free of target lesion revascularization (TLR) for the sirolimus-eluting
(SES) and paclitaxel-eluting stent (PES)
9630
100
90
80
70
60
SES: 90.9%
PES: 81.6%
C
um
ulative survival-free of TLR
 (%
)
Follow-up (months)
Log rank p=0.03
158
Discussion
In the present report we have demonstrated low rates of major adverse cardiac events at 6-months for both the
sirolimus- and paclitaxel-eluting stents when used for the treatment of de novo bifurcation lesions. Independent
predictors for MACE were previous CABG, diabetes mellitus, multivessel disease, and treatment for acute
myocardial infarction. Target lesion revascularization at 9-months was higher in the PES group than the SES
group, with a survival-free of TLR of 81.6% versus 90.9% respectively, p=0.03; stent type was the only
independent predictor of TLR.
The most effective strategy for the treatment of bifurcation lesions with drug-eluting stents is currently
unknown. In the present study, the choice of stenting strategy was at the operators’ discretion. Previous data
from our group following bifurcation stenting with the SES, demonstrated an overall restenosis rate of 23%. 9
The majority of restenoses of the side branch occurred at the ostium following T-stenting. Indeed, the
restenosis rate in the side branch following T-stenting was 16.7% whilst that following other stenting techniques
was 7.1%. We hypothesised that these restenoses might relate to inadequate / incomplete coverage of the
ostium of the side branch thereby reducing the efficacy of the drug-eluting stent. This led to a shift away from a
strategy of T-stenting, towards methods which ensure complete coverage – the crush and culotte techniques of
stenting (figure 2). One potential disadvantage of these strategies however, is that they lead to an area of
double or triple layer of stent struts raising theoretical concerns that the increased dosage of drug at this site
might induce endothelial dysfunction and potentiate the risk of thrombosis. Despite the change in stenting
technique in the present study, the choice of strategy was not an independent predictor for either MACE or the
need for TLR, though interpretation is limited by the lack of randomization, and the relatively small number of
patients in each treatment strategy group.
The SES has been evaluated in one randomized study of bifurcation stenting. 10 This randomized 85
patients to a single SES with balloon-angioplasty of the side branch, versus implantation of 2 SESs. The overall
rate of restenosis at 6 months was 26% (19% in the single stent group versus 28% in the double stent group,
p=NS). However, the study was limited by the high crossover rate with 51% of the patients in the single stent
group crossing to the double stent group because of a suboptimal result in the side branch. In addition, the
approach to stenting technique was not uniform. However, both this randomized study, and the registry data
from our group 9 demonstrate an improvement in the restenosis rates compared with historical data of bare
metal stenting. Despite a restenosis rate of 26%, the rate of TLR in the randomized study was just 8%,
highlighting the fact that restenosis, particularly of the side branch, may not always cause symptoms. The
current study is therefore limited by the lack of angiographic follow up, and cannot fully evaluate restenosis.
Restenosis following bare stent implantation is related to the length of stent, and inversely related to
the diameter. 13 The majority of TLRs were for restenosis within the main vessel stent, yet the nominal stent
diameter was actually bigger for the PES. This probably related to a larger available diameter of PES (3.5mm
versus 3.0mm for the SES), and throughout the study, post-dilatation was carried out whenever necessary. The
mean total length of stent used in the side branch of the PES group was significantly longer than the SES
group. However, neither stent diameter nor length was an independent predictor for subsequent MACE or need
for TLR.
Previous data of bare metal stent implantation in bifurcation lesions, demonstrate rates of target lesion
revascularization of between 16% and 38%. 2-6 Compared with this historical data, in the current study, TLR
was certainly lower for the SES (survival-free of TLR of 95.7% at 6 months). However, regression analysis
demonstrated a significantly higher need for TLR following stenting with the PES compared with the SES, with
the majority of TLRs in the main vessel. This might reflect a difference in the efficacy of the 2 drugs, at least at
the current dosages, or relate to differences in stent design. 14 The SES is a closed-design stent whereby each
cell is bound on all sides with the junction of each strut pair joined to another strut pair junction. The PES
however, is an open-cell design meaning that some of the junction nodes are unattached within the stent
structure. A previous of 54 patients undergoing elective stenting showed that platelet activation was lower in
those receiving a closed versus open-cell designed stent. 15 The same authors examined stent implantation in
the pig model and found that more tissue prolapse occurred following implantation of a stent with an open cell
design. In the present study, though not significantly different between the 2 groups, subacute thrombosis did
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occur in a higher percentage of the PES patients (2.9% versus 1.4%, p=0.4). A large randomized study would
be needed to evaluate this. Importantly, the only independent predictor of stent thrombosis was bifurcation
therapy for acute myocardial infarction. Further studies are needed to evaluate the most effective strategy of
treating bifurcation lesions in the presence of such a high thrombotic environment, however, it would seem
important in this situation to use an aggressive strategy of adjunctive medical therapy such as glycoprotein
IIb/IIIa inhibition.
Both the SES and PES have been evaluated in large randomized studies and compared with their
respective bare stents (Bx Velocity™ and Express™). 16,17 Though the inclusion criteria in these studies were
not absolutely identical, both studies were very similar and included patients with stable or unstable angina and
single de novo lesions; bifurcation lesions were excluded. Both the mean lesion length, and reference vessel
diameter were similar. Evaluation of the angiographic follow-up of those treated with bare stents, showed a
mean in-stent lumen loss of 1.00 ± 0.70mm in SIRIUS (Bx Velocity™), and 0.92 ± 0.58mm in TAXUS-IV
(Express™). The higher late lumen loss in the Bx Velocity™ stent conflicts with the suggestion that the lower
TLR rate with SES in the present study might relate to the difference in stent design. Both the SES and PES
are covered by polymer coatings to facilitate drug-elution. Previous evaluation of other polymers has suggested
that these can in themselves promote varying degrees of an inflammatory response and restenosis, 18 however,
in the same randomized studies, evaluation of the drug-eluting stent cohorts showed excellent results
suggesting safety of the polymers. The mean in-stent late loss was 0.17 ± 0.45mm in SIRIUS, and 0.39 ±
0.50mm in TAXUS-IV, this might perhaps suggest that the SES is more efficacious at inhibiting the
development of neointimal hyperplasia than the PES, though the clinical importance of any difference is
unclear.
Interpretation of the results of the present study with respect to stent type is limited by the lack of
randomization. The REALITY study is a multicenter evaluation of more than 1000 patients with multivessel
disease, randomized to either SES or PES implantation. Patients with bifurcation lesions were not excluded
from this study. Recruitment is complete, and follow-up results are currently pending, but should provide further
data as to whether there is a true difference in efficacy between the 2 stent types.
The most effective strategy for percutaneous therapy of bifurcation lesions with drug-eluting stents
needs to be carefully evaluated in future studies. Interpretation of future randomized studies should take into
account baseline anatomical differences of bifurcation lesions as the best strategy for a true bifurcation lesion
(involving both the main vessel and side branch) may not necessarily be the same as that for lesions affecting
only one of the branches. In addition, restenosis particularly at the side branch may not always lead to a
recurrence in symptoms and follow-up angiography should be carried out to fully evaluate the results.
Study Limitations
The major limitations of this study are that it is a single centre registry and is non-randomized, with the choice
of stenting strategy left entirely at the operators’ discretion. In addition, routine angiographic follow-up data was
not obtained, and additional restenoses giving rise to minimal / no symptoms, particularly at the ostium of the
side branch, cannot be excluded. However, clinical follow-up data was available for >99% providing an
accurate reflection of the rate of clinically important adverse events following therapy of bifurcation lesions in a
consecutive series of patients without exclusion.
Conclusions
The use of both the sirolimus- and paclitaxel-eluting stents for the treatment of de novo bifurcation lesions
appears feasible and safe, both demonstrating relatively low rates of major adverse cardiac events at 9-
months. The increased rate of target lesion revascularization following PES implantation needs to be further
evaluated in a randomized fashion, and at present, the most appropriate technique for bifurcation stenting
remains unclear.
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Abstract
Objectives: To evaluate predictors of an adverse outcome following “crush” bifurcation
stenting.
Background: The “crush” technique is a recently introduced strategy, with limited data
regarding long-term outcomes.
Methods: We identified 231 consecutive patients who underwent “crush” stenting for 241 de
novo bifurcation lesions. Stents used were sirolimus-eluting in 137(56.8%), and paclitaxel-
eluting in 104(43.2%). Clinical follow-up was obtained in 99.6%.
Results: The in-hospital major adverse cardiac event (MACE) rate was 5.2%. At 9-months,
10 (4.3%) patients had an event consistent with post-procedural stent thrombosis. The
survival-free of target lesion revascularisation (TLR) rate was 90.3%; the independent
predictor of TLR was left main stem (LMS) therapy (OR 4.97; 95%CI 2.00 to 12.37,
p=0.001). Survival-free of MACE was 83.5%, independent predictors of MACE were LMS
therapy (OR 3.79; 95%CI 1.76 to 8.14, p=0.001), and treatment of patients with multivessel
disease (OR 4.21; 95%CI: 0.95 to 18.56, p=0.058).
Angiographic follow-up (in 77% lesions) demonstrated a mean late loss of the main
vessel and side branch of 0.30±0.64mm and 0.41±0.67mm respectively, with binary
restenosis rates of 9.1% and 25.3%. Kissing balloon post-dilatation significantly reduced the
side branch late lumen loss (0.24±0.50mm versus 0.58±0.77mm, p<0.001).
Conclusions: With drug-eluting stents, the crush technique is associated with favourable
outcomes for most lesions; however, efficacy appears significantly reduced in LMS
bifurcations, and further research is needed before the technique can be routinely
recommended in this group. The incidence of possible stent thrombosis is of concern and
requires further investigation. Kissing balloon post-dilatation is mandatory to reduce the rate
of side branch restenosis.
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Introduction
The outcome of percutaneous coronary intervention of bifurcation lesions with bare metal stents (BMS) is
hindered by increased rates of procedural complications and long-term major adverse cardiac events compared
with non-bifurcated lesions. 1 Randomized studies have demonstrated that drug-eluting stents (DES) reduce
restenosis when used in relatively simple lesions; 2-5 and recent data have demonstrated efficacy of the
sirolimus-eluting stent (SES)(Cypher™, Cordis/Johnson & Johnson, Warren, NJ) for bifurcation lesions
compared with historical data of BMS. 6-8 In one study of bifurcation lesions, 6 the overall restenosis rate was
23%, with the majority of side branch restenoses occurring at the ostium following use of a T-stenting
technique. Indeed, side branch restenosis occurred in 16.7% following T-stenting, compared with 7.1%
following other stenting techniques. We hypothesised that these restenoses might relate to incomplete
coverage of the side branch ostium thereby reducing the efficacy of the DES.
The “crush” technique of bifurcation stenting with DESs was introduced by Colombo in 2002 as a
relatively simple technique which ensures complete coverage of the side branch ostium (figure 1) thereby
facilitating drug delivery at this site. 9 Initial data of 20 patients treated utilizing this technique with SES suggest
it is a safe method, with an acceptable rate of procedural complications, and no further adverse events up to
30-days follow-up. Recently, angiographic data have shown the importance of simultaneous kissing balloon
post-dilatation in reducing restenosis and need for target lesion revascularization. 10 We evaluated the clinical
and angiographic outcomes of patients treated with either SES or paclitaxel-eluting stent (PES)(Taxus™,
Boston Scientific, Natick, MA) implantation utilizing this strategy at our institutions, and evaluated the predictors
of an adverse outcome.
Figure 1: The crush technique of bifurcation stenting.
A: baseline angiogram with significant stenosis of the left anterior descending / first diagonal bifurcation. B:
both vessels are wired and both stents positioned. A 2.5x12mm Taxus stent is positioned in the side branch
with its’ proximal part well within the main vessel; at the same time, a 3.0x24mm Taxus stent is within the main
vessel, ensuring it completely covers the proximal part of the side branch stent. C: the side branch stent is
deployed and the balloon withdrawn. D: the stent in the main vessel is deployed. E: final result.
Methods
Study population
Demographic and procedural data regarding all patients undergoing angioplasty at EMO Centro Cuore
Columbus, San Raffaele Hospital (Italy), and Thoraxcenter (The Netherlands), are prospectively entered into
dedicated databases. We identified all consecutive patients who underwent bifurcation stenting with the crush
technique utilizing DESs. Initially, therapy was undertaken with the SES beginning in April 2002 when the SES
A E
B
C
Cu
m
165
received CE mark approval. In the first quarter of 2003, patients could also be treated with the PES. Patients
with either stable or unstable angina were included if they were treated for a de novo bifurcation lesion. Those
with acute ST-elevation myocardial infarction were excluded. SESs were available in diameters from 2.25mm to
3.00mm and lengths from 8mm to 33mm; PESs were available in diameters from 2.25mm to 3.5mm and
lengths from 8mm to 32mm.
Procedures and intervention medications
The crush technique is depicted in figure 1, and has been previously described. 9 In short, the procedure
requires a guide catheter of ≥7F. Both the main vessel and side branch are wired and prepared for stent
implantation with pre-dilatation as necessary. The stents are both positioned such that the proximal part of the
side branch lies well within the main vessel, but is completely covered by the stent within the main vessel
(figure 1B). The side branch stent is deployed and the balloon carefully removed ensuring that the stent in the
main vessel remains fixed. The wire within the side branch is commonly also removed, though providing the
wire is not hydrophilic, it may be kept in position. The stent in the main vessel is deployed thereby crushing the
proximal part of the side branch stent (and trapping the side branch wire if still in situ). If present, the wire in the
side branch can then be withdrawn, and post-dilatation of the main vessel stent with high pressure balloon
inflation facilitates use of the side branch wire to re-cross into the side branch to allow kissing balloon post-
dilatation. Kissing balloon post-dilatation was undertaken at the operator’s discretion. The protocol was
approved by the Institutional ethics committees and is in accordance with the principles of Good Clinical
Practice for Trials of Medicinal Products in the European Community and the Declaration of Helsinki. All
patients signed a written informed consent.
During the procedure, intravenous heparin was given to maintain an activated clotting time ≥250
seconds. Patients were preloaded with 300mg clopidogrel, and received life-long aspirin together with 75mg
clopidogrel per day for at least 6-months. The use of glycoprotein IIb/IIIa inhibitors was at the operator’s
discretion.
Clinical Definitions and Follow-up
Clinical follow-up was obtained using either telephone calls or office visit, and evaluated the rate of major
adverse cardiac events (MACE), pre-defined as death, acute myocardial infarction (AMI), or target vessel
revascularization (TVR). The diagnosis of AMI both peri-procedural and at follow-up, required an elevation of
creatine kinase levels to twice the upper limit of normal, together with a rise in creatine kinase-MB fraction.
When in addition to enzyme elevation there were new pathological Q waves on the electrocardiogram, the
event was defined as Q-wave MI. Target lesion revascularization (TLR) was defined as either surgical or
percutaneous reintervention driven by significant (>50%) luminal diameter narrowing either within the stent or
the 5mm borders proximal and distal to the stent, and was undertaken in the presence of either anginal
symptoms or objective evidence of ischemia. TVR was defined as revascularization within the target vessel
including encompassing the target lesion.
Stent thrombosis was defined as an acute coronary syndrome with angiographic documentation of
either vessel occlusion or thrombus within or adjacent to a previously successfully stented vessel, or, in the
absence of angiographic confirmation, either acute AMI in the distribution of the treated vessel, or death not
clearly attributable to other causes. 11,12 Stent thrombosis was categorized according to the timing of the event
into: intra-procedural (angiographic confirmed intra-luminal filling defect within the stent that occurred during the
index procedure), [13] acute (occurred within the first 24 hours after the procedure), subacute (from 24 hours to
30 days) and late (>30 days after the index procedure).
Angiographic evaluation:
Procedural angiographic success was defined as a post-procedural final residual stenosis less than 50% with
Thrombolysis In Myocardial infarction (TIMI) flow 3 in both the main vessel and side branch. Between 6 and 12
months after the index procedure, all living patients were invited back for angiographic follow-up. Coronary
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angiograms were obtained in multiple views after intracoronary injection of nitrates. Quantitative coronary
angiographic (QCA) analysis was performed using one of two validated edge detection systems (CMS, version
5.2, MEDIS, the Netherlands, and the Cardiovascular Angiography Analysis System II (CAAS II), Pie Medical,
The Netherlands. The reference vessel diameter, minimal lumen diameter (MLD) and percent diameter
stenosis were measured at pre-, post-procedure and follow-up. Reference vessel diameter for the side branch
was taken as the diameter of the normal vessel distal to the bifurcation. The late lumen loss was calculated as
the difference between the post procedure and follow-up MLD. 14 Binary restenosis was defined as the
presence of >50% diameter stenosis within the target lesion.
Statistical analysis:
Discrete variables are presented as percentages and compared with Fisher exact test. Continuous variables
are expressed as mean ± standard deviation and compared with Student’s t test. Cumulative survival-free of
adverse events were calculated according to the Kaplan-Meier method. Logistic regression models were
established to investigate independent predictors of TLR and MACE. The following clinical variables were
entered into the analysis model: age, gender, diabetes, stent type, unstable angina, premature antiplatelet
therapy discontinuation, LMS (left main stem) bifurcation, glycoprotein IIb/IIIa inhibitor use, kissing balloon post-
dilatation, nominal stent diameter, and stent length. Odds ratio with corresponding 95% confidence intervals are
reported. All tests were two-tailed, and a p value of <0.05 was considered significant.
Results
The crush technique was utilized in 231 patients (241 lesions), with SES in 137 (56.8%), and PES in 104
(43.2%). The baseline patient and procedural characteristics are presented in tables 1 and 2. The use of
glycoprotein IIb/IIIa inhibitor therapy was significantly higher in the SES group than the PES group (40.8%
versus 19.8%, p=0.001). Attempted kissing balloon post-dilatation was undertaken in 128 lesions, and was
successful in 122 (95%) cases; it was carried out more frequently in the PES group (61.5% versus 42.3% in
SES, p=0.004).
Table 1: Baseline patient demographics
All
n=231
SES
n=130
PES
n=101
p value*
Mean age (years) 62.8 ± 11.2 62.9 ± 11.2 62.6 ± 11.1 0.76
Male sex (%) 193 (83.5) 113 (86.9) 80 (79.2) 0.15
Current smoker (%) 44 (19.0) 24 (18.5) 20 (19.8) 0.87
Diabetes mellitus (%) 46 (19.9) 25 (19.2) 21 (20.8) 0.74
Hypertension (%) 125 (54.1) 76 (58.5) 49 (48.5) 0.14
Hypercholesterolemia (%) 162 (70.1) 91 (70.0) 71 (70.3) 1.0
Family history (%) 103 (44.6) 53 (40.8) 50 (49.5) 0.23
Previous myocardial infarction (%) 95 (41.1) 48 (36.9) 47 (46.5) 0.22
Previous CABG (%) 33 (14.3) 18 (13.8) 15 (14.9) 0.85
Multivessel disease (%) 174 (75.3) 98 (75.4) 76 (75.2) 1.0
Clinical presentation 1.0
Stable angina (%) 172 (74.5) 96 (73.8) 76 (75.2)
Unstable angina (%) 59 (25.5) 34 (26.2) 25 (24.8)
Glycoprotein IIb/IIIa inhibitor usage (%) 73 (31.6) 53 (40.8) 20 (19.8) 0.001
*p value for the SES group versus PES group
CABG: coronary artery bypass graft surgery; PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent
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Clinical Outcomes
The rate of in-hospital adverse events is shown in table 3. There were 3 (1.3%) intra-procedural stent
thromboses (2 in the SES group, 1 in the PES group), 2 of these developed non-Q-wave AMI. The mean total
stent length of these 3 cases was 69 mm and no glycoprotein IIb/IIIa inhibitor had been given electively. After
thrombolytic therapy and further balloon inflation, thrombosis resolved. One additional patient in the SES group
developed a Q-wave MI in hospital due to occlusion of septal branches during the index procedure. By logistic
regression analysis, the only predictor for in-hospital MACE was those patients in whom a glycoprotein IIb/IIIa
inhibitor was used (OR 3.25; 95%CI: 0.99 to 10.60, p=0.051).B
Clinical follow-up data at 9-months was available in 99.6% patients. The cumulative rates of survival-
free of MACE are shown in table 4. Post-procedural angiographically confirmed stent thrombosis occurred in 2
(0.9%) patients (1 acute, 1 subacute) who were both subsequently treated with glycoprotein IIb/IIIa inhibitor
therapy and percutaneous TLR. In addition, 3 further patients died and 5 patients had an AMI within the territory
of the treated vessel, giving a total rate of possible post-procedural stent thrombosis of 4.3%. The
demographics of these 10 patients are presented in table 5. The incidence of post-procedural stent thrombosis
was higher for the PES group than the SES group (6.9% versus 2.2%, p=0.08).
Table 4: Cumulative survival-free of major adverse cardiac events at 9-months
All
n=241
SES
n=137
PES
n=104
p value*
Survival (%) 98.7 99.2 98.0 0.42
Survival-free of Q-wave acute myocardial infarction (%) 96.5 96.9 96.0 0.72
Survival-free of acute myocardial infarction (Q-wave or
non-Q-wave) (%)
90.8 93.1 88.0 0.20
Survival-free of target lesion revascularization (%) 90.3 93.8 85.5 0.046
Survival-free of target vessel revascularization (%) 89.0 93.0 83.6 0.028
Survival-free of major adverse cardiac events (%) 83.5 87.7 78.0 0.053
*p value for the SES group versus PES group
PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent
The overall survival free of MACE and TLR were 83.5% and 90.3%, respectively (figure 2).
Independent predictors for MACE were therapy of the LMS (OR 3.79; 95%CI 1.76 to 8.14, p=0.001), and
therapy of patients with multivessel disease (OR 4.21; 95%CI 0.95 to 18.56, p=0.058). Significantly fewer of the
SES treated patients required TLR compared with those treated with PES. However, logistic regression
demonstrated that the only independent factor for TLR was therapy of the LMS (OR 4.97; 95% CI: 2.00 to
12.37, p=0.001). The rate of survival-free of TLR was 77.8% in those who underwent LMS stenting compared
with 94.2% in the remainder (figure 3).
Quantitative Angiographic Analysis
Procedural angiographic success was achieved in 99.6% lesions. Follow-up coronary angiography was
undertaken in 186 (77.2%) lesions, at a mean period of 8.3±3.7 months. Angiographic data with respect to the
stent type and the use of kissing balloon post-dilatation are presented in tables 6 and 7. There was no
significant difference in angiographic results with respect to the type of stent utilized. However, kissing balloon
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post-dilatation significantly reduced the side branch late lumen loss and binary restenosis. Among the 47
restenotic lesions at the side branch, 34 (72.3%) were focal (<10mm) and located at the ostium.
Discussion
The main findings of this report are: (1) treatment of most bifurcation lesions with DES by the “crush” technique
is associated with low rates of TLR and MACE at 9-months. However, therapy of the left main stem was an
independent predictor of both TLR and MACE; (2) at 9-months, the incidence of possible post-procedural stent
thrombosis was 4.3%; (3) the rate of side branch restenosis was significantly lower in lesions treated with
kissing balloon post-dilatation compared to those without.
Figure 2: Cumulative survival-free of target lesion revascularization (TLR), and major adverse cardiac events
(MACE) following bifurcation stenting utilizing the crush technique.
Figure 3: Cumulative survival-free of target lesion revascularization (TLR) for patients treated with the crush
technique of bifurcation stenting for a left main stem (LMS) lesion compared with those treated for lesions
outside the left main stem (non-LMS).
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Stent coverage of the ostium of the side branch and clinical outcomes
Bifurcation lesions are subject to increased rates of restenosis and need for TLR compared with non-bifurcated
lesions. Historical data of BMSs suggest a TLR rate of 16-38%, with a tendency to increased restenosis
following stenting of both the main vessel and side branch compared with single vessel stenting. 15-19 In the
same studies, the rate of MACE at 6-months ranged between 17-51%. In randomized studies of relatively
simple lesions, DESs reduce restenosis compared with BMSs, though bifurcation lesions were excluded. 2-5
Preliminary data for the SES has recently suggested efficacy in bifurcation lesions. 6-8 However, the most
effective stenting strategy is currently unknown. Previous data of the SES suggested a higher restenosis rate
following T-stenting, with the hypothesis that this might relate to incomplete coverage of the side branch ostium.
6,7 In most bifurcations, the angle at the carina is significantly smaller than 90˚ meaning that even with precise
positioning, the stents are unable to make a “T” and completely cover the bifurcation. 18 The crush technique is
a relatively simple strategy that ensures complete lesion coverage, even for bifurcation lesions that have
extensive disease within the side branch. Preliminary data have suggested acceptable short-term results
suggesting it may therefore be an effective strategy for bifurcation lesions. 9
In the present study, we have demonstrated encouraging long-term results, with a high rate of survival-
free of TLR of 90.3%. Although TLR rates were higher in those treated with PES compared to SES, there were
more patients in this group treated for LMS bifurcation (25.0% versus 15.3%). By logistic regression analysis,
therapy of the LMS was the only independent predictor of TLR. Indeed, at 9-months, the survival-free of TLR
was 77.8% in those who underwent LMS stenting, compared with 94.2% in the remainder. The rate of in-
hospital MACE was 4.8%, the majority comprising non-Q wave AMI. The MACE rate was higher in those who
received a glycoprotein IIb/IIIa inhibitor. However, this is likely to reflect the operators’ decision to use such an
agent only in the situation of a difficult or complicated procedure. There is evidence to suggest improved
efficacy of glycoprotein IIb/IIIa inhibitors with early administration. Further work is needed to evaluate whether
routine pre-procedural administration of such agents to all patients undergoing crush stenting might reduce the
occurrence of in-hospital events.
At 9-months, the overall rate of survival-free of MACE was 83.5%. Independent predictors were the
treatment of multivessel disease, and treatment of the LMS. Recent data has been published specifically
evaluating the results of LMS stenting with DES implantation. 20-23 In all these studies, results suggested lower
rates of restenosis compared with historical data of BMS. The incidence of TLR ranged from 2.0-14.1%. This
appears to be much lower than the LMS cohort in our study where the rate of survival-free of TLR was just
77.8% (compared with 94.2% for non-LMS lesions). However, in the aforementioned studies, restenosis
following LMS bifurcation stenting was higher compared with lesions localised to the ostium or body of the
LMS. Chieffo et al 22 evaluated 85 patients including 69 (81.2%) with disease of the distal LMS. The majority of
these patients were treated with stent implantation to both branches, most (59%) with crush stenting. All 12
patients who required TLR were initially treated with a 2 stent strategy. Park et al 21 demonstrated excellent
results following LMS angioplasty, with a binary restenosis rate of 7.0%. In this study, 70.6% patients were
treated for the LMS bifurcation, and all restenoses occurred in these patients.
Kissing balloon post-dilatation
Although the overall rate of TLR in the present study was relatively low, kissing balloon post-dilatation had a
significant impact on the angiographic results, leading to a significantly larger post-procedural MLD within both
the main vessel and side branch. This larger MLD was maintained in both vessels at follow-up, but was
particularly evident within the side branch. As previously demonstrated by Ge et al, 10 in the present paper,
kissing balloon post-dilatation in the present study significantly reduced both the side branch late lumen loss
(0.24 ± 0.50mm versus 0.58 ± 0.77mm, p<0.001), and binary restenosis rate (9.6% versus 41.3%,
p<0.000001).
The majority (72.3%) of these side branch restenoses were focal and occurred at the ostium. Bench
study results have demonstrated the crush technique to effectively cover the bifurcation lesion, however, the
absence of kissing balloon post-dilatation leads to under-expansion and mal-apposition of the side branch stent
struts. 24 Kissing balloon post-dilatation opens the struts thereby facilitating access to the side branch, and
corrects  stent  deformation  to  provide  optimal  scaffolding  and  delivery  of  drug.   The   crush  technique   is
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technically relatively quick and simple; kissing balloon post-dilatation increases the procedural time and cost,
however, our results suggest that it is a necessity.
Following stent implantation, it can be difficult and time-consuming to re-cross the side branch with a
wire and/or balloon. We recommend routine post-dilatation of the main vessel stent with a balloon (≥nominal
stent diameter) taken to high pressure. Following this, successful access of the side branch and subsequent
post-dilatation, can be achieved in >95% procedures. Stent under-expansion remains one of the major reasons
for restenosis, 25 even in the DES era. 26-28 To enable full stent strut expansion at the side branch ostium, we
initially perform high pressure (>12atm) balloon inflation in the side branch with a balloon ≥nominal stent
diameter. 29 Once both the main vessel and side branch stents have been individually post-dilated at high
pressure, kissing balloon post-dilatation is then undertaken. Notably, the aforementioned bench study 24
emphasised that optimal kissing dilatation requires the size of the balloon in the main vessel ≥nominal stent
diameter.
Bifurcation stenting is known to increase the risk of restenosis with BMS. Accordingly, compared with
the results of randomized studies of non-bifurcation lesions, our results suggest that this also applies to DESs.
Compared with the SIRIUS study, 4 the SES patients in our study demonstrated a higher rate of TLR (5.4%
versus 4.1%) Similarly, compared with the results of TAXUS IV, 5 the PES patients in our study demonstrated a
higher rate of TLR (11.9% versus 3.0%). In addition, compared with these published studies, both groups of
patients in our study had a higher main vessel late lumen loss (0.30±0.60mm versus 0.24±0.47mm for the SES,
and 0.30±0.70mm versus 0.23±0.44mm for the PES).
Stent thrombosis
The 1.3% incidence of intra-procedural stent thrombosis in the present report is slightly higher than the
incidence previously reported in a large series of patients treated with SES (0.7%). 12 The 4.3% incidence of
post-procedural stent thrombosis is of concern, and is higher than the findings of the trials that evaluated DES
implantation in relatively simple lesions (0.4% for SES and 0.6% for PES). 4,5 This may reflect the complexity of
the technique with an increased risk of thrombosis perhaps reflecting the triple layer of stent struts, polymer and
drug at the site of the carina. Notably, in the present study, kissing balloon post-dilatation did not appear to
reduce the risk of stent thrombosis.
The incidence of post-procedural stent thrombosis tended to be higher in the cohort treated with the
PES compared with the SES (6.9% versus 2.2%). This is in accordance with the recently presented results of
the REALITY study. 30 This multicenter study randomized 1353 patients (1911 lesions), to therapy with either
SES or PES. There was a higher rate of stent thrombosis in the PES-treated group (1.8% versus 0.4%,
p=0.02). In the present study, such a high incidence of thrombosis emphasises the importance of an
aggressive strategy of anti-platelet therapy, with administration of dual anti-platelet therapy for a prolonged
(though as yet undefined) period of time. Indeed, 4 of the 10 patients had stopped clopidogrel prior to the
presumed thrombotic event. A recent study has shown that premature discontinuation of dual antiplatelet
therapy is associated with an approximately 30 fold greater risk of stent thrombosis after SES implantation. 11
For patients treated with the crush technique, premature discontinuation of anti-platelet therapy has been
shown to be a predictor of stent thrombosis, 10 and, in conjunction with our results, suggests that the technique
should not be recommended in patients who cannot receive or tolerate dual anti-platelet therapy. Further work
is needed to evaluate the potential benefit of routine pre-procedural administration of glycoprotein IIb/IIIa
inhibitor therapy to all patients treated utilizing this technique.
Study limitations
The main limitation of the present report is its non-randomized design; therefore caution must be taken in
evaluating any differences between the stent types. Furthermore, the study does not make comparison with
alternative stenting strategies. The decision to use both glycoprotein IIb/IIIa inhibitor therapy, and the use of
kissing balloon post-dilatation was at the operators’ discretion and was therefore also not randomized.
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Conclusions
The crush technique of bifurcation stenting with DESs is associated with favourable clinical outcomes when
compared with historical data of BMS. However, the incidence of possible post-procedural stent thrombosis is
of concern, and is higher than that following therapy of more simple lesions, suggesting that an aggressive
strategy of anti-platelet therapy maybe of importance. Importantly, the efficacy of the technique appears to be
reduced in LMS bifurcation lesions, and further research is needed before the technique can be routinely
recommended in this group of patients. When utilizing this technique, kissing balloon post-dilatation is
mandatory to reduce the rate of restenosis of the side branch. Randomized studies are warranted to directly
compare the technique with other bifurcation stenting strategies.
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Abstract
Introduction: The most effective strategy for bifurcation stenting is currently undefined. The
Culotte technique was developed as a method that ensures complete bifurcation lesion
coverage. However, it went out of favour due to a high rate of restenosis when utilizing bare
metal stents. Drug-eluting stents reduce the rate of restenosis and need for repeat lesion
revascularization compared with bare metal stents; we re-evaluated this technique with drug-
eluting stent implantation.
Methods: Between April 2002 and October 2003, 207 patients were treated for at least one
bifurcation lesion with drug-eluting stent implantation to both the main vessel and side
branch. Of these, 23 were treated with the Culotte technique (11.1%) for 24 lesions.
Sirolimus-eluting stents were used in 8.3%, and paclitaxel-eluting stents in the remaining
92.7%.
Results: Clinical follow-up was obtained in 100%. One patient had a myocardial infarction at
14 days (maximum rise in creatine kinase 872IU/L) related to thrombosis occurring in
another lesion, and underwent repeat revascularization. There were no episodes of stent
thrombosis in the Culotte lesions. At 8 months follow-up, there were no deaths and no further
myocardial infarction. One patient required target lesion revascularization (TLR), and a
second underwent target vessel revascularization.  The cumulative rates of survival-free of
TLR and major adverse cardiac events were 94.7% and 84.6% respectively.
Angiographic follow-up was obtained in 16 patients (69.6%) at a mean period of 8.3 ±
4.3months. The late lumen loss for the main vessel and side branch were 0.48 ± 0.56mm
and 0.53 ± 0.33mm respectively, with binary restenosis rates of 18.8% and 12.5%.
Conclusions: In this small study of bifurcation stenting utilizing the Culotte technique with
drug-eluting stent implantation, there was a low rate of major adverse events and need for
target lesion revascularization at 8 months, when compared with historical data of bifurcation
stenting with bare metal stents. Further re-evaluation of this technique utilizing drug-eluting
stents, is warranted in the setting of larger randomized studies.
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Introduction
The outcome of PCI of bifurcation lesions with is hindered by an increased rate of procedural complications, 1
and a high rate of restenosis compared with non-bifurcated lesions. The most effective strategy of bifurcation
stenting is currently undefined, though the majority of historical data assessing bare metal stents evaluated a T-
stenting strategy. 2-6 The angle between the main vessel and side branch in most bifurcation lesions is
significantly smaller than 90˚ making it impossible to make an exact “T” shape even with precise stent
positioning. 4 The Culotte technique ensures complete lesion coverage, however it fell out of favour as studies
with bare metal stents demonstrated a high rate of restenosis at follow-up.
Randomized studies have demonstrated that percutaneous coronary intervention (PCI) with drug-
eluting stent implantation reduces restenosis when used in relatively simple lesions; 7-10 and recent data have
demonstrated efficacy of the sirolimus-eluting stent (SES) for bifurcation lesions compared with historical data
of bare metal stents. 11,12 Data from our group demonstrated that the majority of restenoses of the side branch
occurred at the ostium following T-stenting. 11 Indeed, the restenosis rate in the side branch following T-stenting
was 16.7% whilst that following other stenting techniques was 7.1%. We hypothesised that these restenoses
might relate to inadequate / incomplete coverage of the ostium of the side branch thereby reducing the efficacy
of the drug-eluting stent. In the present study we evaluate the outcome of the Culotte technique utilizing drug-
eluting stents.
Methods
The sirolimus-eluting stent (Cypher™, Johnson & Johnson - Cordis unit) received CE mark approval in April
2002. Since that time, all patients in our institution undergoing PCI have been treated with drug-eluting stent
implantation as the default strategy. During the first quarter of 2003, our strategy switched from the sirolimus-
(SES) to the paclitaxel-eluting stent (PES) (Boston Scientific). All consecutive patients were enrolled
irrespective of clinical presentation and lesion characteristics, and the incidence of major adverse cardiac
events (MACE) was evaluated prospectively during the follow-up. SESs were available in diameters from
2.25mm to 3.00mm and lengths from 8mm to 33mm. PESs were available in diameters from 2.25mm to 3.5mm
and lengths from 8mm to 32mm. Between April 2002 and October 2003, 207 patients with bifurcation lesions
were treated with stenting of both the main vessel and side branch. The choice of stenting strategy was at the
operators’ discretion, and 23 patients (11.1%) were treated utilizing the Culotte technique.
The protocol was approved by the Institutional ethics committee and is in accordance with the
principles of Good Clinical Practice for Trials of Medicinal Products in the European Community and the
Declaration of Helsinki. All patients signed a written informed consent.
Outline of the Culotte technique: The Culotte technique has been well described previously, 13 and an
example is depicted in figure 1. Both vessels are wired and pre-dilatation is generally recommended to facilitate
subsequent stent passage. The vessel with the most acute angulation (usually the side branch) is stented first.
This will “trap” the first wire placed within the main vessel behind the stent struts. The main vessel is therefore
re-wired through the struts of the deployed stent, and the trapped wire is withdrawn. The struts are opened with
balloon dilatation to enable passage of the main vessel stent through the struts such that it lies within the main
vessel, but with its’ proximal part lying within the proximal part of the side branch stent. The main vessel stent is
deployed, thereby “trapping” the wire in the side branch. The side branch is therefore re-wired, and the
“trapped” wire withdrawn. The side branch ostium is dilated to open up the struts of the main vessel, and the
final result is optimised with the use of kissing balloon post-dilatation.
Intervention medications: Before the procedure, patients were preloaded with 300mg clopidogrel, and
received life-long aspirin together with 75mg clopidogrel per day for 6-months. During the procedure,
intravenous heparin was given to maintain an activated clotting time ≥250 seconds; the use of a glycoprotein
IIb/IIIa inhibitor was at the discretion of the operator.
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Figure 1: The Culotte technique of stenting a bifurcation lesion of the left main stem (LMS)(A). Both the left
anterior descending (LAD) and circumflex (LCX) arteries are wired and pre-dilated to facilitate stent
implantation. As the vessel with the most acute angle from the LMS, the LCX is stented first (B). The LAD is re-
wired through the LCX stent struts, and the initial “trapped” LAD wire is withdrawn. Following balloon pre-
dilatation, the LAD stent is positioned through the LCX stent, into the LMS and deployed (C,D). The LCX is re-
wired through the LAD stent struts, and the “trapped” LCX wire withdrawn. Kissing balloon post-dilatation can
then be carried out (E), with an excellent final result (F).
Clinical follow-up: Survival status was assessed by written inquires to the Municipal Civil Registries. Clinical
follow-up was obtained using telephone calls and questionnaires to all living patients, with the referring
physician and general practitioner directly approached whenever necessary. Clinical follow-up evaluated the
rate of major adverse cardiac events (MACE), pre-defined as death, acute myocardial infarction (AMI), or target
vessel revascularization (TVR). The diagnosis of AMI required an elevation of creatine kinase levels to twice
the upper limit of normal, together with a rise in creatine kinase-MB fraction. Target lesion revascularization
(TLR) was defined as either surgical or percutaneous reintervention driven by significant (>50%) luminal
diameter narrowing either within the stent or the 5mm borders proximal and distal to the stent, and was
undertaken in the presence of either anginal symptoms or objective evidence of ischemia. TVR was defined as
revascularization within the target vessel including encompassing the target lesion. The definition of stent
thrombosis was the presence of intra-stent thrombosis, with or without stent occlusion, documented on
angiography.
Angiographic follow-up: Between 6 and 12 months after the index procedure, all patients were invited back
for angiographic follow-up. Coronary angiograms were obtained in multiple views after administration of
intracoronary nitrate. Quantitative coronary angiographic (QCA) analysis was performed using the
Cardiovascular Angiography Analysis System II (CAAS II) (Pie Medical, Maastricht, The Netherlands). The
reference vessel diameter, minimal lumen diameter and percent diameter stenosis were measured at pre-,
post-procedure and follow-up. The late lumen loss was calculated as the difference in post procedure minimal
lumen diameter and that at follow-up. Binary restenosis was defined as the presence of >50% diameter
stenosis within the target lesion.
A
B
C F
E
D
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Statistical analysis:
Discrete variables are presented as percentages and continuous variables are expressed as mean ± standard
deviation. Cumulative survival-free of adverse events were calculated according to the Kaplan-Meier method.
Results
The Culotte technique of stenting was utilized in 24 lesions in 23 patients. The baseline patient and procedural
characteristics are presented in tables 1 and 2. Clinical follow-up data was obtained in 100% patients. One
patient had a myocardial infarction at 14 days (maximum rise in creatine kinase 872IU/L) related to thrombosis
occurring in another lesion, and underwent repeat percutaneous revascularization. There were no episodes of
stent thrombosis in the Culotte lesions. At 8 months follow-up, there were no deaths and no further myocardial
infarction. One patient required target lesion revascularization for restenosis within both the main vessel and
side branch stents. A second patient underwent target vessel revascularization. The cumulative rates of
survival-free of TLR and MACE were 94.7% and 84.6% respectively.
Table 1: Baseline patient demographics
Patients treated with Culotte stenting
n=23
Mean age (years) 63.0 ± 11.8
Male sex (%) 58.3
Current smoker (%) 13.0
Diabetes mellitus (%) 21.7
Hypertension (%) 56.5
Hypercholesterolemia (%) 73.9
Previous myocardial infarction (%) 43.5
Previous CABG (%) 4.3
Multivessel disease (%) 60.9
Clinical presentation
Stable angina (%) 73.9
Unstable angina (%) 21.7
Acute ST-elevation myocardial infarction (%) 4.3
Glycoprotein IIb/IIIa inhibitor usage (%) 30.4
PCI in at least one additional lesion during the index
procedure (%)
43.5
CABG: coronary artery bypass grafting, PCI: percutaneous coronary intervention
Angiographic follow-up was obtained in 16 patients (69.6%) at a mean period of 8.3 ± 4.3months, and results
are presented in table 3.
Discussion
In the present study we have demonstrated efficacy of the Culotte technique of bifurcation stenting when using
drug-eluting stent implantation, with, at 8-months, a high rate of survival-free of major adverse cardiac events
(84.6%) and target lesion revascularization (94.7%), as compared with historical data of alternative stenting
strategies that utilized bare metal stents. These results suggest that the utilization of this technique needs to be
re-evaluated in current practice with drug-eluting stents.
Bifurcation lesions are subject to an increased rate of restenosis and need for repeat lesion
revascularization as compared with non-bifurcated lesions. 1 The Culotte technique ensures complete lesion
coverage, however, studies with bare metal stents demonstrated relatively high rates of TLR of 24-33%, 5,13
with an angiographic restenosis rate in one of these studies of 56%. 13 In addition, the rate of MACE at 1-year
in the smaller study was extremely high at 86.3%. 5 Indeed, several studies of bare metal stents have
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Table 2: Baseline procedural characteristics
Lesions treated with the Culotte technique
n=24
Target vessel
LMS (%) 29.2
LAD / diagonal (%) 45.8
LCX / obtuse marginal (%) 12.5
RCA bifurcation (%) 12.5
Stent type utilized
Sirolimus-eluting stent (%) 8.3
Paclitaxel-eluting stent (%) 91.7
Pre-dilatation of main vessel (%) 62.5
Pre-dilatation of the side branch (%) 37.5
Pre-dilatation with kissing balloons (%) 16.7
Mean number of stents in the main vessel 1.6 ± 0.6
Mean nominal diameter of stent in the main vessel (mm) 2.89 ± 0.41
Mean total lengths of stent in the main vessel (mm) 30.7 ± 14.5
Mean number of stents in side branch 1.1 ± 0.3
Mean nominal diameter of stent in the side branch (mm) 2.78 ± 0.41
Mean total lengths of stent in the side branch (mm) 22.8 ± 11.1
LAD: left anterior descending artery, LCX: circumflex artery, RCA: right coronary artery, LMS: left main stem
Table 3: Quantitative coronary angiography undertaken in 16 lesions.
Main branch Side branch
Reference diameter (mm) 2.44 ± 0.36 2.43 ± 0.66
Length of lesion (mm) 9.1 ± 3.4 8.4 ± 6.2
Minimal lumen diameter (mm)
Pre-procedure 0.85 ± 0.65 0.84 ± 0.74
Post-procedure 2.20 ± 0.35 2.00 ± 0.44
6-month follow-up 1.60 ± 0.57 1.43 ± 0.52
Diameter stenosis (%)
Pre-procedure 70 ± 19 66 ± 26
Post-procedure 15 ± 9 18 ± 11
6-month follow-up 34 ± 20 38 ± 15
Late lumen loss (mm) 0.48 ± 0.56 0.53 ± 0.33
Binary restenosis rate (%) 18.8 12.5
suggested that restenosis rates were generally higher when a more complex “2-stent” strategy is adopted (stent
implantation in both the main vessel and side branch) compared with single stenting only. 2-5 In randomized
studies, drug-eluting stents have been shown to reduce restenosis compared with bare metal stent implantation
in relatively simple lesions, though bifurcation lesions were excluded. 7-10 Further preliminary data for the
sirolimus-eluting stent (SES) has more recently suggested efficacy in bifurcation lesions, 11,12 though the most
effective strategy of stenting is currently unknown. These studies suggested a higher restenosis rate following a
strategy of T-stenting, with the hypothesis that this might relate to incomplete coverage of the side branch
ostium thereby reducing the efficacy of drug-elution. 11,12 In the present study, there was a relatively high
percentage of patients with diabetes mellitus (21.7%), and almost one third were treated for a bifurcation lesion
of the left main stem. We have demonstrated impressive long-term results of the Culotte technique when drug-
eluting stents are utilized, with only one TLR at 8-months. In addition, the survival-free of major adverse events
was 84.6%, with one of the 3 events related to thrombosis of an entirely different lesion.
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The SES has been evaluated in one randomised study of bifurcation comparing a single stent with a 2-
stent strategy. 12 The results suggested that, even with drug-eluting stents, it may be preferable to only stent
the main vessel, and carry out balloon-only angioplasty in the side branch. On follow-up angiography, there
was a trend towards a lower rate of restenosis in those treated with 1 stent compared with a 2-stent strategy
(18.7% versus 28.0%, p=0.5). However, there was a very high rate of crossover from the 1 stent group to the 2
stent group of 51%, related to a sub-optimal result in the side branch. Furthermore, the strategy used in the 2
stent group was at the operators’ discretion and therefore heterogeneous. This study emphasises some of the
difficulties faced when treating bifurcation lesions. At baseline, a true bifurcation will have significant narrowing
of both the main vessel and side branch. However, whatever the baseline anatomy, implantation of a stent
within the main vessel can lead to plaque shift into the side branch therefore compromising side branch flow.
Importantly, occurrence of such shift is unpredictable, 14 and the operator is then faced with the question as to
how to deal with the side branch most effectively. The Culotte technique ensures complete lesion coverage
and, with drug-eluting stents, may offer a useful strategy for treating bifurcation lesions. In particular, it can be
done using a 6F sheath (other techniques such as the crush technique 15 or kissing stents require a guide of at
least 7F), and, by covering the entire lesion, will minimise the importance of any plaque shift. In addition, it can
provide a “backup” strategy for stenting of the side branch if the result following single stent implantation in the
main vessel is sub-optimal. The major drawback to the technique is that it tends to be quite time-consuming,
predominantly related to the need to re-wiring the vessels. Though it has not occurred in our experience, failure
to re-wire the vessels could lead to procedural failure. In addition, there will be a double layer of stent struts in
the proximal vessel. This raises some concerns, as the increased dosage of drug at this site may predispose to
stent thrombosis. The technique needs to be fully evaluated in large studies, and randomization is needed to
compare the relative efficacy of different stenting strategies particularly related to baseline anatomy.
Study limitations
The present study comprises a consecutive series of patients treated with the Culotte technique. However, the
study was small and non-randomized, with no direct comparison of drug-eluting stent implantation utilizing
alternative stenting strategies.
Conclusions
In this small study of bifurcation stenting utilizing the Culotte technique with drug-eluting stent implantation,
there was a low rate of major adverse events and need for target lesion revascularization at 8-months when
compared with historical data of bifurcation stenting with bare metal stents. Further re-evaluation of this
technique utilizing drug-eluting stents, is warranted in the setting of larger randomized studies.
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Abstract
Objectives: We sought to determine the real-world incidence of angiographically confirmed
and possible stent thrombosis (ST) in an unrestricted population during the first 30 days after
bare-metal stent (BMS), sirolimus-eluting stent (SES), and paclitaxel-eluting stent (PES)
implantation.
Background: Current data on ST in drug-eluting stents (DES) have come from randomized
trials with strict entry criteria, which limits their generalizability to daily practice.
Methods: The study population comprised three sequential cohorts of 506 consecutive
patients with BMS, 1,017 consecutive patients with SES, and 989 consecutive patients
treated with PES.
Results: In the first 30 days after stent implantation, 6 BMS (1.2%, 95% confidence interval
[CI] 0.5% to 2.6%; p = 0.9), 10 SES (1.0%, 95% CI 0.5% to 1.8%), and 10 PES (1.0%, 95%
CI 0.6% to 1.9%) patients developed angiographically proven ST. Multiple potential risk
factors were identified in most patients with ST. Bifurcation stenting in the setting of acute
myocardial infarction was an independent risk factor for angiographic ST in the entire
population (odds ratio [OR] 12.9, 95% CI 4.7 to 35.8, p < 0.001). In patients with DES who
had angiographic ST, 30-day mortality was 15%, whereas another 60% suffered a nonfatal
myocardial infarction; no further deaths occurred during six months of follow-up. Including
possible cases, 7 BMS (1.4%, 95% CI 0.7% to 2.8%), 15 SES (1.5%, 95% CI 0.9% to 2.4%),
and 16 PES (1.6%, 95% CI 1.0% to 2.6%) patients had ST.
Conclusions: The unrestricted use of SES or PES is associated with ST rates in the range
expected for BMS. Stent thrombosis was associated with a high morbidity and mortality.
Bifurcation stenting, when performed in patients with acute myocardial infarction, was
associated with an increased risk of ST.
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Introduction
Drug-eluting stents (DES) reduce clinical events related to restenosis. Concerns have been raised regarding
the incidence of stent thrombosis (ST) with the unrestricted use of these stents. Data from the bare-metal stent
(BMS) era report a high morbidity and mortality with ST. 1,2 Evidence for ST in DES has come from randomized
controlled trials with strict entry criteria for the treatment of single lesions, limiting conclusions that are
applicable to the real-world setting. 3-6 Other information has come from electronic registries with inherent
biases that preclude generalization of the findings. A single-center registry recently reported its results with
sirolimus-eluting stents (SES). 7 The aim of this present study is to describe the incidence of ST (both
angiographically proven and including possible cases) in three consecutive populations while analyzing the
unrestricted use of a control BMS group, SES, and paclitaxel-eluting stents (PES).
Methods
Study design and patient population
Since April 2002, SES (Cypher; Cordis Corp., Miami Lakes, Florida, a Johnson & Johnson Company) have
been the stents of choice for all percutaneous coronary interventions irrespective of their clinical presentation or
clinical outcome. 8 In the first quarter of 2003, PES (Taxus; Boston Scientific Corp., Natick, Massachusetts)
replaced SES as the default stent. This present study comprises three sequential cohorts: a control group of
the last 506 consecutive patients treated with BMS before April 2002; 1,017 consecutive patients with SES
treated between April 2002 and February 2003; and 989 consecutive patients with PES treated between
February 2003 and December 2003.
Procedure and antiplatelet management
All interventions were performed according to current standard guidelines, and the final interventional strategy
including periprocedural glycoprotein IIb/IIIa and intravascular ultrasound use, was left to the discretion of the
operator. Patients were pretreated with aspirin and a loading dose of 300 mg of clopidogrel. After their
procedure, all patients were prescribed a lifelong aspirin regimen. Clopidogrel was prescribed for at least one
month in the BMS group, for at least three months in the SES group, 8 and for at least six months in the PES
group.
Follow-up
As part of the national health system, our institution as a tertiary referral center is the only interventional facility
within our catchment area. The survival status of our patients at one and six months after discharge was
obtained from the Municipal Civil Registries. Details of all repeat interventions (surgical and percutaneous)
were collected prospectively during follow-up. Referring physicians and institutions were contacted whenever
necessary for additional information. This protocol was approved by the Hospital Ethics Committee, and written,
informed consent was obtained from every patient.
Definitions
Stent thrombosis was considered to have occurred when confirmed angiographically: either Thrombolysis In
Myocardial Infarction (TIMI) flow grade 0 or 1 or the presence of flow-limiting thrombus (TIMI flow grade 1 or 2)
occurring in an acute (within 24 h of stent implantation) or subacute (between 1 and 30 days) time period after
stent implantation. 9 In addition, a clinical definition of “possible stent thrombosis” was used for patients who
within the first 30 days experienced sudden death, who suffered a fatal out-of-hospital cardiac arrest, or who
suffered a myocardial infarction (MI) that was not clearly attributable to another coronary lesion and who did not
undergo repeat angiography. All deaths and MIs were reviewed independently by two interventional
cardiologists (A.O., E.Mc.F) for “possible stent thrombosis.”
Statistical analysis
Categorical variables were compared using the Fisher exact test and continuous variables with the Student t
test or one-way analysis of variance where appropriate. Univariate and forward stepwise (entry criteria of 0.05
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and exit criteria of 0.10) multivariate logistic regression analysis were performed to identify characteristics or
variables independently associated with stent thrombosis. From the univariate analysis, the following baseline,
clinical, angiographic and procedural variables were entered into the multivariate model: bifurcation stenting,
diabetes, smallest stent diameter, multilesion stenting, and acute myocardial infarction (AMI) as the indication.
All probability values are two-sided, and statistical significance was set at the 0.05 level. A cumulative event
graph consisting of patients with angiographic stent thrombosis was generated plotting the proportion of
patients with stent thrombosis (Y-axis) against time (X-axis) stratified by stent type. Incidences of stent
thrombosis are reported as a percentage with associated 95% confidence intervals (CIs).
Results
Baseline and procedural characteristics
The patients in our cohort were at high risk, with unstable angina or AMI being the indication in more than one-
half of the cases (Table 1). Multivessel disease was present in more than one-half of the population. One-third
of the population had a previous AMI, whereas one-quarter had previous coronary interventions. Glycoprotein
IIb/IIIa use was lower in the SES and PES groups compared with the BMS group.
Table 1: Baseline and Procedural Characteristics
BMS
(n = 506)
SES
(n = 1,017)
PES
(n = 989)
p value
Baseline characteristics
 Age, yrs, mean ± SD 61.0 ± 11.4 61.9 ± 11.3 61.7 ± 11.4 0.3
 Male, % 73 70 74 0.1
 Diabetes, % 16 18 17 0.6
 Hypercholesterolemia, % 52 55 60 <0.01
 Current smoker, % 35 28 28 <0.01
 Hypertension, % 40 41 41 0.9
 Previous MI, % 43 32 35 <0.01
 Previous PCI, % 22 25 26 0.2
 Previous CABG, % 11 9 8 0.2
 Multivessel disease, % 54 57 56 0.4
Indication for index procedure <0.01
 Stable angina, % 42 43 41
 Unstable angina, % 35 36 30
 Acute MI, % 20 19 26
 Silent ischemia, % 3 2 3
Number of vessels treated, mean ± SD 1.4 ± 0.6 1.4 ± 0.6 1.4 ± 0.6 0.8
 LAD, n 281 594 540
 LCx, n 164 332 333
 RCA, n 194 398 384
 Others, n 29 75 90
Total stent length, mm (mean ± SD) 31.9 ± 22.1 42.5 ± 29.6 44.2 ± 29.4 <0.01
Stents implanted, mm (mean ± SD) 1.9 ± 1.1 2.3 ± 1.5 2.2 ± 1.4 <0.01
At least one ≤2.5 mm stent implanted (%) 23 38 38 <0.01
Bifurcations stented, % 5 18 17 <0.01
Glycoprotein IIb/IIIa use (%) 37 21 28 <0.01
BMS = bare metal stent; CABG = coronary artery bypass grafting; LAD = left anterior descending; LCx = left
circumflex; MI = myocardial infarction; PCI = percutaneous coronary intervention; PES = paclitaxel-eluting stent;
RCA = right coronary artery; SES = sirolimus-eluting stent.
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Clinical outcome
Angiographic ST was documented in 26 of 2,512 patients (Table 2). Six cases occurred in the BMS group
(1.2%, 95% CI 0.5% to 2.6%), 10 cases occurred in the SES group (1.0%, 95% CI 0.5% to 1.8%), and 10
cases occurred in the PES group (1.0%, 95% CI 0.6% to 1.9%). The first two SES patients with ST have been
reported previously. 10 Most stent thromboses occurred in the first 11 days, regardless of stent type, with a
mean time to event of 5.8 ± 5.4 days (Fig. 1).
Table 2: Outcome Following Angiographic Stent Thrombosis
BMS SES PES p value
Angiographic stent thrombosis, n (%) 6 (1.2%) 10 (1.0%) 10 (1.0%) 0.9
Clinical presentation
 Acute MI, n 5 7 8
 Angina, n 1 3 2
Maximum total CK, mean ± SD 4,983 ± 2,570 1,268 ± 476 3,361 ± 1,404 <0.01
Maximum CK-MB, mean ± SD 397 ± 186 171 ± 80 322 ± 166 <0.01
Outcome
 30-day mortality, n 0 0 3
 6-month mortality, n 0 0 3
CK = creatine kinase; other abbreviations as in Table 1.
Figure 1: Cumulative incidence of angiographic stent thrombosis stratified by groups against time.
Vertical line = day 11 on horizontal axis. BMS = bare-metal stents; PES = paclitaxel-eluting stents; SES =
sirolimus-eluting stents.
In the BMS population, there were two acute stent thromboses and four subacute stent thromboses. Among the
six patients, ST presented as AMI in five patients. None died during the six months of follow-up (Table 2). In the
combined group of SES and PES (2,006 patients), there were 2 cases of acute ST and 18 cases of subacute
ST (Fig. 1). A detailed description of these patients is given in Table 3. Analysis via intravascular
ultrasonography was performed in four patients. In most patients, at least one recognized risk factor for ST (i.e.,
long stented length, use of small stents, use of multiple stents, and residual dissection after stent implantation)
was present. Importantly, 2 of the 20 patients had not taken clopidogrel.
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Mortality and morbidity
Overall, 20 of 26 patients (77%) re-presented with an AMI, whereas the other 6 re-presented with angina
pectoris (Table 2). Of these 26 patients, 3 (Patients #12, #18, and #20 from Table 3—all in the DES population)
died at days 11, 5, and 3, respectively. Two patients died during reintervention from intractable ventricular
fibrillation, whereas the third underwent emergency surgery after a suboptimal reintervention and could not be
weaned from bypass. The incidence of death at 30 days was 12%, whereas another 65% suffered a nonfatal
MI. Among the survivors of ST, there were no further deaths in the six months after reintervention.
Possible ST
Thirty-day survival data was complete for 98% of patients (Table 4). There were 12 patients who were judged
with “possible stent thrombosis,” of which 9 died and 3 had nonfatal MIs. Of the nine deaths, four were out-of-
hospital sudden deaths, three occurred in hospital with ventricular tachycardia as the initiating preterminal
rhythm, and two had ST-segment elevation and died before they could undergo reangiography. Among those
with MIs, one patient developed a postprocedural enzyme leak, and another developed ventricular fibrillation
requiring multiple cardioversions the day after the procedure. Repeat coronary angiography six months later
demonstrated occluded stents in both of these patients; whereas a third underwent coronary angiography 14
days after stent implantation because of an increase in cardiac enzyme levels, which demonstrated an in-stent
filling defect which was treated with abciximab, and subsequently underwent repeat percutaneous coronary
intervention two weeks later. Including the suspected cases, the combined incidence of angiographic and
possible ST was 1.4% (95% CI 0.7% to 2.8%) in the BMS control group, 1.5% (95% CI 0.9% to 2.4%) in the
SES group, and 1.6% (95% CI 1.0% to 2.6%) in the PES group. In the combined total of 38 documented and
possible ST, there were 12 deaths (32%) and 20 nonfatal MIs (53%) in the first 30 days.
Table 4: Incidence of Stent Thrombosis Classified by Definition
Stent
Type
Number of
Patients
Angiographically Proven
Stent Thrombosis
n (% [95% CI])
Possible Stent
Thrombosis
n (% [95% CI])
All Stent Thrombosis
n (% [95% CI])
BMS 506 6 (1.2% [0.5%–2.6%]) 1 (0.2% [0.0%–1.1%]) 7 (1.4% [0.7%–2.8%])
SES 1,017 10 (1.0% [0.5%–1.8%]) 5 (0.5% [0.2%–1.1%]) 15 (1.5% [0.9%–2.4%])
PES 989 10 (1.0% [0.6%–1.9%]) 6 (0.6% [0.3%–1.3%]) 16 (1.6% [1.0%–2.6%])
CI = confidence interval; other abbreviations as in Table 1.
Multivariate analysis
By univariate analysis, bifurcation stenting was the only significant factor (p = 0.01). Multivariate analysis was
performed with the following covariates based on their significance on univariate analysis as well as their
potential clinical impact: diabetes (p = 0.07), smallest stent diameter (p = 0.13), multilesion stenting (p = 0.17),
AMI as the indication (p = 0.3), and bifurcation stenting. By multivariate analysis, bifurcation stenting was the
only independent predictor of ST (odds ratio [OR] 3.0, 95% CI 1.3 to 6.8, p < 0.01). When the interaction of
bifurcation stenting by AMI was entered as a covariate, it was highly significant (OR 12.9, 95% CI 4.7 to 35.8, p
< 0.001), and bifurcation stenting as a covariate was no longer significant.
Discussion
The main findings in this study can be summarized as follows: 1) the incidence of angiographic ST in an
unselected, complex DES population was low ( 1.0%), within the same range as the corresponding BMS
population and concordant with previously published results from the BMS era; 2) the inclusion of possible ST
increases the overall incidence of ST to 1.5%; 3) angiographically proven ST was associated with a high
mortality and morbidity; 4) patients who developed ST often had multiple high-risk features, regardless of stent
type; and 5) the association of bifurcation stenting for AMI was a highly significant independent risk factor for
ST.
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The availability of DES as the default stent at our institution has allowed us to analyze this new
technology in an unrestricted population, 8 a population that would have comprised any BMS population in the
pre-DES era. Therefore, this availability allows us to analyze incidences in an “all-comers” population because
patients were enrolled irrespective of clinical presentation or outcome. In this population sample, angiographic
ST rates in the first 30 days for both DES, i.e., SES and PES, occurred within the range as that reported in the
BMS era. 1,2,11,12
The angiographic definition used is the most accurate for diagnosis but may underestimate the true
incidence of ST because some patients who have a presumed ST may die before receiving medical attention.
Conversely, the use of major adverse cardiac events (i.e., death and MI in addition to the angiographic findings)
to define ST overestimates the true incidence because not all patients who die suddenly or suffer a MI do so
because of ST. 13 This consideration is important in our heterogeneous unrestricted population with multivessel
disease, previous MI, and previous revascularization. Furthermore, not all patients who die will undergo
autopsy studies to determine the cause of death. To attenuate this overestimation and to provide an accurate
figure, we have adjudicated all deaths and noncatheterized, nonfatal MIs within the first 30 days in the three
groups and included them with the angiographically proven patients to provide an overall incidence for each
group.
The incidences of ST for both groups of DES are within the range reported in the larger randomized
clinical trials of DES 3-6 despite longer total stent length, multivessel treatment, and a heterogeneous population
(Table 5). This incidence complements information already available from the randomized trials regarding the
safety of these new devices.
Table 5: Clinical Trials on Drug-Eluting Stents
Trial Name Number of Patients in Drug-
Eluting Arm
Total Stent Length mm
(Mean ± SD)
Incidence of Stent Thrombosis
in the First 30 Days (%)
SIRIUS (3) 533 23.0 ± 8.6 0.2*
E-SIRIUS (6) 157 21.5 ± 6.7 1.1*
C-SIRIUS (5) 50 23.8 ± 8.4 2.0*
TAXUS-IV (4) 662 21.9 ± 8.1 0.3†
SES group 1,017 42.5 ± 29.6 ‡1.0–1.5§
PES group 989 44.2 ± 29.4 ‡1.0–1.6§
Abbreviations as in Table 1.
* Definition of stent thrombosis was not stated.
† Stent thrombosis defined as angiographically proven, or cardiac death or myocardial infarction in the first 30
days.
‡ Stent thrombosis defined as angiographically proven.
§ Stent thrombosis defined as angiographically proven, or adjudicated death or myocardial infarction in the first
30 days.
Angiographic ST was associated with a high mortality and morbidity in our study. Within the DES population, 15
patients (75%) experienced a MI as their diagnosis at the second presentation, and 3 (15%) died during the
reintervention procedure. The inclusion of possible ST patients increased the mortality to 32%. Given the small
number of events, the fact that no deaths occurred in the BMS group was most likely due to chance. These
results are in concordance with the results of a large BMS registry. 2
Previous studies have demonstrated that residual dissection, 1,11 long stents, 1 small final lumen
diameter, 1 and use of multiple stents 2 are risk factors for the development of ST. In our series, multiple risk
factors were identified in most patients who developed ST. Patients with ST had more multiple lesions treated,
smaller minimum stent diameters, and longer stent lengths compared with those without ST; however, these
factors were not significant on univariate analysis. What did emerge and which has not been previously
reported is that patients undergoing bifurcation stenting had a higher incidence of ST compared with those
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without bifurcation stenting. A recent study on bifurcations reported a 3.5% incidence of ST, which is higher
than the overall incidence in this population. 14
Although stent implantation for AMI was not significant on univariate analysis, the interaction of AMI
and bifurcation stenting when entered as a covariate for ST on multivariate analysis emerged as a highly
significant independent predictor, and bifurcation stenting as a covariate was no longer significant. This result
confirms a clinical suspicion in our department regarding the increased risk of ST in patients treated with
bifurcation stenting in the setting of AMI.
Mechanical reasons that predispose to ST can be modified by interventional technique. Optimizing
stent placement including, if necessary, intravascular ultrasound-guided postdilation, kissing balloon
postdilation with bifurcation stenting, and careful inspection for residual dissection after stent implantation, may
further reduce the incidence of ST.
Pharmacologic reasons for ST, i.e., inadequate antiplatelet therapy, are patient-specific factors. Recent
research literature has focused on “resistance” to either aspirin 15 or to clopidogrel. 16 Currently, most
laboratories do not routinely test for antiplatelet resistance. In our series, two patients who had not taken their
prescribed clopidogrel after the procedure developed ST.
This report covers ST occurring in the first 30 days after stent implantation only, during which all
patients received dual antiplatelet therapy. The duration of clopidogrel therapy differed among the three groups;
in part, it reflects uncertainty with regards to re-endothelialization after DES implantation. Late ST has been
reported to occur with BMS 17 and with DES, 18 including a reported fatality 19 after clopidogrel discontinuation.
At this stage, the incidence of late ST in the DES era is unknown, and further studies are required to clarify this
potential late complication.
Comment on sample size and statistical comparisons
Because ST occurs at a low incidence ( 1.0 to 1.5%), a small sample size may underestimate or overestimate
the true incidence. In a previously published report from our institution, we reported an angiographic incidence
of 0.4% in 508 patients. 8 In the present study we extended the population to incorporate the entire period of
DES used to date at our institution (n = 2,006) to allow a more accurate analysis of the true incidence of ST in
the DES population. Despite having 2,512 patients, the low and small/negligible absolute difference in
incidence precludes formal statistical comparisons of ST rates among the three groups because it lacks
sufficient statistical power. To achieve adequate power would require sample sizes in the order of >100,000
patients. To date, this study is the largest series of patients reported on in the DES era.
Study limitations
These single-center registry data complement available randomized data, as they reflect the results of
unrestricted DES use.
Conclusions
Despite having a more complex cohort with high-risk inclusion criteria, longer stent lengths, and more complex
procedural features, the incidence of ST with DES are in the same range as the BMS population observed in
our present study. They also are in agreement with previously reported data by others from the BMS era and
with those results reported on in the earlier randomized DES trials. Furthermore, the two groups of DES, i.e.,
SES and PES, share an incidence of 1.0% to 1.5%. Stent thrombosis is associated with a high morbidity and
mortality.
As extensively documented in previous reports with BMS, mechanical reasons were observed to be frequent
associations for ST with DES. In this study, bifurcation stenting in the setting of AMI was a highly significant
independent predictor for angiographic ST.
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Abstract
Background: The factors associated with the occurrence of restenosis after sirolimus-eluting
stent (SES) implantation in complex cases are currently unknown.
Methods and Results: A cohort of consecutive complex patients treated with SES
implantation was selected according to the following criteria: (1) treatment of acute
myocardial infarction, (2) treatment of in-stent restenosis, (3) 2.25-mm diameter SES, (4) left
main coronary stenting, (5) chronic total occlusion, (6) stented segment >36 mm, and (7)
bifurcation stenting. The present study population was composed of 238 patients (441
lesions) for whom 6-month angiographic follow-up data were obtained (70% of eligible
patients). Significant clinical, angiographic, and procedural predictors of post-SES restenosis
were evaluated. Binary in-segment restenosis was diagnosed in 7.9% of lesions (6.3% in-
stent, 0.9% at the proximal edge, 0.7% at the distal edge). The following characteristics were
identified as independent multivariate predictors: treatment of in-stent restenosis (OR 4.16,
95% CI 1.63 to 11.01; P<0.01), ostial location (OR 4.84, 95% CI 1.81 to 12.07; P<0.01),
diabetes (OR 2.63, 95% CI 1.14 to 6.31; P=0.02), total stented length (per 10-mm increase;
OR 1.42, 95% CI 1.21 to 1.68; P<0.01), reference diameter (per 1.0-mm increase; OR 0.46,
95% CI 0.24 to 0.87; P=0.03), and left anterior descending artery (OR 0.30, 95% CI 0.10 to
0.69; P<0.01).
Conclusions: Angiographic restenosis after SES implantation in complex patients is an
infrequent event, occurring mainly in association with lesion-based characteristics and
diabetes mellitus.
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Introduction
In-stent restenosis is the major limitation hampering the medium-term efficacy of coronary stenting. Several
reports have evaluated the impact of baseline and procedural characteristics on the risk of subsequent
restenosis after bare metal stent implantation, with a number of high-risk parameters, such as diabetes, lesion
length, and vessel size, being consistently identified in most studies.1–7 Unfortunately, these characteristics are
commonly found in the daily practice, where treatment of complex patients frequently appears as a challenging
therapeutic dilemma.
Sirolimus-eluting stents (SESs) have been proven to strikingly decrease neointimal growth, leading to a
marked reduction in restenosis rates.8–10 In the RAndomized study with the sirolimus-eluting Bx VElocity
balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions (RAVEL),8 no
cases of binary angiographic restenosis were seen after SES implantation. Moreover, restenosis was
significantly reduced from 36.3% with conventional stents to 8.9% with SESs in the randomized SIRolImUS-
eluting Bx velocity balloon expandable stent trial (SIRIUS)9 and from 42.3% to 5.9% in the E-SIRIUS trial,10 with
diabetes, small vessel size, and long lesions being identified as predictors of post-SES restenosis in the SIRIUS
trial.9 Nevertheless, these randomized studies have been largely restricted to selected patients treated with
single-lesion elective stenting. The factors related to angiographic restenosis after SES implantation in highly
complex subsets are currently unknown.
SES implantation was recently shown to effectively improve the 1-year clinical outcomes in "real world"
practice in patients enrolled in the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital
(RESEARCH) study.11 In the RESEARCH study, a parallel angiographic substudy was conducted to evaluate
the late angiographic findings of complex patients treated with SESs. The present report aimed to evaluate the
value of clinical, angiographic, and procedural factors in predicting the risk of binary restenosis in highly
complex patients treated with SES implantation in the RESEARCH study.
Methods
Study Design and Patient Population
The design of the RESEARCH study has been reported previously.11 In brief, SES implantation (Cypher;
Johnson & Johnson-Cordis unit, Cordis Europa NV) was introduced as the default strategy for all patients
undergoing percutaneous coronary interventions in our institution after April 2002. All procedures were
performed according to standard techniques, and the final interventional strategy was left to the discretion of the
operator, with the aim of achieving a final residual stenosis <50% by online quantitative coronary angiography in
the presence of TIMI (Thrombolysis In Myocardial Infarction) 3 grade flow. The use of periprocedural
glycoprotein IIb/IIIa inhibitors and antithrombotic medications was left entirely to the discretion of the attending
team.
Patients receiving SESs were considered candidates for angiographic reevaluation if they had at least 1
of the following characteristics: (1) treatment of acute myocardial infarction, (2) treatment of in-stent restenosis,
(3) use of a very small SES (2.25-mm nominal diameter), (4) treatment of left main coronary, (5) treatment of
chronic total occlusion (>3 months), (6) total adjacent stented segment longer than 36 mm, and (7) bifurcation
stenting (SES implanted in both the main vessel and the side branch). Patients with the aforementioned
characteristics who had not undergone repeat intervention in the first month and had not presented any formal
medical contraindication for angiographic restudy were considered eligible for angiographic follow-up at 6 to 8
months. Coronary angiograms performed prematurely because of clinical indications were used as the follow-
up angiography if performed after 4 months or if restenosis was detected. In other cases, a second angiogram
was obtained between 6 and 8 months. Importantly, although all patients were approached for angiographic
follow-up, patient refusal was not considered as an exclusion criterion to be enrolled in the RESEARCH study.
Angiographic restudy was not requested for nonresidents of the Netherlands.
During the first 6 months of enrollment, a total of 362 consecutive patients had at least 1 of the high-risk
criteria listed above (57% of all patients treated with SESs in the period). Of these, 2 patients moved to another
country, 10 had died within the first 6 months of follow-up, 6 had repeat intervention before 30 days (surgical or
percutaneous), and 3 were considered to have a medical contraindication to the angiographic follow-up (1
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patient with previous stroke and disabling dementia, 1 with severe allergic contrast reaction at the index
procedure, and 1 with end-stage hepatic failure due to autoimmune hepatitis). Of the remaining 341 patients,
angiographic reevaluation at 204±34 days was obtained for 238 patients (70% of eligible patients), who
compose the present study population.
Quantitative Coronary Angiography
Quantitative coronary angiographic analysis was performed as described previously with a validated computer-
based edge-detection system (CASS II, Pie Medical).12 Interpolated reference diameter, minimal luminal
diameter, and diameter stenosis were obtained at baseline, after stenting, and at follow-up. In-stent restenosis
was defined by diameter stenosis >50% and was classified as in-stent if inside the stent or in-segment if located
within the stented segment plus the 5-mm segments distal or proximal to the stent margins.9 Restenosis at an
ostial location (within 3 mm of the vessel origin) was classified as in-stent unless clearly located outside the
limits of the SES.13
Statistical Analysis
Continuous variables are presented as mean±SD and were compared with Student’s unpaired t test.
Categorical variables are presented as counts and percentages and compared with the Fisher exact test.
Demographic, clinical, procedural, and angiographic variables were tested in univariate and multivariate logistic
analyses for their value in predicting binary restenosis. All variables shown in Tables 1 and 2  were considered
in multivariate logistic regression analyses regardless of their univariate findings. The final model was built
iteratively and evaluated for lack of fit with the Hosmer-Lemeshow test. Global predictive accuracy was
assessed by means of the C-index (area under the receiver operating characteristic curve). Finally, an internal
validation was performed with a bootstrap technique.14 The model was repeatedly applied to 1000 replicated
bootstrap samples, and the C-index for each individual sample was calculated. The C-index obtained from each
bootstrap sample was then subtracted from the initial C-index value of the original population. The average of
the differences was considered as a measure of optimism in the model fit. Finally, a corrected C-index was
calcu
Table 1: Clinical Characteristics of 238 Patients Treated With SES Implantation
Characteristic No.
Male gender 73
Age, y 60 ± 12
Height, cm 172 ± 9
Weight, kg 82 ± 14
Hypercholesterolemia 58
Hypertension 56
Diabetes mellitus 22
Insulin-dependent diabetes 6
Non-insulin-dependent diabetes 16
Previous myocardial infarction 32
Previous bypass surgery 11
Previous percutaneous intervention 28
1-vessel disease 40
2-vessel disease 35
Vessel disease
3-vessel disease 25
Stable angina 54
Unstable angina 21
Clinical presentation
Acute myocardial infarction 26
Periprocedural IIb/IIIa inhibitor 27
Values are percentages or mean±SD
*Total cholesterol >200 mg/dL or receiving lipid-lowering treatment
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Table 2: Procedural and Angiographic Characteristics of 441 Lesions Treated With SES Implantation
Characteristics No.
Left main coronary 3
Left anterior descending 43
Left circumflex 22
Right coronary artery 30
Treated vessel
Bypass graft 3
A 6
B1 23
B2 43
Lesion type
C 28
Chronic total occlusion >3 months 8
Moderate/severe angiographic calcification 7
Ostial location 22
Bifurcation treatment 22
Treatment of in-stent restenosis 13
No. of stents implanted 1.41 ± 0.81
Overlapping stents 39
Total stented length, mm 26.0 ± 20.3
Stented length >36 mm 17
Use of 2.25-mm SES 18
Reference diameter, mm 2.50 ± 0.61
Preprocedure minimal luminal diameter, mm 0.69 ± 0.54
Preprocedure diameter stenosis, % 72.2 ± 20.0
Lesion length, mm 16.1 ± 11.8
Postprocedure minimal luminal diameter, mm 2.13 ± 0.58
Postprocedure diameter stenosis, % 17.2 ± 11.1
Follow-up minimal luminal diameter, mm 2.10 ± 0.69
Follow-up diameter stenosis, % 22.8 ± 19.9
Late loss, mm 0.04 ± 0.49
In-stent 6.3
Proximal edge 0.9
Binary restenosis
Distal edge 0.7
Values are percentages or mean±SD
*SES implantation in both the main vessel and the side branch
calculated by subtracting the average of the optimism estimates from the original C-index. The bootstrap
correction has been described as a nearly unbiased internal validation, which penalizes for any model
overfitting.14 Presented 95% CIs of all multivariate estimates were derived from the bootstrap analysis.
Results
Among the 238 patients (441 lesions) included in this analysis, 13 (6%) had left main coronary stenting, 35
(15%) had at least 1 chronic total occlusion, 45 (19%) received sirolimus stents to treat at least 1 restenotic
lesion, 50 (21%) had bifurcation stenting, 62 (26%) were in the acute phase of a myocardial infarction, 68 (28%)
had at least one 2.25-mm SES implanted, and 83 (35%) had very long stenting (>36 mm) in at least 1 vessel
(Tables 1 and 2). On average, 1.41±0.81 stents were implanted per lesion, and 39% of lesions had at least 2
stents that overlapped. Most lesions were classified as American College of Cardiology/American Heart
Association type B2 or C (71%); 22% received bifurcation stenting (stent implanted in both the main vessel and
the side branch); 8% were chronic total occlusions (duration >3 months); and 3% were located in the left main
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coronary. Mean vessel size was 2.50±0.61 mm (range 1.00 to 4.59 mm), and the average stented length was
26.0±20.3 mm (range 8 to 117 mm).
At the follow-up angiogram, 7.9% of lesions had binary in-segment restenosis. Of these, 6.3% were
located inside the stent (in-stent), 0.9% were located in the proximal edge, and the remaining 0.7% occurred at
the distal edge. Because of the limited number of lesions with edge restenosis (7 observations), additional
analyses were performed for all lesions grouped as in-segment restenosis.
Table 3: Clinical, Procedural, and Angiographic Univariate Predictors of In-Segment Restenosis After SES
Restenosis
OR 95% CI p
Bypass graft 4.61 1.39 – 15.33 0.01
Treatment of in-stent restenosis 3.66 1.68 – 7.96 <0.01
Previous bypass surgery 3.24 1.42 – 7.41 <0.01
Bifurcation stenting (side branch position) 2.77 1.15 – 6.33 0.02
Ostial location 2.66 1.30 – 5.46 <0.01
Diabetes mellitus 2.54 1.24 – 5.21 0.01
No. of stents implanted 1.62 1.19 – 2.22 <0.01
Postprocedure diameter stenosis (per 10% increase) 1.55 1.14 – 2.10 <0.01
Total stented length (per 10-mm increase) 1.30 1.14 – 1.48 <0.01
Preprocedure minimal luminal diameter 0.46 0.22 – 0.95 0.04
Postprocedure minimal luminal diameter 0.39 0.20 – 0.76 <0.01
Left anterior descending artery 0.37 0.16 – 0.82 0.02
Acute myocardial infarction 0 <0.01
Table 4: Clinical, Procedural, and Angiographic Multivariate Predictors of In-Segment Restenosis After SES
Restenosis*
OR 95% CI p
Treatment of in-stent restenosis 4.16 1.63 – 11.01 <0.01
Ostial location 4.84 1.81 – 12.07 <0.01
Diabetes mellitus 2.63 1.14 – 6.31 0.02
Total stented length (per 10-mm increase) 1.42 1.21 – 1.68 <0.01
Reference diameter (per 1.0-mm increase) 0.46 0.24 – 0.87 0.03
Left anterior descending artery 0.30 0.10 – 0.69 <0.01
*Intercept coefficient, -2.34.
Table 5: Actual Rates of Post-SES In-Segment Restenosis According to the Presence of High-Risk
Characteristics*
In-Segment Restenosis Rate, %
Treatment of in-stent restenosis 19.6
Ostial location 14.7
Diabetes mellitus 14.3
Stented length >26 mm 13.9
Reference diameter <2.17 mm 10.3
Non-LAD location 10.8
LAD indicates left anterior descending artery.
 *Presence of multivariate independent predictors.
Higher tercile for stented length.
Lower tercile for reference diameter.
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The Figure shows the univariate relationship between demographic, angiographic, and procedural
characteristics and the incidence of post-SES restenosis, and significant univariate parameters are shown in
Table 3. In the multivariate analysis, the following variables were identified as independent predictors of
restenosis: treatment of in-stent restenosis, ostial location, presence of diabetes mellitus, total stented length,
reference diameter, and left anterior descending artery location (Table 4). The final multivariate model fit the
data well (Hosmer-Lemeshow test P=0.94; 2=2.93; df=8) and had a good predictive accuracy (C-index 0.83),
which was virtually unchanged after the bootstrap correction (corrected C-index 0.82). Actual restenosis rates
for patients with "high-risk" characteristics (derived from the multivariate model) are shown in Table 5.
Discussion
The present study reported on the predictors of angiographic restenosis after SES implantation in complex
patients. Overall, our series included patients with smaller vessels and longer lesions than in other trials
conducted to date.8–10 Moreover, a considerable proportion of patients had previous in-stent restenosis,
bifurcation stenting, chronic total occlusions, thrombus-containing lesions, and calcified vessels, conditions that
were formally excluded from previous trials. Nevertheless, binary restenosis after SES implantation in such a
complex patient population was detected in only a minority of cases (7.9% of lesions). The expected restenosis
rate for de novo lesions included in the present report would range from 40.1% to 43.0% if treated with bare
metal stents, as calculated from prediction equations derived from previous meta-analysis with conventional
stents.3,6
In the SIRIUS trial, small vessel size, long lesion length, and diabetes were shown to significantly
increase the incidence of restenosis after SES.9 These characteristics were confirmed as predictors of post-
SES restenosis in the present study, which additionally extended the list of independent parameters to include
ostial location and treatment of in-stent restenosis (as negative factors) and left anterior descending artery
location (as a protective factor). Interestingly, most characteristics identified as predictors of post-SES
restenosis have long been recognized as major predictors of restenosis after balloon angioplasty or
conventional bare stent implantation.1–7,15–17 It seems intuitive to assume that the increased incidence of
restenosis after SES implantation in patients with these risk factors may reflect an extreme background
tendency to tissue reaction and neointimal growth, which was not sufficiently inhibited by the antiproliferative
action of the drug.
Restenosis after SES has been shown to be associated with incomplete lesion coverage in some
cases, as detected by intravascular ultrasound.13 In the present study, lesions involving ostial sites had a higher
risk of restenosis, which may be related, at least in part, to technical difficulties in stent positioning and vessel
scaffolding at the ostium. We may speculate that the presence of "traditional" risk factors for restenosis may
potentially act as a predisposing factor that will lead to restenosis in case a subtle device-related or procedure-
related local failure is eventually superimposed. Unfortunately, small gaps between stents and minor ruptures in
the metallic stent mesh or in the polymer integrity are not detectable by conventional coronary angiography13
and could not be evaluated in the present report.
The treatment of in-stent restenosis with SES was associated with a more than 4-fold increase in the
risk of restenosis after adjustment for other independent variables. Although SES implantation has been
associated with low rates of repeat restenosis after treatment of noncomplex in-stent restenosis,18,19 the efficacy
of this device for more complicated cases remains to be established.20,21 Redilation of restenotic lesions (ie,
exposure to "double injury") has been shown to trigger a peculiar local vascular response, distinct from that
observed after the first dilation.22 Modifications in the reparative mechanisms, especially after endovascular
brachytherapy,20 may decrease the responsiveness of restenotic lesions to the antiproliferative drug.
Curiously, lesions located in the left anterior descending artery had a decreased restenosis rate in the
present series. Whether this factor represents a true protective characteristic has to be further investigated in
future studies. Although post-SES restenosis was not detected in any patient admitted with acute myocardial
infarction, this characteristic was not included in our final multivariate model, which suggests that perhaps acute
myocardial infarction at admission per se was not an important factor affecting restenosis in the present study
jjjjk
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Figure: Univariate OR of binary angiographic in-segment restenosis after SES restenosis according to
demographic, clinical, procedural, and angiographic characteristics. NIDDM indicates non–insulin-dependent
diabetes mellitus; IDDM, insulin-dependent diabetes mellitus; pre, preprocedure; and post, postprocedure.
Diabetes
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IDDM
Previous CABG
Stable angina
0.00 1.00 2.00 3.00 4.00 5.00
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Ostial location
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population. Post-SES restenosis in the present study was almost entirely restricted to the segment inside the
stent ( 80% of restenoses). This finding represents a major difference from previous trials with SES, in which
restenosis more frequently occurred at the stent edges.9,10 In the RESEARCH study, all operators were strongly
advised to actively cover the entire injured vessel area and to avoid both residual dissection at stent borders
and gaps between stents. In addition, the stent placement strategy aimed to cover the treated segment "from
healthy tissue to healthy tissue," to avoid having the free borders of the stents terminate in grossly diseased
segments. However, it remains speculative whether these procedural strategies might have had any impact in
reducing the incidence of restenosis at the stent edges.
Study Limitations
The present report may suffer from its relatively limited study population, which was restricted to complex
patients who fulfilled predefined criteria to be included in this angiographic substudy. Therefore, our results
cannot be directly extrapolated to the entire cohort of consecutive patients treated in the RESEARCH study,
and further analyses are needed to fully assess the angiographic outcomes of subsets not included in the
present study. Ten patients with early death could not be restudied at 6 months, and a higher rate of
angiographic follow-up ( 70% in this study) would be desirable for a comprehensive evaluation. However, the
present study was designed to enroll all unselected patients treated in our institution, and patient refusal for
angiographic follow-up did not preclude enrollment in the RESEARCH study. Obviously, this real-life scenario
differs substantially from that of randomized trials and limits the compliance to angiographic restudy.
Conclusions
Angiographic restenosis after SES implantation in complex patients is an infrequent event (7.9% of lesions),
occurring mainly in association with local, lesion-based characteristics and diabetes mellitus.
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Abstract
Objectives: We investigated the efficacy of paclitaxel-eluting stents (PES) compared to
sirolimus-eluting stents (SES) when used without restriction in unselected patients.
Background: Both SES and PES have been separately shown to be efficacious when
compared to bare stents. In unselected patients, no direct comparison between the two
devices has been performed.
Methods: Paclitaxel-eluting stents have been used as the stent of choice for all
percutaneous coronary interventions in the prospective Taxus-Stent Evaluated At Rotterdam
Cardiology Hospital (T-SEARCH) registry. A total of 576 consecutive patients with de novo
coronary artery disease exclusively treated with PES were compared with 508 patients
treated with SES from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology
Hospital (RESEARCH) registry.
Results: The PES patients were more frequently male, more frequently treated for acute
myocardial infarction, had longer total stent lengths, and more frequently received
glycoprotein IIb/IIIa inhibitors. At one year, the raw cumulative incidence of major adverse
cardiac events was 13.9% in the PES group and 10.5% in the SES group (unadjusted
hazard ratio [HR] 1.33, 95% confidence interval [CI] 0.95 to 1.88, p = 0.1). Correction for
differences in the two groups resulted in an adjusted HR of 1.16 (95% CI 0.81 to 1.64, p =
0.4, using significant univariate variables) and an adjusted HR of 1.20 (95% CI 0.85 to 1.70,
p = 0.3, using independent predictors). The one-year cumulative incidence of clinically driven
target vessel revascularization was 5.4% versus 3.7%, respectively (HR 1.38, 95% CI 0.79
to 2.43, p = 0.3).
Conclusions: The universal use of PES in an unrestricted setting is safe and is associated
with a similar adjusted outcome compared to SES. The inferior trend in crude outcome seen
in PES was due to its higher-risk population. A larger, randomized study enrolling an
unselected population may assist in determining the relative superiority of either device.
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Introduction
Sirolimus-eluting stents (SES, Cypher, Cordis, Johnson and Johnson, Miami Lakes, Florida) 1 and paclitaxel-
eluting stents (PES, TAXUS, Boston Scientific Corp., Natick, Massachusetts) 2 have both been independently
shown to reduce the need for repeat intervention when compared to bare-metal stents (BMS) in separate
randomized clinical trials. The Food and Drug Administration approvals for these devices were granted in 2003
and 2004, respectively, and it is estimated that drug-eluting stents (DES) currently comprise 70% of the stent
market in the U.S. The randomized controlled trials on which approval was granted enrolled highly selected
patients with single lesions that could be covered with one DES and were compared against BMS which is not
representative of daily clinical practice.
Our group has previously published the results of the Rapamycin-Eluting Stent Evaluated At Rotterdam
Cardiology Hospital (RESEARCH) registry, which demonstrated that routine implantation of SES resulted in a
reduction in major adverse cardiac events (MACE), principally driven by a reduction in target vessel
revascularization (TVR) when compared with a historical BMS control group. 3 The PES were commercialized
subsequent to SES, based on the results of randomized controlled trials. 4,5 The beneficial effect of PES in
patients treated in daily practice remains to be defined. The aim of this study was to report the one-year
outcomes of unrestricted/universal use of PES in patients with de novo coronary artery lesions and to compare
its efficacy against our historical SES cohort. 3
Methods
Study design and patient population
The Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registry is a prospective single-
center registry with the main purpose of evaluating the safety and efficacy of PES implantation for consecutive
unselected patients treated in daily practice. Its conceptual design and methodology are similar to that of the
RESEARCH registry 6 and follows the dynamic registry design described by Rothman and Greenland. 7
Since February 16, 2003, when PES was granted Conformité Européenne approval, it replaced SES as
the default stent for every percutaneous coronary intervention. Up until September 30, 2003, a total of 576
patients with de novo lesions were treated exclusively with PES and are included in the present report (PES
group). This comprised 83.7% of all patients with de novo disease who received coronary stents. In this period,
only 12 patients received BMS exclusively (11 were due to requirement for stents >3.5mm, 1 patient had
elevated liver enzymes that precluded long-term clopidogrel therapy). Patients treated with PES and BMS in
the same procedure (20 patients), those treated with PES and SES (20 patients), those treated with SES only
(15 patients), and patients enrolled in other drug-eluting trials (44 patients) were not included in the present
report. The PES are available in diameters of 2.25 mm, 2.5 mm, 3.0 mm, and 3.5 mm and in lengths of 8 to 32
mm in 4-mm increments for each available diameter.
This PES group was compared with a control group that comprised the active arm of the RESEARCH
registry, that is the 508 patients with de novo disease treated solely with SES (SES group). Thus, the report
consists of 1,084 patients treated with DES, differentiated by the type of drug coating on the stent, either
sirolimus or paclitaxel.
Procedures and postintervention medications
Interventions were performed according to current standard procedures, with the final interventional strategy
(including direct stenting, postdilation, periprocedural glycoprotein IIb/IIIa inhibitor, and use of intravascular
ultrasound) left entirely up to the operator's discretion. 6 Angiographic success was defined as residual stenosis
≤30% by visual analysis in the presence of Thrombolysis In Myocardial Infarction (TIMI) flow grade 3. Patients
were advised to maintain lifelong aspirin (at least 80 mg/day) and were pretreated with 300 mg clopidogrel.
Postprocedural clopidogrel treatment differed between the two groups. Patients treated with PES were
prescribed at least six months of clopidogrel (75 mg/day), based on existing data from randomized, controlled
trials. 5 For patients treated with SES, clopidogrel was prescribed for at least three months, unless one of the
following was present (in which case clopidogrel was maintained for at least six months): multiple SES
implantation (≥3 stents), total stent length ≥36 mm, chronic total occlusion, and bifurcations.
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End point definitions and clinical follow-up
The primary outcome was the occurrence of MACE, defined as a composite of: 1) all cause death, 2) nonfatal
myocardial infarction (MI), or 3) TVR. Myocardial infarction was diagnosed by a rise in the creatine kinase-MB
fraction (CK-MB) of more than three times the upper limit of normal according to American Heart
Association/American College of Cardiology guidelines. 8 In patients who underwent coronary artery bypass
surgery during the follow-up period, a periprocedural MI was diagnosed by a rise in the CK-MB level of five
times the upper limit of normal. 9 For patients who presented with an acute MI, a diagnosis of re-MI in the acute
phase required a fall and rise of CK-MB of 50% above the previous level. 10 Target lesion revascularization was
defined as a repeat intervention (surgical or percutaneous) to treat a luminal stenosis within the stent or in the
5-mm distal or proximal segments adjacent to the stent. Target vessel revascularization was defined as a re-
intervention driven by any lesion located in the same epicardial vessel. Thrombotic stent occlusion was defined
as angiographically documented complete occlusion (TIMI flow grade 0 or 1) or flow-limiting thrombus (TIMI
flow grade 1 or 2) in a previously successfully treated artery. A committee of three cardiologists (A.O., J.A., and
E.M.F.) reviewed all MACE.
All patients underwent clinical follow-up. Information about the in-hospital outcomes was obtained from
our institutional electronic clinical database and by review of the hospital records for those discharged to
referring hospitals (patients were referred from a total of 14 local hospitals). Postdischarge survival status was
obtained from the Municipal Civil Registries at 1, 6, and 12 months. All repeat interventions (surgical and
percutaneous) and re-hospitalizations were prospectively collected during the follow-up. Questionnaires
regarding adverse events, anginal status, and medication use were sent to all living patients at 6 and 12
months. Referring physicians and institutions were contacted for additional information if required.
In both groups, follow-up coronary angiography was clinically driven by symptoms or signs suggestive
of myocardial ischemia or mandated by the operator at the end of the index procedure predominantly for
complex procedures. In the PES group, three specific subgroups were restudied: left main stem stenting, crush-
bifurcation procedures, and patients who were concomitantly in a vulnerable plaque study involving non-treated
vessels (in total, 27% [n = 154] of PES patients underwent re-study during follow-up, including 14% [n = 81]
that were clinically driven). In the SES group, the following “complex patient” subgroups were re-studied:
bifurcation lesions, left main stem stenting, chronic total occlusions, very small vessels, long stent length (36
mm), and acute MI (in total, 40% [n = 204] of SES patients were re-studied, including 8% [n = 40] that were
clinically driven). Because of the well-known effect of angiographic re-evaluation in increasing the incidence of
repeat revascularization, 11 all re-interventions were retrospectively adjudicated and classified as either
clinically driven or non-clinically driven. Clinically driven repeat revascularization was defined as any
intervention motivated by a significant luminal stenosis (≥50% diameter stenosis) in the presence of anginal
symptoms and/or proven myocardial ischemia in the target vessel territory by noninvasive testing.
Statistical analysis
Continuous variables are presented as mean ± standard deviation, and were compared using the Student
unpaired t test. Categorical variables are presented as counts and percentages and compared by means of the
Fisher exact test. All statistical tests were two-tailed. Patients lost to follow-up were considered at risk until the
date of last contact, at which point they were censored. The cumulative incidence of adverse events was
estimated according to the Kaplan-Meier method, and Cox proportional hazards models were used to assess
differences between the two strategies. Separate Cox regression analyses were performed to identify
independent predictors of adverse events, using clinical, angiographic, and procedural variables contained in
Table 1 and Table 2. The Cox proportional hazards regression models were used to control for differences
between groups, and the final results are presented as adjusted hazard ratios (HRs).
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Table 1: Baseline Characteristics
SES group
(n = 508)
PES group
(n = 576)
p value
Male, % 68 74 0.04
Age, yrs ± SD 61 ± 11 62 ± 11 0.4
Diabetes, % 18 18 0.8
Non–insulin-dependent, % 12 13 0.5
Insulin-dependent, % 6 5 0.7
Hypertension, % 41 42 0.9
Hypercholesterolemia, % 56 62 0.03
Current smoking, % 31 29 0.6
Previous myocardial infarction, % 30 35 0.13
Previous angioplasty, % 19 18 0.8
Previous coronary bypass surgery, % 9 6 0.05
Single-vessel disease, % 46 44 0.5
Multivessel disease, % 54 56 0.5
Clinical presentation < 0.001
 Stable angina, % 45 45
 Unstable angina, % 37 27
 Acute myocardial infarction, % 18 28
 Cardiogenic shock, % 10 13
PES = paclitaxel-eluting stent; SES = sirolimus-eluting stent.
 Relative to patients with acute myocardial infarction.
Table 2: Procedural Characteristics
SES group
(n = 508)
PES group
(n = 576)
p value
Treated vessel
Left anterior descending, % 59 55 0.3
Left circumflex, % 32 33 0.6
Right coronary artery, % 39 38 0.9
Left main coronary, % 3 4 0.3
Bypass graft, % 3 3 1.0
Lesion type
 Type A or B1, % 47 32 < 0.001
 Type B2 or C, % 76 87 < 0.001
Multivessel treatment, % 32 29 0.3
Glycoprotein IIb/IIIa inhibitor, % 19 28 0.002
Clopidogrel prescription, months ± SD 4.0 ± 2.0 6 ± 0 < 0.05
Bifurcation stenting, % 16 16 0.9
No. of stented segments ± SD 2.0 ± 1.0 1.7 ± 0.9 < 0.001
No. of stented vessels ± SD 1.3 ± 0.6 1.3 ± 0.6 0.8
No. of implanted stents ± SD 2.1 ± 1.4 2.2 ± 1.5 0.09
Total stented length per patient, mm ± SD 38.7 ± 23.7 42.9 ± 31.2 0.02
Nominal stent diameter ≤2.5 mm, % 36 35 0.7
Total stent length >33 mm, % 45 48 0.5
Angiographic success of all lesions, % 97 97 0.9
Abbreviations as in Table 1.
 Percentage of patients with at least 1 lesion type within the category.
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Results
Baseline and procedural characteristics
The PES patients were more often male, had more MI as their presenting symptom, more cardiogenic shock,
more complex lesions treated, longer total stent lengths, and more frequently received glycoprotein IIb/IIIa
inhibitors (Table 1 and Table 2). Fewer PES patients had a history of previous bypass surgery, and fewer
segments per patient were stented, although the number of vessels treated per patient was identical. Other
baseline and procedural characteristics were similar.
Clinical outcome
First 30 days
No significant differences were noted between groups with respect to the incidences of death, death or MI,
TVR, or MACE in the first month (Table 3). Mortality in the first 30 days was 2.1% in the PES group and 1.6% in
the SES group (p = 0.7). In both groups, most deaths occurred in patients with cardiogenic shock.
Angiographically proven stent thrombosis occurred in six patients in the PES group, four of whom were treated
for AMI, the other two presented with unstable angina. Two patients with AMI also underwent bifurcation
stenting, as did one with unstable angina. In total, three patients with bifurcation stenting experienced stent
thrombosis. In the SES group, two patients were diagnosed with stent thrombosis. One patient died as a result
of stent thrombosis in the PES group.
Table 3: Major Adverse Cardiac Events in the First Month Following Stent Implantation
0 to 1 Month SES group
(n = 508)
PES group
(n = 576)
p value
Death, n (%) 8 (1.6) 12 (2.1) 0.7
Nonfatal myocardial infarction, n (%) 12 (2.4) 17 (3.0) 0.6
Target lesion revascularization, n (%) 6 (1.2) 7 (1.2) 1.0
Target vessel revascularization, n (%)† 6 (1.2) 13 (2.3) 0.2
Any event, n (%) 23 (4.5) 34 (5.9) 0.3
Stent thrombosis, n (%)‡ 2 (0.4) 6 (1.0) 0.3
Abbreviations as in Table 1.
 By Fisher exact test.
† Includes target lesion revascularization.
‡ Angiographically documented stent thrombosis requiring repeat intervention.
One year
The MACE components are presented in Figure 1 and Figure 2. At one year, 5.3% of patients in the PES group
and 3.4% in the SES group had died (HR 1.69, 95% confidence interval [CI] 0.93 to 3.00, p = 0.08). In total,
8.8% of patients in the PES group versus 7.0% in the SES group had either died or suffered a nonfatal re-MI
(HR 1.28, 95% CI 0.84 to 1.95, p = 0.3). The incidence of TVR was similar in the SES and PES groups: 7.3%
versus 5.1% (HR 1.31, 95% CI 0.81 to 2.13, p = 0.3). Clinically driven TVR was reduced by a similar magnitude
in both groups, specifically 3.7% versus 5.4%, respectively (HR 1.38, 95% CI 0.79 to 2.43, p = 0.3). Post-hoc
analysis of clinically driven TVR demonstrates that confidence limits crossed unity, with point estimates close to
unity in the subgroups analyzed (Fig. 3). Regarding the primary end point of MACE (the composite of death, MI,
or TVR), Kaplan-Meier estimates were 13.9% in the PES group versus 10.5% in the SES group (unadjusted
HR 1.33, 95% CI 0.95 to 1.88, p = 0.10).
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Figure 1: Unadjusted Kaplan-Meier event curves at one year.
CI = confidence interval; PES = paclitaxel-eluting stent; SES = sirolimus-eluting stent.
A: Cumulative risk of death.
B: Cumulative risk of death or myocardial infarction.
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C: Cumulative risk of death, myocardial infarction, or target vessel revascularization.
Figure 2: Unadjusted one-year cumulative risk of clinically driven target vessel revascularization.
Abbreviations as in Figure 1.
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Figure 3: Hazard ratios (HR) of stent type at one-year follow-up for clinically driven target vessel
revascularization in subgroups of patients according to baseline and procedural characteristics.
MI = myocardial infarction; other abbreviations as in Figure 1.
There were two cases of late (>6 months to 1 year) stent thrombosis documented angiographically in the PES
group. In one, it occurred eight months after the index procedure while the patient was on antiplatelet
monotherapy with aspirin. The second occurred 11 months after the index procedure after the patient had
temporarily suspended antiplatelet therapy (aspirin) for noncardiac surgery.
Predictors of adverse events
To assess the independent predictors of MACE at one year, two separate multivariate analyses were
performed. First, a model was built using all baseline and procedural characteristics shown in Table 1 and
Table 2. Forward stepwise regression was performed with entry and stay criteria of 0.05 and 0.10, respectively.
The following variables were significant: cardiogenic shock, female gender, multivessel disease, diabetes
mellitus, left main stenting, bifurcation stenting, and lesion type B2/C (Table 4). A second model built using the
same variables with the end point of TVR at one year revealed bifurcation stenting was the only significant
independent predictor of TVR.
Adjustment for differences between groups
The Cox regression models were used to adjust the two groups by correcting for multiple potential confounders
in the baseline and procedural characteristics. First, a model was built forcing stent type and all independent
predictors from Table 4 (see Table 5). All previously significant variables remained significant except for lesion
type B2/C. The adjusted HR for use of PES became even less significant, decreasing from 1.33 (95% CI 0.95
to 1.88, p = 0.10) to 1.20 (95% CI 0.85 to 1.70, p = 0.3), after controlling for the increased complexity in the
PES group.
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Table 4: Multivariate Predictors of Major Adverse Cardiac Events at One Year (Cox Proportional Hazards
Model)
HR 95% CI p value
Major adverse cardiac events
       Cardiogenic shock (stable angina  as reference variable) 4.54 2.44–8.48 < 0.001
       Female gender 1.72 1.22–2.43 0.002
       Multivessel disease 1.74 1.19–2.55 0.005
       Diabetes mellitus 1.65 1.12–2.42 0.01
       Left main stenting 1.96 1.10–3.48 0.02
       Bifurcation stenting 1.59 1.06–2.38 0.03
       Lesion type B2 or C 1.85 1.01–3.40 0.047
Target vessel revascularization
       Bifurcation stenting 2.77 1.68–4.57 < 0.001
CI = confidence interval; HR = hazard ratio.
 Major adverse cardiac events: death, myocardial infarction, or target vessel revascularization.
Table 5: Hazard Ratios by Stent Type of Major Adverse Cardiac Events After Adjustment
HR 95% CI p value
MACE†
       Unadjusted 1.33 0.95–1.88 0.10
       Adjusted for significant predictors of MACE 1.20 0.85–1.70 0.3
       Adjusted for significant univariate variables‡ 1.16 0.81–1.64 0.4
TVR
       Unadjusted 1.31 0.81–2.13 0.26
       Adjusted for significant predictors of TVR 1.33 0.82–2.15 0.25
Abbreviations as in Table 4.
 Stent type coded as: 0 = sirolimus-eluting stent, 1 = paclitaxel eluting stent.
† Major adverse cardiac events: death, myocardial infarction, or target vessel revascularization (TVR).
‡ Significant univariate variables for major adverse cardiac event (MACE) were the significant predictors plus
total stent length and number of stents implanted.
A second model was then built forcing stent type and significant univariate variables (independent predictors
plus total stent length and number of stents), and the adjusted outcome of MACE at one year was similar
between SES and PES (adjusted HR 1.16, 95% CI 0.81 to 1.64, p = 0.4). Finally, stent type was also not a
significant predictor of TVR when adjusted for bifurcation stenting (adjusted HR 1.33, 95% CI 0.82 to 2.15, p =
0.25).
Discussion
The major finding of this report is that the unrestricted use of PES in de novo lesions is associated with a
nonsignificant difference in outcome compared to SES, both unadjusted and when controlled for significant
baseline and procedural characteristics. The trend toward an inferior crude outcome with PES was due to the
more complex characteristics of the group.
The two sequential registries were separated by a four-month interval. Several differences in baseline
characteristics were noted. More MIs including patients in cardiogenic shock were treated in the T-SEARCH
registry because of the implementation of a local pre-hospital protocol that triaged more patients to primary
percutaneous coronary intervention. More complex lesions were treated in the T-SEARCH registry, with a shift
from type A/B1 to B2/C lesions, with more stents being implanted in the T-SEARCH registry. This in part
reflects the increased complexity of cases being performed with time and as operators and referring physicians
becoming more aware and familiar with DES.
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The primary end point of this trial was overall MACE, and the results for this comparison are presented
both unadjusted and following adjustment for significant predictive variables (Table 5). With the
commercialization of PES, our institution switched completely from SES to PES, precluding randomization.
Therefore, it was intuitive to present the data as such and imperative to statistically correct by using significant
predictive variables to account for the increased complexity seen in the PES group. To preserve the
prospective, consecutive, and unselected nature of both registries, and the requirement to control for multiple
significant variables, the Cox regression model was used. Our results demonstrate that, following adjustment,
the HR was closer to unity compared to the crude result, further confirming the increased complexity in the PES
group.
The multivariate analysis (Table 4) for independent predictors of MACE is unique as it is an analysis of
1,084 DES patients treated in an unrestricted setting. In a total cohort of DES patients, cardiogenic shock,
female gender, multivessel disease, diabetes mellitus, left main stenting, bifurcation stenting, and treatment of
a complex lesion significantly predicted an adverse outcome. From this list, patients who possess these
characteristics should undergo more regular clinical surveillance.
The major advantage of DES has been to reduce the need for repeat revascularization. 1-3 In our study,
the incidence TVR at one year with PES was not significantly different from the results obtained with SES.
Furthermore, when the adjusted end point of clinically driven TVR was used (Fig. 2), similar outcomes were
reproduced, thus confirming that both drug-eluting systems serve to reduce clinical restenosis in an unselected
population.
A nonsignificantly higher incidence of angiographic stent thrombosis in the first 30 days was noted in
the PES cohort (1.0% in SES vs. 0.4% in PES, p = 0.3). However, it is important to emphasize that, owing to
the infrequent occurrence of this event, large numbers of patients are required to assess this complication
properly. We have shown that in a larger population, the incidence rates in both DES were in the same range:
1.0% (95% CI 0.6% to 1.9%) in PES and 1.0% (95% CI 0.5% to 1.8%) in SES. 12
At the time the T-SEARCH registry was conducted, TAXUS II 5 and the Randomized Comparison of a
Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization (RAVEL) 13 were the two
published trials available with one-year MACE results from the eluting stent arms of 10.9% (slow-release arm)
and 5.8%, respectively. Based on those results, the group sample sizes of our study would have been
adequately powered to show a difference.
Subsequent to that, the results of larger trials of both devices—TAXUS IV and Sirolimus-Eluting Stent
in Coronary Lesions (SIRIUS)—were published and demonstrated a smaller difference (8.4% vs. 7.1%,
respectively). The population of this registry is an all-inclusive unrestricted one, a sample that is representative
of the population seen in a tertiary catheterization laboratory. Therefore, this population is directly comparable
to daily practice and the results do not require extrapolation as for randomized trials. The results of this registry
complement published randomized trials.
Conclusions
The universal use of PES in an unrestricted setting is safe, and associated with a non-significant adjusted
difference in outcome at one year compared to SES, with a trend toward worse outcomes in the PES cohort, in
part owing to its higher-risk profile. Both DES reduce the need for repeat intervention in the real world setting of
complex patient and procedural characteristics.
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Chronic total occlusions
The number of patients undergoing coronary revascularization is rising, and there has been an increase in the
proportion of patients being treated with percutaneous intervention compared with coronary artery bypass
surgery (Chapter 3). In keeping with this, between 1992 and 2002 there was a steady rise in the number of
percutaneous interventions for chronic total occlusions (CTOs) carried out at the Thoraxcenter. However,
despite the evolution of specialized technologies, the success rate for CTO recanalization remained fairly
constant, with an overall success rate of 65%. Successful recanalization of a CTO has important implications
with, at 5 years, a significantly higher rate of survival compared with those following an unsuccessful
recanalization attempt.
Until the introduction of drug-eluting stents, intra-coronary radiation therapy was the gold standard for
the treatment of in-stent restenosis, with relatively low rates of recurrence at 6 months. However, long-term
follow-up has since demonstrated that these patients are at risk of late recurrence of stenosis. In addition,
impairment of re-endothelialization following radiation therapy increase the risk of vessel occlusion due to
thrombosis. We evaluated all patients treated with intra-coronary radiation therapy at the Thoraxcenter, and
found that over a mean follow-up of 40.3 months, there was a high rate of vessel occlusion (12.3%) (Chapter
4), Prolongation of dual anti-platelet therapy to 6 months duration was insufficient to protect against the
development of occlusion, which was associated with significant morbidity.
Several angiographic features have been identified as predictors for successful recanalization, and the
presence or absence of these can influence the decision regarding whether percutaneous revascularization is
attempted or the patient is referred directly for bypass surgery. We evaluated the role of pre-operative non-
invasive imaging with multi-slice computed tomographic (MSCT) coronary angiography to predict the outcome
of attempted CTO recanalization and therefore identify those patients most likely to benefit from attempted
percutaneous revascularization (Chapter 5). By multivariate analysis of the clinical, angiographic and MSCT
features, we found three independent predictors of angioplasty failure: the presence of a blunt stump by
angiography, length of occlusion >15mm (demonstrated on MSCT), and severe calcification (demonstrated on
MSCT). This suggests therefore that MSCT can be helpful in the therapeutic decision-making for patients who
have CTO.
Importantly, a failed CTO recanalization attempt can be associated with a significant procedural-related
complication rate including a 1% risk of death (Chapter 3). New technologies must therefore focus on a safe
approach to successful recanalization. One novel technology dedicated to CTO recanalization is the
SafeCross™ system (Chapters 6, 7 and 8). This system combines guidance to help steer the wire, with the
capability to penetrate through the occlusion with radiofrequency ablation. Near infra-red light is emitted and the
system uses optical coherence reflectometry to determine the position of the wire tip in relation to the vessel
wall. The ablation is only enabled when the system detects that the wire is intraluminal and heading in a correct
direction away from the vessel wall. In our experience, we found the system to be a useful adjunct, with
successful recanalization achieved in 52% CTO cases that had previously had an unsuccessful attempt using
conventional means. Importantly, there were no complications related to use of the device. The device was
successfully used even in a heavily calcified occlusion of the ostium of the left anterior descending artery
(Chapter 7). The most common reason for unsuccessful CTO recanalization is failure to cross the lesion with a
guidewire. This can be improved with technologies such as the SafeCross™ system, however subsequent
failure commonly reflects the inability to cross the occlusion with a balloon. The rotablator can be a useful
adjunctive device in this situation to facilitate subsequent dilatation and stent implantation (Chapter 8).
Prior to the introduction of drug-eluting stents, the majority of major adverse cardiac events following
successful CTO recanalization are related to the need for repeat intervention (Chapter 3). In large randomised
studies, drug-eluting stents have been shown to reduce the rate of restenosis and the need for target vessel
revascularization compared with bare metal stents when used in relatively simple lesions. Patients with more
complex lesions such as CTOs were excluded from these studies. We evaluated whether sirolimus- and
paclitaxel-eluting stents were also effective in improving outcomes for patients with a CTO (Chapters 9 and 10).
At 1 year, patients treated with a sirolimus-eluting stent had a significantly higher rate of survival-free of major
adverse cardiac events compared with patients treated with bare metal stents (96.4% versus 82.8%, p<0.05).
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Furthermore, follow-up angiography at 6-months showed that the sirolimus-eluting stent effectively suppressed
neointimal proliferation, and was associated with a low late lumen loss of just 0.13 ± 0.46mm. We subsequently
also evaluated the clinical outcomes of patients treated with paclitaxel-eluting stents (Chapter 10). Following
therapy of a CTO of >3 months duration, the cumulative survival-free of target vessel revascularization was
97.4% for patients treated with sirolimus-eluting stents, 96.4% for paclitaxel-eluting stents, and significantly
lower at 80.8% for bare metal stents (p=0.01). These data demonstrate efficacy of both the sirolimus- and
paclitaxel-eluting stents in reducing restenosis and the need for repeat reintervention compared with bare metal
stents. This improvement in outcomes means an expansion in the complexity of those lesions deemed suitable
for percutaneous intervention. Chronic total occlusion of the left main stem is a very rare lesion, but we
demonstrate that in contemporary practice, it can be successfully treated with drug-eluting stent implantation
(Chapter 11).
Bifurcations
A variety of techniques have been proposed to treat bifurcation lesions (Chapters 12 and 13). However, when
bare metal stents are utilised, techniques involving stenting of the side branch are associated with a higher rate
of restenosis compared with strategies whereby only the main vessel is stented. We evaluated the efficacy of
drug-eluting stents in consecutive patients treated for at least one bifurcation lesion (Chapter 14). In these
patients, the side branch was stented in addition to the main vessel as it seemed intuitive when using these
stents to cover the entire lesion. At 6 months, the incidence of major adverse cardiac events was 10.3%, which
is lower than that documented in published data of bare metal stents. The incidence of target lesion
revascularization was 8.6%. Follow-up angiography demonstrated restenosis rates of the main vessel and side
branch of 9.1% and 13.6% respectively, with an overall restenosis rate of 22.7%. The majority of restenoses of
the side branch occurred at the ostium following T-stenting. Indeed, the restenosis rate in the side branch
following T-stenting was 16.7% whilst that following other stenting techniques was 7.1%. The major problem
with T-stenting relates to the degree of angulation between the main vessel and side branch. If this angle
approximates 90˚, precise stent positioning in both vessels can completely cover the lesion. However, the
majority of bifurcation lesions have an angle of <70˚. We hypothesised that the side branch restenoses seen in
our study might relate to inadequate or incomplete coverage of the ostium thereby reducing the efficacy of the
drug-eluting stent. This led to a shift away from a strategy of T-stenting, towards methods which ensure
complete coverage – the crush and Culotte techniques of stenting (Chapter 15). However, despite the change
in stenting technique, the choice of strategy was not an independent predictor for either major adverse cardiac
events or the need for target lesion revascularization. It is unlikely that any single strategy will be optimal for all
bifurcations due to the diversity of these lesions with differences of vessel size, angulation, and plaque
distribution.
Following stenting of bifurcation lesions, we found a difference in outcomes with respect to stent type in
favour of fewer repeat target lesion revascularization in the sirolimus-eluting stent group as compared with
those treated with paclitaxel-eluting stents (Chapter 15). However, this result must be taken with caution in view
of the lack of randomisation of the data. Indeed, in chapter 20, we show that for the total populations treated
with drug-eluting stent implantation, stent type (sirolimus-eluting versus paclitaxel-eluting) was not an
independent predictor of either major adverse cardiac events or the need for target vessel revascularization.
The crush technique of bifurcation stenting is a new strategy that ensures complete lesion coverage,
and was introduced specifically to be used with drug-eluting stents. We evaluated the outcomes of 231
consecutive patients treated using this technique for 241 de novo bifurcation lesions (Chapter 16). The rate of
in-hospital major adverse cardiac events was 5.2%. At 9-months, the incidence of possible post-procedural
stent thrombosis was of concern, with 10 (4.3%) patients having had a possible event. The rate of survival-free
of target lesion revascularization was 90.3%, and survival-free of major adverse cardiac events was 83.5%.
Therapy of the left main stem was an independent predictor for adverse events, and further research is needed
before this technique can be routinely recommended in this group. Angiographic follow-up demonstrated a
mean late loss of 0.30±0.64mm and 0.41±0.67mm for the main vessel and side branch respectively, with binary
restenosis rates of 9.1% and 25.3%. Kissing balloon post-dilatation significantly reduced the side branch late
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lumen loss (0.24±0.50mm versus 0.58±0.77mm, p<0.001) and binary restenosis rates (9.6% versus 41.3%,
p<0.0001), and should therefore be carried out routinely in all cases to reduce the rate of restenosis.
The Culotte technique of bifurcation stenting is also a strategy that ensures complete lesion coverage.
However, the technique fell out of favour because of high restenosis rates following bare metal stent
implantation. We evaluated the outcomes of a series of patients treated with this technique using drug-eluting
stents and showed promising clinical and angiographic outcomes (Chapter 17). These results warrant the re-
evaluation of the Culotte technique utilizing drug-eluting stents, in the setting of large randomized studies.
Chronic total occlusions, bifurcations, and the RESEARCH and T-SEARCH Registries
From April 2002, drug-eluting stents were used as the default strategy for all patients undergoing percutaneous
coronary intervention. Initially, patients were treated with the sirolimus-eluting stent, then during the first quarter
of 2003, our strategy switched to using paclitaxel-eluting stents in all patients. These patients comprise the
RESEARCH and T-SEARCH Registries respectively. All consecutive patients were enrolled irrespective of
clinical presentation and lesion characteristics, and the incidence of major adverse cardiac events was
prospectively evaluated during follow-up.
By multivariate analysis, the treatment of chronic total occlusions was not found to be an independent
predictor of stent thrombosis, restenosis, or adverse cardiac events including target vessel revascularization.
However, our data show that in the era of drug-eluting stents, percutaneous coronary intervention of bifurcation
lesions is associated with an increased risk of adverse events. Drug-eluting stents impair the process of re-
endothelialization compared with bare metal stents, and there are concerns that this might lead to an increased
risk of stent thrombosis. We evaluated >2,500 consecutive patients, and show that in unselected patient
populations treated with either sirolimus-eluting or paclitaxel-eluting stents, the incidence of stent thrombosis at
30 days is within the range seen following bare stent implantation (Chapter 18). The only independent predictor
for stent thrombosis was bifurcation stenting in the setting of acute myocardial infarction. This emphasises the
importance of optimal pharmacotherapy in this group, and suggests that it may be preferable to use a single
stent strategy for bifurcation lesions treated in this setting.
During the first 6 months of the RESEARCH Registry, patients treated for complex disease were invited
back for follow-up coronary angiography. These were patients treated for acute myocardial infarction, in-stent
restenosis, left main stem stenting, chronic total occlusion, bifurcation stenting, those who received a 2.25mm
stent, and those treated with a stented segment length >36mm. Bifurcation stenting (side branch position) was
a univariate predictor of restenosis (OR 2.77; 95% CI: 1.15-6.33, p=0.02), though this was no longer a predictor
on multivariate analysis (Chapter 19).
 We subsequently evaluated the clinical outcomes of all patients treated with drug-eluting stents for de
novo lesions (Chapter 20). Use of the paclitaxel-eluting stent was associated with a non-significant difference in
outcome compared with the sirolimus-eluting stent. However, when the entire population was evaluated for
predictors of adverse outcomes, bifurcation stenting was an independent predictor of major adverse cardiac
events (HR 1.59; 95%CI: 1.06-2.38, p=0.03), and was the only independent predictor of target vessel
revascularization (HR 2.77; 95%CI: 1.68-4.57, p<0.001).
Conclusions
In the therapy of chronic total occlusions and bifurcation lesions, sirolimus- and paclitaxel-eluting stents are
effective in reducing restenosis compared with bare metal stents. Successful chronic total occlusion therapy
infers a significant improvement in long-term survival, and therefore justifies an aggressive strategy of
recanalization. However, failed recanalization may be associated acutely with an adverse event, and new
technologies must focus on a safe approach to successful recanalization.
The most effective strategy of stenting of bifurcation lesions is currently undefined, and further
randomised studies are warranted taking into account factors such as vessel size, angulation between the main
vessel and side branch, and plaque distribution at baseline. In contemporary coronary interventional practice
utilizing drug-eluting stents, bifurcation lesions continue to pose a problem in terms of being associated with an
increased risk of major adverse cardiac events and target vessel revascularization.   
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Samenvatting en Conclusies
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Chronische totale occlusies
Het aantal patienten dat een coronaire revascularisatie ondergaat neemt gestaag toe en deze tendens is
grotendeels toe te schrijven aan de toename van het aantal percutane coronaire interventies ten nadele van
coronaire bypass operaties (hoofdstuk 3). In analogie hiermee was er in het Thoraxcentrum tussen 1992 en
2002 eveneens een duidelijke toename in het aantal percutane interventies voor chronische totale occlusies
(CTO’s). Hoewel er in deze periode een belangrijke technologische vooruitgang is geweest, bleef de kans op
succesvolle recanalisatie relatief constant, namelijk om en bij de 65%. Een succesvolle recanalisatie van een
CTO heeft nochtans belangrijke prognostische implicaties: deze patienten hebben een betere 5-jaarsoverleving
in vergelijking met de groep waarbij recanalisatie niet lukt.
Tot de introductie van drug-eluting-stents was intracoronaire brachytherapie de aangewezen therapie
voor de behandeling van in-stent-restenose aangezien met deze therapie de kans op recidief restenose relatief
laag was 6 maanden behandeling. Lange-termijn resultaten hebben evenwel aangetoond dat patienten
behandeld met brachytherapie een hoger risico vertonen op  het ontwikkelen van laattijdige restenose.
Bovendien verhoogt brachytherapie de kans op coronaire thrombose doordat het interfereert met het normale
re-endothelialisatieproces. In hoofdstuk 4 rapporteren we de resultaten van alle patienten die in het
Thoraxcentrum behandeld werden met coronaire brachytherapie: na een gemiddelde follow-up van 40.3
maanden was er een hoge mate van bloedvatocclusie (12.3%). Combinatietherapie met 2 klassen van
bloedplaatjesaggregantia gedurende een periode van 6 maanden heeft bovendien geen beschermend effect
tegen het ontstaan van bloedvatocclusie, hetgeen gepaard gaat met een belangrijke morbiditeit.
Er zijn verschillende angiografische karakteristieken gekend die het succes van een recanalisatie
voorspellen. Het aan- of afwezig zijn van deze kenmerken beinvloedt mee de beslissing om een patient voor
percutane coronaire revascularisatie dan wel voor coronaire bypass chirurgie te verwijzen. In hoofdstuk 5
beschrijven we de toegevoegde waarde van niet-invasieve beeldvorming met multi-slice computer tomografie
(MSCT) van de coronaire bloedvaten als voorbereidend onderzoek voor het uitvoeren van de revascularisatie.
We hebben de rol van MSCT onderzocht  voor het voorspellen van de kans op succes van een percutane
coronaire interventie van een CTO en met andere woorden nagegaan welke patienten een redelijk hoog
slaagpercentage hebben. Multivariaat analyse van klinische, angiografische en MSCT kenmerken leverde 3
onafhankelijke variabelen op die geassocieerd zijn met een lage slaagkans van de percutane interventie: de
aanwezigheid van een abrupt stopbeeld op het conventionele angiogram, een geoccludeerd bloedvat segment
van >15mm (MSCT variabele) evenals een sterk verkalkt segment van de coronair arterie (MSCT variabele).
Deze bevindingen suggereren dat MSCT mogelijk een rol heeft bij de beslissing om een patient met een CTO
al dan niet via percutane weg te behandelen.
In hoofdstuk 3 beschrijven we dat een niet succesvolle percutane recanalisatiepoging voor een CTO
kan gerelateerd zijn aan majeure complicaties waaronder een mortaliteitsrisico van 1%. Nieuwe technologische
verbeteringen zijn bijgevolg noodzakelijk om de recanalisatiepoging succesvoller en tegelijkertijd veiliger te
maken. Een van deze nieuwe technieken voor de behandeling van CTO’s is het SafeCross™ system
(hoofdstuk 6 tot en met 8). Dit systeem combineert 2 eigenschappen: (1) het biedt ondersteuning bij het
maneuvreren van de draad, en (2) door middel van radiofrekwentie ablatie is het mogelijk hard materiaal te
doorbreken. Het systeem maakt gebruik van optical coherence tomografie om de positie van de draadtip in
relatie tot de bloedvatwand te bepalen. Ablatie is enkel mogelijk wanneer de tip van de draad centraal in het
bloedvat wordt gedetecteerd en in de juiste richting, weg van de bloedvatwand, opschuift. Onze ervaring met
dit systeem is gunstig aangezien het toeliet 52% van de patiënten, die reeds een eerste niet-succesvolle
percutane revascularisatiepoging achter de rug hadden, deze keer met succes te behandelen. Belangrijk te
vermelden is dat er bij gebruik van dit systeem geen complicaties optraden. Zelfs bij een ernstig verkalkte
occlusie vanaf de oorsprong van de LAD (left anterior descending arterie) was het SafeCross™ systeem
succesvol (hoofdstuk 7). De voornaamste reden voor het niet slagen van een recanalisatiepoging van een CTO
is de onmogelijkheid om met een draad de occlusie te passeren.  Het SafeCross™ systeem biedt wat dit betreft
een hogere slaagkans. Casussen die dan nog niet lukken zijn gewoonlijk gerelateerd aan de ballon die de
occlusie niet kan passeren. Rotablatie kan in deze situatie zinvol zijn aangezien het de ballondilatatie en
vervolgens de stentplaatsing vergemakkelijkt (hoofdstuk 8).
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In de periode voor de introductie van drug-eluting stents, was het merendeel van de majeure cardiale
events na succesvolle recanalisatie van een CTO te wijten aan de noodzaak tot herinterventie (hoofdstuk 3). In
grote gerandomiseerde studies werd aangetoond dat het gebruik van drug-eluting stents bij de behandeling
van relatief eenvoudige lesies de incidentie van restenose en de noodzaak tot herinterventie van het
behandelde bloedvat (ook wel ‘target vessel’ revascularisatie genoemd) in belangrijke mate hebben
gereduceerd in vergelijking met niet-gecoate stents (ook wel ‘bare metal stents’ genoemd). Patienten met
complexe lesies zoals CTO’s werden evenwel niet geincludeerd in deze studies. In hoofdstuk 9 en 10
beschrijven we of drug-eluting stents, met name sirolimus-eluting en paclitaxel-eluting stent, ook de outcome
verbeteren van patienten met CTO’s. Patienten die behandeld werden met een sirolimus-eluting stent hadden 1
jaar na de interventie een significant hogere overleving vrij van majeure cardiale events in vergelijking met de
controlegroep waarin ‘bare metal stents’ werden gebruikt (96.4% versus 82.8%, p<0.05). Bovendien bleek uit
de controle angiografie 6 maanden na de interventie dat sirolimus-eluting stents effectief de ontwikkeling van
neointimahyperplasie onderdrukken hetgeen resulteerde in een ‘late lumen loss’ van slechts 0.13 ± 0.46mm. In
hoofdstuk 10 beschrijven we de klinische outcome van patienten die met een paclitaxel-eluting stent werden
behandeld. Na behandeling van een CTO van minstens 3 maanden oud, was het percentage patienten waarbij
geen nieuwe herinterventie van het behandelde bloedvat meer noodzakelijk was significant hoger in de drug-
eluting stent groep (97.4% voor sirolimus, 96.4% voor paclitaxel) in vergelijking met de ‘bare metal stent’ groep
(80.8%) (P-waarde= 0.01). Deze bevindingen bewijzen de efficientie van zowel de sirolimus- als paclitaxel-
eluting stent wat betreft afname van restenose en de nood tot herinterventie in vergelijking met b’are metal
stents’. Deze duidelijke verbetering in outcome, ook na behandeling van meer complexe lesies, laat een
verruiming toe van de indicaties voor percutane coronaire interventies. Een chronische totale occlusie van de
linker hoofdstam is een uitzonderlijk gegeven: in hoofdstuk 11 illustreren we dat dit type lesie tegenwoordig
succesvol kan behandeld worden mits gebruik gemaakt wordt van een drug-eluting stent.
Bifurcaties
De aanpak van coronaire bifurcatie lesies is niet uniform en verklaart het grote aantal percutane
behandelingsmethoden (hoofdstuk 12 en 13). Wanneer ‘bare metal stents’ worden gebruikt voor de
behandeling van het zijvat, blijkt de incidentie van restenose hoger te zijn in vergelijking met een meer
eenvoudige behandelingsstrategie waarbij enkel het hoofdvat gestent wordt. In hoofdstuk 14 rapporteren we de
efficientie van drug-eluting stents in een consecutieve groep van patienten waarbij percutane interventie van
minstens 1 bifurcatielesie noodzakelijk was. In deze groep patienten werd afgezien van het hoofdvat
systematisch ook het zijvat gestent aangezien het intuitief gezien beter lijkt om gans de lesie te overdekken met
een drug-eluting stent. Na 6 maanden was de incidentie van majeure cardiale events 10.3%, een duidelijke
afname in vergelijking met gepubliceerde data met ‘bare metal stents’. De incidentie van ‘target lesie’
revascularisatie was 8.6%. Bij controle angiografie werd restenose gedocumenteerd bij 22.7% der patienten:
9.1% vertoonde restenose in het hoofdvat, 13.6% in het zijvat. Restenose van het zijvat deed zich voornamelijk
voor ter hoogte van het ostium, met name bij patienten behandeld volgens de T-stent techniek: in deze groep
patienten kwam restenose voor bij 16.7% der patienten, in tegenstelling tot andere behandelingsstrategieen
waar restenose voorkwam bij 7.1% der patienten. Het belangrijkste probleem van de T-stent techniek is
gerelateerd aan de hoek tussen het hoofd- en zijvat. Een hoek van 90 graden laat een accurate positionering
van de stent toe waarbij de lesie volledig overdekt wordt. In het merendeel der bifurcatielesies bedraagt de
hoek evenwel minder dan 70 graden. Onze hypothese was dat het optreden van restenose van de zijtak in de
beschreven groep patienten mogelijks gerelateerd is aan inadekwate of onvolledige overdekking van het
ostium waardoor de effectiviteit van drug-eluting stents afneemt. Deze bevinding heeft ertoe geleid dat T-
stenting minder gebruikt wordt ten voordele van behandelingsmethoden die per definitie het ostium van het
zijvat mee overdekken, met name de Crush en Culotte techniek (hoofdstuk 15). Deze verandering in
behandelingsmethode was evenwel geen onafhankelijke predictor voor majeure cardiale events of ‘target lesie’
revascularisatie. Het is onwaarschijnlijk dat 1 bepaalde behandelingsstrategie optimaal is voor ieder type
bifurcatie lesie als gevolg van de grote verscheidenheid aan bifurcatiepathologie: belangrijke elementen hierin
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zijn de verschillen in grootte van het bloedvat, de grootte van de hoek tussen hoofd- en zijvat, en de distributie
van de plaque.
Na stenting van bifurcatie lesies vonden wij een verschil in outcome in functie van het type drug-eluting
stent dat werd gebruikt: ‘target lesie’ revascularisatie was minder frekwent bij patiënten behandeld met een
sirolimus-eluting stent in vergelijking met patiënten behandeld met een paclitaxel-eluting stent (hoofdstuk 15).
Dit verschil moet evenwel kritisch bekeken worden aangezien het geen gerandomiseerde studie betrof. In
hoofdstuk 20 tonen we namelijk aan dat in de totale populatie die met een drug-eluting stent werd behandeld,
het type drug-eluting stent (sirolimus- versus paclitaxel-eluting stent) geen onafhankelijk predictor was voor wat
betreft majeure cardiale events of de nood voor ‘target vessel’  revascularisatie.
Bifurcatiestenting volgens de Crush techniek is een nieuwe behandelingsmethode die specifiek
geïntroduceerd werd voor gebruik met drug-eluting stents en maakt het mogelijk de lesie in hoofd- en zijvat
volledig te overdekken. Hoofdstuk 16 beschrijft de outcome van 231 consecutieve patiënten, met in totaal 241
de novo bifurcatie lesies, die volgens de Crush methode werden behandeld. In-hospitaal majeure cardiale
events deden zich voor bij 5.2% der patienten. De resultaten na een gemiddelde follow-up van 9 maanden
waren de volgende: 1/ 10 patienten (4.3% der studiepopulatie) ontwikkelden mogelijks een subacute of
laattijdige stent thrombose, een zorgwekkende bevinding; 2/ de overleving vrij van ‘target lesion’
revascularisatie was 90.3%, en de  overleving vrij van majeure cardiale events was 83.5%; 3/ Crush stenting
van de hoofdstam was een onafhankelijke predictor voor het optreden van cardiale events: deze bevinding
vereist verder onderzoek vooraleer Crush stenting kan worden aanbevolen als een routinetechniek voor de
behandeling van een significante hoofdstamlesie; 4/ follow-up door middel van angiografie toonde aan dat de
gemiddelde ‘late loss’ voor het hoofd- en zijvat respectievelijk 0.3±0.64mm en 0.41±0.67mm was en de
incidentie van restenose respectievelijk 9.1% en 25.3%; 5/ ‘Kissing balloon’ postdilatatie reduceerde op
significante wijze ‘late lumen loss’ (0.24±0.50mm versus 0.58±0.77mm, p<0.001) evenals de incidentie van
restenose (9.6% versus 41.3%, p<0.0001) van het zijvat, en zou om die reden systematisch moeten worden
gebruikt ter reductie van de incidentie van restenose.
Bifurcatiestenting volgens de Culotte techniek is een ander type strategie die eveneens zorgt voor een
volledige overdekking van de lesie. Wegens een hoge incidentie van restenose bij patiënten behandeld met
‘bare metal stents’ werd deze techniek evenwel minder populair. Hoofdstuk 17  beschrijft een serie patiënten
behandeld met drug-eluting stents volgens de Culotte techniek waarbij de klinische en angiografische outcome
veelbelovend was. Deze resultaten creëeren de noodzaak de Culotte techniek in de setting van drug-eluting
stents te herevalueren in grote gerandomiseerde studies.
Chronische totale occlusies, bifurcaties, en de RESEARCH en T-SEARCH registraties
Sedert april 2002 worden in het Thoraxcentrum te Rotterdam drug-eluting stents gebruikt als standaard
behandeling bij alle patiënten die een percutane coronaire interventie ondergaan. Tot het eerste kwartaal van
2003 werden alle patiënten behandeld met een sirolimus-eluting stent en vervolgens werd overgeschakeld op
paclitaxel-eluting stents. Deze patiënten maken deel uit van respectievelijk de RESEARCH en T-SEARCH
registratie. In deze registraties werden systematisch alle patiënten geincludeerd ongeacht de klinische
presentatie of lesie karakteristieken. In beide registraties wordt de incidentie van majeure cardiale events
prospectief geëvalueerd.
Uit multivariaat analyse blijkt dat het gebruik van drug-eluting stents voor chronisch totale occlusies
geen onafhankelijke predictor is voor stent thrombose, restenose of het optreden van cardiale events, inclusief
de nood aan ‘target vessel’ revascularisatie. De registratiegegevens tonen evenwel aan de percutane
behandeling van bifurcatielesies geassocieerd is met een hoger risico op cardiale events. Drug-eluting stents
verstoren het normale re-endothelialisatieproces in vergelijking met ‘bare metal stents’, en hebben aanleiding
gegeven tot de bezorgdheid dat dit kan leiden tot een hoger risico op stent thrombose. In een serie van meer
dan 2500 consecutieve patienten hebben we aangetoond dat in een niet-geselecteerde patientenpopulatie  die
behandeld werden met een sirolimus- of paclitaxel-eluting stent, de incidentie van stent thrombose gedurende
de eerste 30 dagen na de behandeling vergelijkbaar is met de incidentie bij gebruik van ‘bare metal stents’
(hoofdstuk 18). De enige onafhankelijke predictor voor het optreden van stent thrombose was bifurcatiestenting
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bij patiënten behandeld voor een acuut myocardinfarct. Deze bevinding benadrukt het belang van optimale
medicamenteuse therapie in deze patientengroep en suggereert dat bij de behandeling van bifurcatielesies in
de setting van een acuut myocardinfarct een eenvoudige strategie waarbij enkel het hoofdvat gestent wordt te
verkiezen is.
Gedurende de eerste 6 maanden van de RESEARCH registratie werden alle patiënten die behandeld
werden voor complexe lesies uitgenodigd voor een controle angiografie. Het betrof patiënten behandeld
wegens een acuut myocardinfarct, in-stent restenose, stenting van de hoofdstam, chronische totale occlusies,
bifurcatiestenting, vernauwingen van kleine bloedvaten waarbij een 2.25mm stent gebruikt werd, of patiënten
waarbij het gestente bloedvat segment meer dan 36mm betrof. Bifurcatiestenting was een predictor voor het
optreden van restenose op niveau van het zijvat bij univariaat analyse (OR 2.77; 95% CI: 1.15-6.33, p=0.02),
doch niet bij multivariaat analyse (hoofdstuk 19).
Hoofdstuk 20 beschrijft de klinische outcome van alle patiënten die behandeld werden met een drug-
eluting stent voor de novo lesies. Het gebruik van een paclitaxel-eluting stent was geassocieerd met een niet-
significant verschil in outcome in vergelijking met de sirolimus-eluting stent. Bifurcatiestenting was evenwel een
onafhankelijke predictor van majeure cardiale events (HR 1.59; 95% CI: 1.06-2.38, p=0.03), en de enige
onafhankelijke predictor voor wat betreft ‘ target vessel’ revascularisatie (HR 2.77; 95% CI: 1.68-4.57,
p<0.001).
Conclusies
Voor de behandeling van chronische totale occlusies en bifurcatielesies zijn de sirolimus- en paclitaxel-eluting
stent effectief in vergelijking met ‘bare metal stents’ voor wat betreft reductie van restenose. Succesvolle
behandeling van een chronische totale occlusie gaat gepaard met een significante verbetering van de
overleving op lange termijn en rechtvaardigt bijgevolg een agressieve recanalisatiestrategie. Een niet-
succesvolle recanalisatiepoging kan in de acute fase evenwel geassocieerd zijn met een majeur event en
maakt het noodzakelijk nieuwe technologiëen te ontwikkelen die op een veilige manier de kans op succes
verhogen.
De meest effectieve strategie bij de behandeling van bifurcatielesies is tot op heden niet gekend.
Gerandomiseerde studies die rekening houden met de grootte van het bloedvat, de hoek tussen hoofd- en
zijvat, en de distributie van de plaque zijn noodzakelijk om hierin duidelijkheid te verschaffen. Ook in de huidige
praktijk van interventiecardiologie waarbij gebruik gemaakt wordt van drug-eluting stents, is het
behandelingsresultaat van bifurcatie lesies niet optimaal aangezien dit type lesies geassocieerd blijft met een
verhoogd risico op majeure cardiale events en ‘target vessel’ revascularisatie.
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